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INTRODUCTION 
Chapter 1 
1.0 INTRODUCTION 
Breast cancer is the most conmlon malignant tumor among women, with an 
estimated 135,000 new cases and 58,000 recorded deaths per year in the Europeau 
Community in 1990 [1]. With respect to the Netherlands, the most recent data of The 
Netherlands Cancer Registry show an incidence of nearly 10.000 new cases of primary 
breast cancer and about 3500 breast cancer deaths per year [2]. In women breast 
cancer comprises one-third (33,2%) of all types of cancer. Ultimately about one out 
of 10 women wiII get breast cancer during her life and one out of every 22 women 
wiII sooner or later die as a consequence of metastatic disease [2]. 
Among the solid tumors breast cancer is one of the few types of cancers sensitive to 
different systemic treatment reginJens both with respect to endocrine- and 
chemotherapy. Both treatment modalities are nowadays standard practice in the 
treatment of breast cancer, either to achieve cure, or prolongation of (relapse-free) 
survival in the adjuvant setting, or to palliate metastatic disease. The efficacy of the 
different forms of systemic treatment is dependent on patients- and tumor 
characteristics [3]. 
1.1 Endocrine treatment of breast cancer 
More than 100 years have past since Beatson empirically performed the first 
oophorectomy in a patient with metastatic breast cancer, and documented the 
regression of skin metastases [4]. It is only since a few decades however that Iwe are 
beginning to understand the biology that explains why Beatson was successful. For 
many years standard endocrine manipulation for the treatment of breast cancer has 
been directed toward inhibiting, ablating, or otherwise interfering with estrogen 
activity (Table I) [5,6]. 
The efficacy of such manipulation depends on the phase of the disease and tumor-load. 
While cure is possible in a subset of patients with prinlary disease, in contrast, in 
ullselected patients with metastatic disease only prolongation of survival can be 
reached. The median duration of respollse of rust-line endocrine therapy is between 
one and two years [7-10]. The question was raised whether combinations of hormones 
or sequential hormonal therapy with agents with different mechanisms of action could 
improve treatment outcome. Several trials have been initiated addressing this issue. 
Most of the randomized trials performed were based on mdimental understanding of 
the mechanisms of action of endocrine therapy and have not led to a real successful 
combination of endocrine therapies. 
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Tahle I 100 years in the development of 
endocrine therapy' 
1896 oophorectomy 
1922 ovarian irradiation 
1939 androgens 
1944 synthetic estrogens 
1951 progestins 
1952 pituitary irradiation 
1953 adrenalectomy 
1953 hypophysectomy 
1971 anti-estrogens 
1973 aromatase inhibitors 
1982 LHRH agonists 
1987 antiprogestins 
1993 upureu anti-estrogens 
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In spite of higher initial response rates with some of the hormonal combinations, 
survival was not inflnenced and toxicity was often increased [11-19]. 
It is only since the last decades that we learned that the development and function of 
the mammary gland depends on the coordinated action of estrogen, prolactin, 
progesterone, adrenal corticosteroids, insulin, growth hormone, and thyroid hormone 
[20]. Besides estrogen, many steroid and peptide hormones, but also growth factors 
and other trophic substances, have been recognized that are involved in the growth 
regulation of the normal breast and of breast cancer (Table II). 
Together with this enhanced knowledge of endocrine/paracrine/growth factor involve-
ment in breast cancer growth, the number of available endocrine agents has been 
drastically increased in the past twenty years (Table Ill) [9,20-24]. This offers now 
many new points of action in the endocrine therapy of breast cancer, making 
combinations of (new) endocrine agents more attractive. 
11 
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Table II Hormones and other factors involved in the growth regulation of breast 
cancer (directly and indirectly)'1 
1. Steroid hormones 
2. Peptide hormones 
3. Other trophic factors 
4. Growth factors 
5. Secretory proteins 
estrogens, progesterone, androgens, 
glucocorticosteroids 
prolactin, growth hormone, insulin, somatostatin, 
calcitonin (LH, FSH, ACTH). 
iodothyronines (T4, T3), vito D, retinoids, 
polyamines, melatonine. 
insulin-like growth factors (IGF-l, IGF-2), 
epidermal growth factor (EGF), transforming 
growth factors (TGF-ll', and (3), platelet-derived 
growth factor (PDGF), fibroblast growth factors 
(FGF), mammary derived growth factor 1 
(MDGF-I). 
Table ill New endocrine agents and new treatment modalities" 
1 ) Pure anti estrogens 
2 ) LHRH analogues 
3 ) Aromatase inhibitors 
4 ) Antiprogestins 
5 ) Somatostatin analogues with or without prolactin inhibitors 
6 ) Potent metallopeptide analogues 
7 ) Radiolabelled hormones (SS-A-Yttrium) 
8 ) Specific growth factor pathway interfering therapy 
9 ) - Inhibition of angiogenesis 
- Inhibition of metastatic capacity 
10) Sensibilisation for chemotherapy by recruitment of tumor cells in S-phase 
1.2 Chemotherapy of breast cancer 
Cytotoxic chemotherapeutic agents form the other main group of systemic 
treatment of breast cancer [25-29]. Since the initial use of cytotoxic drugs in humans 
in 1942, virtually every new member of this class of drugs developed has been tested 
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for breast cancer. In the adjuvant setting chemotherapy is as effective as hormonal 
therapy in pre-menopausal patients, but less effective in post-menopausal patients. 
Used as single agent in disseminated breast cancer anthracyclines, cyclophosphamide, 
methotrexate and fluorouracil induce objective responses in about 20-40 % of the 
patients. These agents are the cornerstones of breast cancer chemotherapy nowadays, 
together with promising new agents as pacHtaxel and docetaxel (Table IV) [30-34]. 
Table IV Activity of single agent chemotherapy 
in metastatic breast cancerJO·" 
Response 
rate(%) 
Fluorouracil 27 
Methotrexate 28 
Cyclophosphamide 33 
Doxorubicin 32 
Epirubicin 34 
Mitoxantrone 20 
PacHtaxel 17-62 
Docetaxel 44-73 
Also combination chemotherapy has been extensively tested in breast cancer. When 
treating patients with metastatic disease, response rates in flrst-line therapy of about 
40-50% can be achieved with the combination of CMF (cyclophosphamide, 
methotrexate and fluorouracil), whereas CAF or CEF, anthracycline (doxorubicin or 
epirubicin) containing schemes are claimed to be the most effective ones with response 
rates of 50-60% (35-37). However, with these schemes only 10-20% of the patients 
achieve a complete remission usnally of short duration, and side-effects of 
chemotherapy are often snbstantial. 
1.3 Selected new treatment modalities 
Although combination chemotherapy and new endocrine agents have improved the 
therapeutic beneflt for breast cancer patients in the past decades, a plateau in response 
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rates, duration of response and survival has been reached, and no further 
improvements can be expected with the standard treatment schemes. Extension of the 
pharmacopeia and enhanced knowledge about the mechanisms of response and 
resistance of tumor cells to different kinds of therapy have led to investigations based 
on more basic knowledge. Interest arose in testing: 
a) endocrine stimulation of breast cancer followed by chemotherapy, because of the 
preclinically acquired knowledge that hormonal agents can recruit tumor cells into S-
phase and because proliferative cells are more sensitive for chemotherapy, 
b) frequently administered low-dose or chronic low-dose chemotherapy, to increase 
exposure time of tumor cells to cell cycle phase specific drugs, 
c) diminishing side-effects of chemotherapy by administering a low-dose per time 
period, without loss of efficacy, 
d) new analogues of chemotherapeutic drugs, 
e) combinations of growth-inhibiting endocrine agents, using the extended knowledge 
of hormonal growth regulation of breast cancer. 
It was the scope of this thesis to investigate some of these new strategies in breast 
cancer treatment. 
1.3.1 Combinations of growth-stimulating hormones and chemotherapy 
Lippman et al. were among the first to describe kinetic changes in breast cancer 
cells caused by estrogens and antiestrogens [38J. Tamoxifen decreased the 
incorporation of thymidine and resulted in a growth inhibition as compared to 
untreated controls. When the "growth-blockade" by tamoxifen was removed, DNA 
synthesis in these cells increased rapidly. It was suggested that tamoxifen had led to 
synchronization of the tumor cells, and estrogen rescue was suggested as the 
mechanism to explain the rapid increase in DNA synthesis after tamoxifen removal. 
Later on other investigators found that anti- hormones and pharmacologic 
concentrations of steroid- or peptide hormones could block hormone dependent breast 
cancer cells in the GoG,-phase of the cell cycle, thereby reducing the percentage of 
cells in the S- and G,M-phases of the cell cycle [39-4IJ. On the other hand, physiolo-
gic concentrations of hormones and several growth factors were fonnd to induce the 
semi-synchronous recmitment of a population of Go/G,-phase cells into the cell cycle 
(S/G,M-phase) and shorten the overall cell cycle time [38,42J.1t was hypothesized that 
recmitment of a population of Go/G,-phase breast cancer cells into the active phases 
of the tell cycle followed by cell cycle specific drugs might lead to an augmented 
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cytotoxic effect of such manipulation compared to unstimulated controls. In 1978 
Weichselbaum et al. were the first to describe an augmented cytotoxic effect of 1-{3-D 
arabinofuranosylcytosine, an S-phase specific dlUg, in hormone responsive MCF-7 
human breast cancer cells in vitro pretreated with 10.9 M 17{3 estradiol [43). Since 
then this concept of hormonal reclUitment has been addressed by several investigators. 
Pretreatment with estradiol or a combination of estradiol, insulin, EGF and 
dexamethasone enhanced the effect of several cytotoxic dlUgs in MCF-7 cells, and in 
primary breast tumor cells cultured in agar [44-46). The same results were found for 
estrogen pretreatment followed by cyclophosphamide in the hormone responsive MXT 
mouse mammary tumor, in vitro and in vivo [47-49) and for testosterone stimulation 
preceding chemotherapy in the androgen responsive Shionogi mammary carcinoma 
tumor in castrated mice [50). Results from these preclinical studies indicated that 
growth promotion could indeed result in an augmented cytotoxic effect of subsequent 
administered chemotherapy under certain experimental conditions. 
Several clinical trials have been performed using combinations of growth 
stimulating hormones and chemotherapy in metastatic and locally advanced breast 
cancer [9,51-62). The growth promoting hormones were used to create a higher 
proliferation index in the tumor, in order to make the cells more vulnerable to 
subsequent cytotoxic therapy. Some trials reported a high complete remission rate (up 
to 49%), or survival advantage [51-54), others did not find any benefit from hormonal 
reclUitment followed by chemotherapy [55-63). Furthermore, clinical investigations 
have shown that estrogen stimulation can enhance the labelling index in primary 
tumors [55), and a significant positive relationship was found between clinical 
regression after neo-adjuvant chemotherapy and pretreatment proliferative activity in 
primary breast cancer [64). However, in the various trials different treatment schemes 
have been used preventing clear conclusions about the value of growth promotion 
followed by chemotherapy. At present, we do not know which combinations and time 
intervals of the hormones and chemotherapy are most optimal. We investigated ill vitro 
(chapter 2-5) and ill vivo (chapter 6) the effects of hormonal manipulation followed by 
administration of chemotherapy. 
1.3.2 Freqllellf or chronic low-dose chemotherapy 
Weekly low-dose doxorubicin plus mitoxantrone 
Metastatic breast cancer is still all incurable disease. Therefore, for this stage of the 
disease the development of treatments which are effective and (relatively) well 
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tolerated is important for palliation. Recently acquired knowledge of the action of 
chemotherapeutic drugs on the cellular level, and of the influence of multidrug 
resistance and kinetic resistance on the efficacy of the drugs has led to the 
development of new schemes with the standard drugs. 
Doxorubicin is a major drug in cancer therapy, and nowadays one of the cornerstones 
of breast cancer therapy. Although the precise mechanism of antineoplastic action of 
doxorubicin is not fully understood, the drug can intercalate DNA and inhibit 
replication and transcription of DNA and inhibit DNA repair, inhibit topoisomerase 
II activity and affect regulation of gene expression and integrity and activity of cellular 
membranes [65-71). Furthermore the drug can be reduced to semiquinone free radicals 
by NADPH cytochrome p450 reductase [72-73). For many years doxorubicin has been 
the most effective drug as a single agent in the standard three-weekly schedules in the 
treatment of metastatic breast cancer with a 40% response rate in the fIrst line and 
about 20%-30% response in second-line therapy. Toxicity of the drug witll the higher 
dosed schemes however, is impressive in terms of induction of cytopenia, complete 
alopecia in all patients and frequent induction of nausea and emesis. The most 
important long-term side-effect is the cardiotoxicity. This cardiotoxicity is associated 
with lipid peroxydation of the membrane of myocardial cells by free radicals, and 
impairment of mitochondrial function such as disturbances in the intracellular calcium 
transport, depressed adenosine diphosphate-stimulated respiration and alterations of 
membrane structure and function [74-77). Therefore, application of a weekly low-dose 
schedule of doxorubicin might be attractive in order to decrease the occurrence and 
severity of side-effects WitilOut loss of efficacy [78-80). 
Mitoxantrone is an anthraquinone derivate of doxorubicin. The drug displays at 
least 3 modes of action: stabilization of the topoisomerase-DNA cleavable complex, 
aggregation and compaction of DNA via electrostatic cross-linking, and oxidative 
activation with free radical generation [81). The drug is active in breast cancer 
treatment, bnt in direct comparison with doxorubicin, it induces slightly lower 
response rates [81-83). However, mitoxantrone is less toxic as manifested in the 
frequency of alopecia, nausea/vomiting and mucositis [83,84). Mitoxantrone is also 
less cardiotoxic for the drugs produces few if any free radicals via the NADPH 
cytochrome P-450 reductase pathway nor via membrane lipid peroxidation [81). In 
weekly low-dose therapy the drug has shown responses in a small study in elderly 
patients [85J. Preclinical data suggested that mitoxantrone caused a concentration-
dependent inhibition of doxorubicin stimulated lipid peroxydation in liver microsomes 
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of rabbits [86]. Therefore, ia the study described ia chapter 7 we iavestigated the 
effects of weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy 
in metastatic breast cancer. 
Chronic low-dose etoposide 
Etoposide has been used in the treatment of various kinds of tumors, but has 
shown unsatisfactory activity in breast cancer when used in a short-term i.v. or oral 
(mostly day 1-5) schedule [87]. Etoposide is a podophyllotoxin derivate, and the drug 
exerts its action by inhibitiag the topoisomerase II ellZyme involved ia the process of 
unwinding and cleaving DNA during replication. Topoisomerase II expression 
iacreases in the S-phase and peaks in the late G,M-phase of the cell cycle, making 
etoposide a phase specific drug. Moreover, the binding of etoposide to the cleavable 
complex is rapidly reversible [88]. This makes the drug attractive for use in a 
prolonged administration scheme for slowly proliferatiag tumors like breast cancer. 
Furthermore the bioavailability of etoposide is high for low doses [89-91]. 
Etoposide has shown activity as a protracted low-dose oral scheme in several solid 
tumors, with acceptable toxicity [92-95]. Chapter 8 describes the results of a study 
with long-term low-dose oral admiaistration of etoposide as second-liae chemotherapy 
ia patients with metastatic breast cancer. 
1.3.3 New chemotherapeutic alla/ogues 
Carboplatia plus etoposide 
Cisplatin and cisplatin-based combination chemotherapy has shown significant 
effectiveness in breast cancer when used as first-line therapy [96]. However, because 
of its toxicity and relative inconvenience of administration, cisplatia has not become 
standard therapy in breast cancer. The advent of cisplatia analogues with less 
nephrotoxicity and the feasibility of administration in the outpatient settiag has offered 
new possibilities for this class of drugs. 
Like cisplatin, carboplatia forms DNA-DNA iaterstrand- as well as DNA-proteiacross 
links [97]. Also nuclear protein phosphorylation has been described ia rat tissues, and 
the drug may form iatrastrand DNA cross links [97]. 
Monotherapy with carboplatia or combinations of carboplatin with etoposide, or 
fluorouracil, have been used mainly as second-liae chemotherapy ia metastatic breast 
cancer, and have shown low response rates of less than 20 % objective responses [98-
100]. Little is known about the efficacy and toxicity of a combiaation of carboplatin 
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and etoposide as first-line chemotherapy in breast cancer. In chapter 9 we describe the 
results of a phase II study with the combination of carboplatin and etoposide as flrst-
line therapy in metastatic breast cancer. 
Epirubicin 
Epirubicin is the 4'epimer of doxorubicin and differs only from the mother 
componnd by the 4' -hydroxyl group in the equatorial rather than the axial orientation. 
The mechanism of antitumor activity of epirubicin is comparable to that of 
doxorubicin. However, due to this steric modification there are several biochemical 
differences compared to doxorubicin: a) the DNA-epirubicin complex is less stable, 
b) influx of epirubicin into tumor cells is faster but retention is lower, c) the ability 
of the epirubicin-iron complex to peroxidize lipids is lower, and the epirubicin 
coordination complex with metal ions is different from that of doxorubicin [101]. It 
can be expected that these alterations in biochemistry may result in a different toxicity 
profile of epirubicin compared to doxorubicin. In the first clinical trials it was 
suggested that use of epirubicin might result in an antitumor efficacy comparable to 
that of doxorubicin, but would induce less myelo- and cardio-toxicity [102,103]. There 
are however only a few studies comparing directly both drugs in an equimolar or 
equimyelotoxic dose [104]. The results of these (mostly smaller) studies are 
conflicting. No significant differences in response rates were found between the two 
drugs when administered in an equimolar dose, nor in an expected equimyelotoxic 
dose. In the latter trials the dose of epirubicin ranged from 1.4 to 1.5 times the dose 
of doxorubicin. When equimolar doses of epirubicin and doxorubicin were used in 
combination treatment with cyclophoshamide and fluorouracil no statistical differences 
in response rates or survival were observed between the two drugs, but the epirubicin 
combination resulted in less myelosuppression and acute gastrointestinal toxicity, and 
less cardiac effects when similar cumulative doses were given. The EORTC Breast 
Cancer Cooperative Group performed the largest study directly comparing both 
anthracyclines on an expected equimyelotoxic base. Results of this study are shown 
in chapter 10. 
1.3.4 Combinations of growth-inhibiting liormonal therapy 
Successfully combining tlVO or more hormonal agents remains theoretically and 
practically an important challenge [105]. Standard endocrine therapy usually employs 
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antisteroidal agents to inhibit estrogen stimulation of tumor growth [5]. However, 
otber steroid and peptide hormones are also important in breast development and 
function [Table III] [23,106]. Recent preclinical research has shown that in addition 
to estradiol insulin-like growth factors (IGF-I and IGF-2) are potent stimnlators of 
breast cancer growth in vitro [107,108]. In vivo the pituitary-derived growth hormone 
regulates the secretion ofIGF-1 by the liver and otber tissues. 
A new approach in breast cancer treatment is manipulation of the hypothalamic-
pituitary function to inhibit prolactin and growth hormone secretion. Single agent 
treatment of metastatic breast cancer with dopamine agonists (inhibitors of prolactin 
secretion) or with somatostatin (growth hormone release inhibiting hormOJle) 
analogues, however, has shown only moderate benefit [22,109-113]. An explanation 
for this lack of success of single agent dopamine agonists can be the fact that, in 
humans, growtb hormone also acts as a potent ligand for the lactogenic receptor [114-
119]. Furthermore, estrogens can counteract the growth inhibitory effects of dopamine 
agonists or somatostatin (analogues) [120,121]. Therefore, and in view of the 
observations that somatostatin analogues can a)decrease growth hormone and IGF-l 
secretion, b)inhibit human tumor ceIl growth in vitro and in animal models directly 
when somatostatin receptors are present, and because 40-75 % of the primary breast 
cancers are somatostatin receptor positive [122-126], clinical treatment with a 
combination of a somatostatin analogue and an antiprolactin might be more 
worthwhile. Results of this combined treatment thus far published show a low response 
rate in heavily pretreated patients [21,127-129]. However, the most attractive 
combination for the treatment of breast cancer might be the combination of an 
antisteroidal agent with a somatostatin analogue and an antiprolactin. In chapter II of 
this thesis the clinical implications and endocrine effects of such combination treatment 
in post-menopausal metastatic breast cancer are investigated. 
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ABSTRACT 
The cytotoxic effect of doxorubicin on human breast cancer cells (MCF-7) 
appeared to be correlated with drug concentration, exposure time and cellular uptake 
of doxorubicin. The effects of short-term stimulation of the growth of MCF-7 cells 
with 30 pM oestradiol was investigated with respect to the uptake of doxorubicin and 
cell kill. Culture of MCF-7 cells in steroid hormone-deprived medium resulted in an 
approx. 90% arrest of the cells in the GOGI-phase of the cell cycle. Growth 
stimulation with 30 pM oestradiol caused a 3-5-fold increase in the number of cells 
in S-G2M phase at between 18 and 24 h after administration of oestradiol to the 
medium. Incubation of oestradiol-stimulated cells with 0.37 I'M doxorubicin during 
both I and 6 h resulted in an augmented inhibition of cell growth compared to 
unstimulated controls. An enhanced cellular uptake of doxorubicin after administration 
of oestradiol was observed only after an incubation period of 6 h and not of I h. 
These observations suggest that both an increased sensitivity to doxorubicin and an 
augmented cellular uptake of the drug may underlie the cytotoxic effects of 
doxorubicin after pretreatment with oestradiol. 
INTRODUCTION 
In the past 10-15 years combination chemotherapy as well as treatment with new 
(anti-)steroidal agents have improved the therapeutic benefit for breast cancer patients 
[1,2). However, for several years a plateau phase has been reached with respect to 
response rate, duration of response and survival. At its best hormonal treatment or 
chemotherapy can reach a maximal response rate of 50-75 % in (subgroups of) patients 
with metastatic breast cancer, with a mean duration of response of about 12 or 8 
months respectively. Combination therapy with cytostatics and growth inhibitory 
hormones may cause a modest improvement in treatment results compared to single 
treatment modalities, especially in postmenopausal patients with steroid receptor 
positive tumours [3-6). However, response rates generally do not surpass 75%, and 
the results of different studies are conflicting. Treatment with growth inhibitory 
hormones can even decrease the efficacy of chemotherapy in subgroups of patients [4). 
Growth inhibitory hormones can interfere with the action of cytostatic drugs indirectly 
by influencing drug metabolism and immune function, and directly by influencing 
cellular uptake of cytostatic drugs or cell kinetics [7). One of the reasons for treatment 
failure could be the apparently high proportion of tumour cells in the resting phase of 
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the cell cycle, in which phase cells are generally less sensitive to chemotherapeutic 
agents [7,8]. 
A new approach in the treatment of breast cancer patients involves short-term 
stinmlation of tumour cell growth to improve the therapeutic ratio of cytotoxic agents 
[7,9]. Oestradiol and some other hormones and growth factors can induce reclUitment 
of quiescent cells into the proliferative phase of the cell cycle, causing cells to be more 
vulnerable to subsequent administration of cytotoxic agents [10,11]. The results of 
different experinlental studies have shown that pretreatment of tumour cells with 
physiological and low pharmacological dosages of oestrogens can enhance the 
cytotoxic effect of chemotherapeutic agents ill vitro [7,9-11]. 
The flrst clinical studies involving such hormonal manipulation showed an 
inIprovement in the percentage of complete remissions and/or survival [12-15], while 
in only a few small studies no beneflt of oestrogen reclUitment with subsequent 
chemotherapy has been reported [16,17]. However, the points most open to discussion 
are the following: (a) the inIportance of cell synchronization using tamoxifen prior to 
stinIulation of tumour cells; (b) the choice of the growth stinIulatory agents to be used 
in addition to oestrogens (if necessary); (c) the optimal dosages of the growth stinIuli; 
and (d) the optinIal duration of the stinIulation period. Furthermore, at present very 
little is known on the effects of short-term hormonal stinIulation of tumour cells upon 
the degree of cellular uptake of cytostatic agents. 
Therefore, using human breast cancer (MCF-7) cells as an experimental mod,lwe 
have investigated the effects of pretreatulent of these cells with oestradiol on their 
uptake of dOxolUbicin and the subsequent tumour cell kill. This study shows the 
results of experinlents in which the effects of various tillIe periods of oestradiol 
stinmlation and doxorubicin incubation were investigated. 
MATERIALS AND METHODS 
Cell culture 
MCF-7 human breast cancer cells were originally obtained from EG&G Mason 
Research Institute, Worcester, U.S.A. in its 219th passage. Cells were routinely 
cultured in RPM! 1640 medium containing 5mg/l phenol red and supplemented with 
penicillin (100 units/ml), streptomycin (100 I'g/ml), insulin (10 I'g/ml) and 10% heat-
inactivated foetal calf selUm (Le. complete growth medium). Cultures were maintained 
at 37°C in a humidifled atmosphere of 5 % CO, in air and cells were passaged weekly. 
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For experiments, cells of exponentially growing cells in culture were harvested after 
incubation for 5 min at 37°C with 2 mJ of 0.25 % trypsin in Dulbecco's phosphate 
buffered saline, lacking Ca2+ and Mg2+ (DPBS). Subsequently, cells were seeded in 
T25 flasks (ca 10' cellslflask) in complete growth medium or in RPMI 1640 medium 
containing phenol red and supplemented with 10% steroid-depleted male human 
serum, penicillin (100 units/mJ) and streptomycin (100 "g/mJ) (i.e. experin,ental 
medium). Previous experillIents in our laboratory had shown only an approx. 10% 
stillIulation of growth by oestradiol, when cells were cultured in RPMI-1640 medium 
containing phenol red, supplemented with steroid-depleted foetal calf serum [18). 
Replacing the foetal calf serum by 10% steroid-depleted male human serum, as applied 
by Devleeschouwer et aI., revealed a 4-6-fold stillIulation of growth witlI already very 
low concentrations of oestradiol, 10-100 pM [19, 20). Doxorubicin as doxorubicin 
hydrochloridellactosum (in H20) and oestradiol (in ethanol) were added as indicated 
in the legends to the figures. Steroid depletion of male human serum was performed 
by two 45 min incubation at 50°C with 0.5% charcoal-0.05% dextran T-70 (w/v), 
with an intermediate 2 h incubation at 37°C with sulphatase (2 U/mJ). 
Estimation of cell survival following exposure to doxombicin 
Monolayer cultures were incubated for different tillIe periods (1-72 h) in tlIe 
absence and presence of doxorubicin at concentrations as indicated in the legends to 
the figures. Immediately after the incubation period the monolayer cells were washed 
with 0.15 M NaCI and supplied with drug-free complete growth medium. After daily 
medium refreshment, cells were harvested by trypsinization and cell number 
determined with a haemocytometer. 
Hormonalmanipulatioll and flow cytometer analysis 
Medium containing 30 pM oestradiol or the equivalent volume of tlIe solvent 
etlIanol (final ethanol concentration 0.025%) was added to MCF-7 cell cultures after 
6 days of incubation in steroid-deprived experillIentalmedium. At different tillIe points 
after oestradiol addition cells were harvested by trypsinization and pelleted by' 
centrifugation for 5 min at 100 g. Cells were subsequently resllspended in 150 "I PBS 
containing 0.01 mg/ml propidium iodide (PI), 1 mg/mJ ribonuclease A and 1 % Triton 
X-100. Incubation with PI was performed for 10 min at room temperature. After 
washing of the cells with 0.15 M NaCl, the PI fluorescence of the nuclei was 
determined witlI a Fluorescence Activated Cell Sorter (FACS 440, Becton and Dickinson). 
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Incubation with doxorubicill alld determillation of cellular doxorubicill colllellt 
Monolayer cells were incubated with different concentrations of doxorubicin, 
ranging from 0.037 to 37 I'M, as mentioned in the legends to the figures. At the 
indicated time points, cells of triplicate incubations were harvested by trypsinization 
and washed with 0.15 M NaCI. Cells from three TIS-flasks were used for the 
extraction of cellular anthracycline as previously described by Kokenberg et al. [21]. 
The other TIS-flasks of replicate cultures were used for the estimation of cell survival. 
Doxorubicin contents of cellular extracts were measured by high performance liquid 
chromatography (HPLC) according to a method adapted from Israel et al. [22]. The 
detection limit after extraction from biological fluid was 10 ng doxorubicin/m!. The 
metabolite doxorubicinol was detected. 
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Figure 1 
Survival of MCF-7 cells after incubation with doxorubicin. MCF-7 cells grown for 2 days in complete 
growth medium were incubated at 0 h in the absence (_) or presence of 0.037 (*). 0.37 (0), 3.7 (0). 
37(.) I'M doxorubicin. The incubation times with doxoruhicin were 1 (left panel), 24 (middle panel) 
and 72 It (right panel), At the indicated time points the number of cells in the flasks of triplicate 
cultures was determined. 
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Statistical analysis 
The significance of differences between the results obtained wifhfhe different 
incubation conditions was calculated using Wilcoxon's test. 
RESULTS 
The effects of drug cOllcellfratioll alld exposure time on cellular content of doxorubicin 
alld cell grolVth 
Exposure of MCF-7 human breast cancer cells ill vitro to different concentrations 
of doxorubicin results in a dose-dependent antiproliferative effect offhe drug (Fig. 1). 
Moreover, the antiproliterative effect in the sense of inhibition of cell growth or even 
decrease in cell number appeared not only to be correlated with the drug concentration 
of doxorubicin but also with the duration of exposure. In this respect, the cellular 
uptake of doxorubicin appeared positively correlated with both drug concentration and 
duration of exposure (Table I). 
EXTRACELLULAR 
DOX (I'M) 
Table 1 
0.037 
0.37 
3.7 
37 
CELLULAR DOX 
(p moIlIO' cells ± SD) 
DOX (lh) DOX (24h) 
85 48 
(± 32) (± 9) 
330 565 
(± 103) (± 56) 
3486 7694 
(± 2333) (± 1747) 
7378 41066 
(± 2116) (± 6108) 
The effects of the drug concentration in medium and drug exposure time on cellular content of 
doxorubicin (DOX). Monolayer cells were incubated with doxorubicin (0.037, 0.37,3.7 and 37 ,uM) 
for 1 and 24 h. The cellular uptake of the drug was measured by HPLC. 
At the lowest extracellular concentration of doxorubicin (0.037 I'M) there was no 
significant difference between cellular uptake after 1 and 24 h of incubation. The 
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absence of an expected increased uptake after 24 h might be caused by the fact that 
such low concentrations were at the lower limits of detection. 
With respect to growth inhibition, long-term incnbation with the lower dosages of 
doxorubicin was as efficient as short-term exposures with 10 times higher dosages 
(Fig. 1). 
Effects of oestradiol all cell cycle 
Incubation of resting MCF-7 cell cultures with a low concentration of oestradiol 
($0 pM) resulted in an increase in the number of actively proliferating cells, as 
measured by PI-fluorescence with flow cytometry (Fig. 2). 
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Figure 2 
Effect of oestradiol on cell cycle distribution. MCF-7 cells were cultured for 6 days in steroid 
hormone-deprived experimental medium. Cell cycle distribution, measured by PI-fluorescence, is 
plotted for control cultures and cultures stimulated with oestradiol for 24 h. The percentage of cells 
in the S-G2M-phase was calculated from the areas of the peaks as depicted in this figure. 
The maximal increase in the number of cells in S-G2M phase was found to occur 24 
h after the oestradiol pulse (Fig. 3). This fraction increased in this time period from 
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approx. 20 to 50% (Fig. 3), while in the control group only 10% of the cells in the 
S-G2M phase of the cell cycle were observed at 24 h. 
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Figure 3 
Kinetics of the oestradiol effect on cell cycle distribution. MCF-7 ceJls were cultured for 6 days in 
steroid hormone-deprived experimental medium. At the indicated time points the percentage of cells 
in S·G2M-phase, deternuned by flow cytometry, is plotted for the oestradiol (30pM) stimulated and 
unstimulated cultures. 
Effect of oestradiol 011 cellular doxombicill uptake alld tUlIlour cell growth 
Pretreatment of MCF-7 tumour cells with 30 pM oestradiol caused a significantly 
(P < 0.05) higher cellular uptake of doxorubicin (259 ± 11 pmoll106 cells; mean ± 
S.D., n=3), when incubated with 0.37 I'M doxorubicin during 6 h (Fig.4) and 
compared to unstimulated cells (177 ± 16 pmoll106 cells; mean ± S.D., n=3). Such 
an increased cellular uptake of doxorubicin was not found after an incubation period 
of 1 h (94 ± 2 vs, 94 ± 8 pmoll106 cells; mean ± S.D., n=2). However, with 
respect to cell growth, pretreatment with oestradiol appeared to enhance the cytotoxic 
efficacy of doxorubicin (0.37I'M) both during 1- and 6- h incubations (Fig. 5). It has 
to be noted that a net decrease in cell number caused by doxorubicin was observed not 
prior than 72 h after an incubation period of 6 hours with the drug (Fig. 5). 
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Figure 4 
Effect of oestradiol pretreatment on the cellular uptake of doxombicin. Cellular doxorubicin content 
was measured by HPLC after 1 and 6 h incubation with doxorubicin (0.37 ,uM) in oestradiol (30 pM) 
stimulated (+) and unstimulated (-) control cultures. The 6 h incubation with doxorubicin started 19 
h after the administration of oestradiol. The 1 h incubation started 24 h after oestradiol stimulation. 
DISCUSSION 
Chemotherapy of metastatic breast cancer has currently reached a plateau in 
therapeutic results with response rates in the range of 50-75% [1,2). Moreover, in 
early breast cancer adjuvant therapy mostly fails to accomplish cure [23). It seems 
therefore, that no further improvement can be expected from the currently used multi-
drug therapies alone [23,24). Even combined hormono-chemotherapy, which ~t its best 
results in an additive effect in subgroups of patients, causes an objective but only 
temporary response in approx. 75 % of the patients [3-6]. An explanation for the lack 
of cure and the temporary nature of the response in patients with metastatic disease 
may be found in the observation that, spontaneously or due to growth-inhibitory 
endocrine therapy, a significant proportion of the tumour cells are in the resting phase 
of the cell cycle. As a result, tumour cells display cytokinetic drug resistance even to 
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high dosages of chemotherapeutic agents. Most of these agents, including doxorubicin, 
7 7 
DOX 611 
6 6 
5 5 
'" co 
-'5 4 4 
'" W <D 
~= 
=> 
z 
--' 
--' 3 3 w 
u 
2 2 
o ..L-,.-,---r---r a ..L-,,--r---,-
1 24 n 1 &8 6 24 72 120 
T I ME AfTER START OF OOXORUB I C I N I NCUBA TI ON (lj) 
Figure 5 
Effect of oestradiol pretreatment on the cytotoxicity of doxorubicin. After oestradiol (30 pM) 
stimulation and incubation with 0.37 pM doxorubicin during 1 and 6 h as indicated in Fig 4, replicate 
cultures were washed and drug~free complete growth medium was added to the flasks. At the 
indicated time points the number of cells in the flasks was determined and growth curves plotted. In 
the left panel it is shown that after 168 h, growth inhibition by a I-b incubation with 0.37 IlM 
doxorubicin is significantly higher when the cultures are pretreated with oestradiol (1.7 ± 0.14 x 106 
cells vs 2.93 ± 0.13 x 10 6 cells, mean ± S.D., n =3) (P<O.OS). In the right panel the decrease 
in cell number 120 II after a 6 II incubation with doxorubicin is significantly higher in the cultures 
pretreated with oestradiol (0.20 ± 0.02 x 10' cells vs 0.49 ± 0.04 x 10' cells; mean ± S.D., n=3) 
CP<O.05). [Control plus oestradiol Co), control without oestradiol Ce), doxorubicin plus oestradiol 
stimulation Co), doxorubicin without oestradiol stimulation C-). 
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are primarily effective on proliferating cells. In agreement with these ftndings are the 
results of a study of Sulkes et al [25), which show that slowly growing primary breast 
caucers with a low labelling index (LI) are not or less sensitive to chemotherapy as 
compared to tumours with a high LI. Recently, it has been shown that growth-
stimulatory hormones (such as oestrogens) can increase the cell sensitivity to cytotoxic 
chemotherapy by increasing the number of actively proliferating cells in these tumours 
[10,11). Several clinical studies, in which tlle effects of oestrogen 'rescue' or 
recruitment of tumour cells in the treatment schedule were investigated, show high 
complete response rates and sometimes an increase in overall survival [12,15). There 
are also a few reported studies in which no signiftcant beneftt of this treatment 
modality was found [16,17). NeverUJeless, the results of these studies are difftcult to 
compare because of a great variation in treatment schedules. These differences involve 
the dose and the choice of chemotherapeutic agents and oestrogens, the use of 
tamoxifen, the way and duration of treatment, and time scheduling of the drug used. 
At present the optimal treatment protocol is unknown. 
The results of our study suggest that for optimal cell kill the time interval between 
administration of oestrogens and doxorubicin should be around 18-24 h, as shown by 
an increase in the number of proliferating cells from about 10-20% to 50-60% in 
several experiments. Pretreatment of human breast cancer cells with oestradiol from 
19-24 h before administration of doxorubicin results in increased cytotoxic efftcacy of 
the drug. This is the ftrst report showing that pretreatment with a physiological dose 
of oestradiol can increase the cellular uptake of doxorubicin. Inhibition of cell growth 
appeared to be correlated with the cellular content of doxorubicin. Moreover, 
pretreatment Witll oestradiol increased cytotoxicity also after short-term (1 h) 
incubation with doxorubicin WitllOut enhanced cellular uptake of the drug. These 
observations suggest that both an increased sensitivity to doxorubicin and an 
augmented cellular uptake of the drug may underlie the present cytotoxic effects of 
doxorubicin. 
Apart from the time of administration, the dose of oestradiol probably is also 
important in view of the fmding that pharmacological dosages (10-', 1O-'M) caused 
reduced cellular uptake and antimetabolic effects of methotrexate and nevertheless 
resulted in reduced cell growth. Thus, short-term pretreatment with a pharmacological 
dose of oestradiol may indeed enhance drug sensitivity of tumour cells, but it may 
possibly prevent additioual beneftcial effects by increased cellular uptake of cytotoxic 
drugs as observed after pretreatment of cells with physiological dosages of oestradiol. 
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However, the oestradiol-stimulated drug uptake may only affect the uptake of specific 
cytotoxic drugs, such as doxorubicin. OOler drugs may even show a decreased uptake 
resulting form effects of oestradiol on drug transport via the cell membrane [26]. 
In conclusion, our study shows that the optimal interval between the start of 
pretreatment with oestradiol and administration of doxorubicin is 18-24 h. During this 
period a 3-5-fold increase in the number of proliferating MCF-7 cells was observed. 
Cells showed a higher uptake of doxorubici.n and an increased sensitivity to 
doxorubicin, which resulted in increased cell kill. Combined treatment with specific 
hormones and growth factors can improve .the cytotoxic ratio of doxorubicin [11]. 
Therefore, further studies should focus on combinations of hormones and growth 
factors with respect to recruitment of resting cells prior to chemotherapy. 
Acknowledgements 
The authors would like to thank Mrs E. Mooi-Kokenberg and Mr K. van der Stuyt for 
their assistance, Mrs A. Sugiarsi and Mrs M.J. Slotboom for their secretarial help, 
and J. Marselje for preparing the prints. This work was supported by grant RRTI 87-
11 from The Dutch Cancer Society 'Koningin Wilhelmina Fonds'. 
REFERENCES 
1. Henderson IG, Hayes DF, Come S, Harris JR and Canellos G. New agents and 
new medical treatments for advanced breast cancer. Semin Onco11987; 14: 34-64. 
2. Williams CJ. Choosing systemic therapy for metastatic breast cancer. Rev 
Endocrine Rei Cancer 1985; 20: 19-26. 
3. Mouridsen HT, Rose C, Engelsman E, Sylvester Rand Rotmensz N. Combined 
cytotoxic and endocrine therapy in postmenopausal patients with advanced breast 
cancer. A randomized study of CMF versus CMF plus tamoxifen. Eur J Cancer 
Clin Oncol 1985; 21: 291-299. 
4. Fisher B, Redmond C, Brown A et al. Adjuvant chemotherapy with and without 
tamoxifen in the treatment of primary breast cancer: 5 years results from the 
national surgical adjuvant breast and bowel project trial. J Clin Oncol 1986; 4: 
459-471. 
5. Coconni G, De lisi V, Bani C et al. Chemotherapy versus combination of 
chemotherapy and endocrine therapy in advanced breast cancer. A prospective 
randomized study. Cancer 1983; 51: 581-588. 
6. Kiang DT, Gay J, Goldman A, and Kennedy BJ. A randomized trial of 
chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 
1985; 313: 1241-1246. 
40 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
Chapter 2 
Osborne CK. Hormonal manipulation of tumour cells in combination with 
chemotherapy. In: Klijn JGM, Paridaens R, Foekens JA, eds. Hormonal 
Manipulation of Cancer: Peptides, Growth Factors and New (Anti)steroidal Agents. 
EORTC Monograph Series, New York, Raven Press, 1987; vol 18, pp. 469-476. 
Tokita Nand Raju MR. Cell cycle dependent Adriamycin uptake in Chinese 
hamsters cells. Eur J Cancer Clin Oneal 1985; 21: 243-247. 
Weichselbaum RR, Hellman S, Piro AJ, Nove JJ and Little JB. Proliferation 
kinetics of a human breast cancer cell line in vitro following treatment with 17-{3-
estradiol and 1-{3-D-arabinofuranosylcytosine. Cancer Res 1978; 38: 2339-2342. 
Clarke R, Berg HW van der, Kennedy DJ and Murphy RF. Estrogen receptor 
status and the response of human breast cancer cell lines to a combination of 
methotrexate and 17-{3-oestradiol. Br J Cancer 1985; 51: 365-369. 
Hug V, Johnston D, Finders M and Hortobagyi G. Use of growth stimulatory 
hormones to improve the in vitro therapeutic index of doxorubicin for human 
breast tumors. Cancer Res 1986; 46: 147-152. 
Allegra JC. Methotrexate and 5-fluorouracil following tanlOxifen and premarin in 
advanced breast cancer. Semin Oneal 1983; 10: suppl 2, 23-28. 
Paridaens R, Blank van der Wijst J, Julien JP et al. Aminoglutethimide and 
estrogenic stinmlation before chemotherapy for treatment of advanced breast 
cancer. Preliminary results of a phase II study conducted by EORTC breast cancer 
cooperative group. J Steroid Biochem 1985; 23: 1181-1183. 
Conte PF, Pronzato P, Rubagotti A et al. Conventional versus cytokinetic 
polychemotherapy with estrogenic recruitment in metastatic breast cancer: results 
of a randomized cooperative trial. J Clin Oneal 1987; 5: 339-347. I 
Lippman ME, Cassidy J, Wesley M and Young RC. A randomized attempt to 
increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by 
hormonal synchronization. J Clin Oneal 1984; 2: 28-36. 
Lipton A, Santen RJ, Harvey HA et al. A randomized trial of aminoglutethimide 
± estrogen before chemotherapy in advanced breast cancer. Am J Clin Oneal 
(CCT) 1987; 10: 65-70. 
Eisenhower EA, Bowman D and Pritchard KI. Tamoxifen and conjugated estrogens 
(premarin) followed by sequenced methotrexate and 5-FU in refractory advanced 
breast cancer. Cancer Treat Rep 1984; 68: 1421-1422. 
Blankenstein MA, Henkelman MS and Klijn JGM. Direct inhibitory effect of a 
luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer 
cells. Eur J Cancer Clin Oneal 1985; 21: 1493-1499. 
Devleeschouwer N, Olea Serrano Nand Leclerq G. Influence of the nature of 
serum on the estrogen sensitivity of the MCF-7 breast cancer cell line. Ann New 
York Acad Sci 1986; 464: 493-495. 
Foekens JA, Henkehnan MS, Fukkink JF, Blankenstein MA and Klijn JGM. 
Combined effects of buserelin, estradiol and tamoxifen on the growth of MCF-7 
human breast cancer cells in vitro. Biochem. Biophys Res Commun 1986; 140: 
550-556. 
41 
Chapter 2 
21. Kokenberg E, Sonneveld P, Nooter K, Steuyt K van der and LOwenberg B. 
Quantitative evaluation of intracellular uptake of daunorubicin in acute myeloid 
leukemia: a method analysis. Cancer Chemother Pharmacol 1986; 17: 63-68. 
22. Israel M, Pegg WJ, Wilkinson PM, Garnick MB. Liquid chromatographic analysis 
of adriamycin and metabolites in biological fluids. J Liquid Chromatography 1978; 
6: 795-809. 
23. Consensus conference. Adjuvant chemotherapy for breast cancer. JAMA 1985; 
254: 3461-3463. 
24. Bonadonna G and Valagussa P. Adjuvant systemic therapy for resectable breast 
cancer. J Clin Oncol 1985; 3: 259-275. 
25. Sulkes A, Livingston RB and Murphy WK. Tritiated thymidine labelling index and 
response in human breast cancer. J Nat! Cancer Inst 1979, 62, 513-515. 
26. Clarke R, van den Berg HW, Kennedy DG and Murphy RF. Reduction of the anti-
metabolic and anti-proliferative effects of methotrexate by 17f3-oestradiol in a 
human breast carcinoma cell line, MDA-MB-436. Eur J Cancer Clin Oncol 1983; 
19: 19-24. 
42 
CHAPTER 3 
EFFECT OF HORMONAL MANIPULATION AND 
DOXORUBICIN ADMINISTRATION ON CELL CYCLE 
KINETICS OF HUMAN BREAST CANCER CELLS. 
M. BOllfellba[l, A.M. SielllVerts', l. G.M. Klijl/, H.A. Peters', 
H.L.J.M. Krijllell', P. SOlllleveld' alld l.A. Foekells'. 
'Department of Medical Oncology; 'Division of Endocrine Oncology (Biochemistry 
and Endocrinology), Rotterdam Cancer Institute (Dr Daniel den Hoed Klilliek), 
Rotterdam, The Netherlands; 'Department of Haematology, University IHospital 
Dijkzigt, Rotterdam, The Netherlands. 
British Journal of Cancer 1989; 60: 688-692 
Chapter 3 
SUMMARY 
Dual-parameter flow cytometry, following bromodeoxyuridine (BrdUrd) incorpora-
tion and propidium iodide (PI) uptake into DNA, was used to study the effect of 
oestradiol andlor insulin on cell cycle kinetics of human breast cancer cells ill vitro. 
After a lag-period of 6-12 h, an optimum in the percentage of S-phase cells was 
reached between 18 and 24 h after hormone administration. A 1 h pulse of oestradiol 
was as effective as the continuous presence of oestradiol in pushing the cells from 
quiescent growing cultures into the cell cycle. A 1 h pulse of insulin was less effective 
than continuous administration. The addition of doxorubicin resulted in an accumula-
tion of the cells in the late S/G,M-phases. It is concluded that dual-parameter flow 
cytometry allows accurate assessment of the effects of hormones and chemotherapy 
on the cell cycle. Therefore this method is very suitable for studying the interaction 
of hormones and chemotherapy on cell growth. 
INTRODUCTION 
Slowly proliferating tumours like breast cancer are in general less sensitive to the 
lethal effects of cytotoxic drugs than rapidly proliferating malignancies. One of the 
explanations for this relative insensitivity can be kinetic resistance [1). Growth 
stimulation of slowly growing breast tumour cells ill vitro, followed by cell cycle 
active chemotherapy, results in an augmented cytotoxic effect of the chemotherapeutic 
drug [2-5). This recruitment concept has been clinically applied with diverse results 
[6-10). However, little is known with respect to optimal conditions for selection and 
scheduling of growth stimuli and cytostatics. Studies using cell cultures may provide 
valuable information for designing future treatment protocols in line with the 
recruitment principle. These studies require an accurate method to determine the 
number of cells in the distinct phases of the cell cycle, the duration of the cell cycle 
and the effects of growth stimuli and chemotherapeutic agents thereon. A commonly 
used method to establish the DNA distribution in cells involves the uptake of 
propidium iodide (Pl). A major disadvantage of this rapid and reproducible method 
is that advanced mathematical models are needed to estimate approximately the 
percentages of the cells in the separate phases of the cell cycle. Moreover, after partial 
synchronisation of cells by growth arrest and subsequent stimulation, the amount of 
cells appearing in the early S-phase will remain undetected when using models based 
on a Gaussian distribution of cells. These disadvantages are circumvented by a dual-
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parameter flow cytometric method involving BrdUrd-incorporation and PI-uptake [11]. 
We have studied recruitment of growth-delayed MCF-7 human breast cancer cells into 
the cell cycle after oestradiol andlor insulin administration, and the cytokinetic effects 
of doxorubicin administration thereon. 
MATERIALS AND METHODS 
Cell culture 
The MCF-7 cell line was obtained from E. G. & G. Mason Research Institute 
(Worcester, MA, USA) in its 219th passage. Cells were grown in a humidified 
atmosphere of 5% CO, in air at 37°C in complete growth medium (RPMI-1640 
medium containing 5 p.g m!" phenol red, supplemented with 10% heat-inactivated (30 
min at 56°C) fetal calf serum (FCS), 100 U mI" penicillin, 100p.g mi" streptomycin, 
50 p.g mI" gentamycin and 10 p.g mI" porcine insulin. For experiments, loga-
rithmically growing cell cultures were trypsinised and seeded in T25-flasks at a density 
of 0.5 x 10' cells per flask, in experimental medium, i.e. RPMI-1640 medium, 
without phenol red and insulin, supplemented with antibiotics and 4.5 % steroid 
hormone .depleted FCS (obtained by treatment twice with 0.5% charcoal, 0.05% 
dextran T-70 (w/v) for 45 min at 50°C, and an intermediate 2 h incubation at 37°C 
with 2 U ml" of suI ph at as e). Cells were precultured for 2 days. Experimental medium 
without additions (control), or supplemented with 0.03, 0.5 or 1.0 nM oestradiol 
(Merck, Darmstadt, FRG) , 1.7 I'M porcine insulin (Organon BV, Oss, The 
Netherlands), or the combination of 1 nM oestradiol and 1.7 I'M insulin, was added 
to the cell cultures. Medium was renewed every day unless indicated otherwise in the 
legends to the figures. In experiments studying the effects of doxorubicin (Adriablasti-
na; Farrnitalia, Milan, Italy), medium containing 0.2 p.g 011-' doxorubicin + 1 nM 
oestradiol was added for 6 h to the cultures, which had been pretreated for 15 h with 
medium containing 1 nM oestradiol, i.e. the stimulated cultures. In the control groups 
the same procedure was used but without oestradiol addition. After two washes after 
doxorubicin incubation, the cells were allowed to continue growth in complete growth 
medium. Medium was renewed every 48 h. 
Cell harvest 
Thirty minutes before harvesting, BrdUrd (Serva, Heidelberg, FRG) was added to 
the monolayer cultures (final concentration of 10 I'M) and incubated at 37"C in 5 % 
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CO2 in air. Cells were washed twice with phosphate buffered saline (pBS), and were 
harvested by a 5 min incubation at 37°C with 0.5 mI trypsinlEDTA) 0.05/0.02%; 
Biochrom, Berlin) in 2 mI PBS, and addition of 1 ml trypsin iohibitor (0.1 mg mi"; 
Sigma, St. Louis, MO, USA) in PBS. All aliquot of the cell suspension was collected 
for cell count using a haemacytometer, and the remainder of the cells were pelleted 
at 100 g for 5 min, resuspended in 100 1'1 PBS, fixed for 30 min at O°C with 2 mI 
70% ethanol (-200C), and stored at -20°C before preparation for analysis by flow 
cytometry. 
FlolV cytometry 
Labellillg alld stailling procedure (allli-BrdUrd FITCIPJ) 
Fixed cells were pelleted for 5 min at 100 g, incubated with 2 mI of 4 M HCI for 
20 min at 18°C, and after centrifugation the nuclei were incubated for 10 min at O°C, 
in 0.5 mI 0.1 M phosphate buffer (pH 4.5), containing 0.1 mg mi" pepsin (Sigma, St. 
Louis, MO, USA). The nuclei were pelleted and washed with 2 mI 0.1 M borate 
buffer (pH 8.5). Following centrifugation the nuclei were incubated for 30 min at O°C 
with a 1:20 dilution of Anti-BrdU-FITC-conjugate (Becton & Dickinson, Mountain 
View, USA) in a final volume of 100 1'1 PBS containing 0.25% Tween-20, and 5% 
bovine serum albumin (BSA), spun down after addition of 2 mI 0.5% Tween-20 in 
PBS, and incubated for 10 min. at O°C ill 2 mI PBS containing 0.25% Tween-20 and 
10 I'g mi" PI. Pelleted nuclei were resuspended in 0.5-1.0 mI PBS containing 0.5% 
Tween-20 and were analysed by flow cytometry. 
Measuremelll of FITC- alld Pl-jluorescence 
The FITC- and PI-fluorescence of individual nuclei were measured using a Becton 
and Dickinson (Sumlyvale, CA, USA) fluorescence-activated cell sorter (FACS 440). 
In the FACS 440 system the nuclei traversed the light beam of a Spectra-Physics 5-W 
Argon laser tuned at 488 nm, 0.4 W. Emitted light passed a 560 nm dichroic beam 
splitter. Excitation and emission wavelengths of FITC and PI were 494/517 and 
540/625 nm, respectively. Green (FITC) fluorescence was measured through a 530/30-
nm band-pass ftlter and red (PI) fluorescence through a KV 550 cut-offftlter. Emitted 
light was registered at a photomultiplier. Signals were amplified linearly. The 
instrument was calibrated with 1.0 and 2.83 I'm diameter fluorescent standard beads 
(Polysciences Inc., Warrington, PA, USA). Cell debris was excluded from analysis 
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by elevating the threshold of the red fluorescence. The flow rate was set at 500-1000 
nuclei s·'. For each sample at least 10' cells were analysed. 
Data analysis was performed using a Hewlett Packard 68B system. PI-fluorescence 
was recorded as a histogram of fluorescence intensity. From this histogram the 
percentage of nuclei in the different phases of the cell cycle was estimated with 
graphical methods and a fitting method (SPIT) using mean fluorescence [12]. Cell 
cycle distribution after labeling with anti-BrdUrd FITC and PI was performed using 
the windowing technique. Windows were set around the regions of GoG/SfG2M-phase 
cells in the dot plots [12]. 
RESULTS 
The cell cycle distribution of MCF-7 cells in culture was established by analysis of 
DNA distribution using PI-uptake and by dual-parameter flow cytometry. The 
histogram obtained after PI-uptake in nuclei of MCF-7 cells 12 h after a 1 h pulse 
with 30 pM oestradiol is shown in Figure la. The CV of the GoG,-peak was 4.5 %. 
By dual-parameter flow cytometry it is shown that of the total amount of cells present 
in the S-phase (35%), a high proportion is actually in the early S-phase (Figure Ib), 
cells which were not detected when only PI-uptake was used. Analysis of the DNA 
histogram (Figure la) by graphical and a 'simple' fitted method to assess the 
percentage of S-phase cells resulted in an underestimation of the amount of cells in S-
phase. Depending on the methods used [12], 16-29% of the cells were observed in S-
phase. Even sophisticated mathematical programs will result in an underestimation of 
the amount of S-phase cells, because these cells are hidden under the GoG,-peak. 
Moreover, by analysis of DNA histograms obtained with PI-fluorescence only, no 
discrimination can be made between cells which are arrested in the S-phase and cells 
which are actively synthesising DNA. For reasons mentioned above, the PI-method 
is not appropriate to study accurately changes in cell cycle kinetics resulting from 
perturbation with cell cycle active cytotoxic agents. We have therefore applied the 
method of dual-parameter flow cytometry with PI-and Anti-BrdUrd FITC to study cell 
cycle kinetics of MCF-7 breast cancer cells and the effects of growth-stinlUlating 
hormones and doxorubicin thereon. 
Growth of MCF-7 cells which were seeded and maintained in medium deprived of 
steroid hormones was remarkably decreased. The amount of cells in the S-phase of the 
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cell cycle declines from 30-40% at the time of seeding to approximately 10-\5% at 
the start of the experiment, i.e. time point zero. Figure 2 shows by dot plots the wave 
A 
\. S 
Red fluorescence (DNA content) 
Red fluorescence (DNA content) 
Figure 1 
Cell cycle distribution of MCF-7 cells. Cells were harvested 12 h after a I h pulse with 30 pM 
oestradiol. R, Histogram of DNA, propidium iodide (PI) uptake, indicated by red fluorescence only. 
b, Dual-parameter flow cytometry with PI (x axis) and anti-BrdUrd FITC fluorescence (y axis). Cells 
in the marked area represent cells actively synthesising DNA, i.e. cells in S-phase. Black spot below 
the marked area on the left side represents GoGI-phase cells, and the black spot on the right side 
represents G2M-phase cells. The GoGI-peak in histogram a corresponds with the left black spot in b 
plus the ceJls in early S-phase lying in-line above this black spot. 
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Figure 2 
Cell cycle distribution of MCF-7 cells, measured by dual-parameter flow cytometry 6-36 h after start 
of stimulation with 1 oM oestradiol (E.J compared to controls. The left column shows a clear increase 
in cells in S-phase. especially 18-24 it after oestradiol administration. For detailed information see: 
the method section and the legend to Figure 1. 
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of cells going into S-phase after oestradiol administration. Figure 3a shows the kinetics 
of accumulation of cells in the S-phase as a result of stimulation (for up to 26 h) with 
1 nM oestradiol, 1.7 I'M insulin and the combination of both hormones. After a lag 
period of about 6-12 h (as also concluded from additional experiments, data not 
shown), the percentage of cells in the S-phase augments rapidly with an optimum 
between 18 and 24 h after addition of hormones. Stimulation with insulin minlics the 
pattern obtained by oestradiol treatment, whereas the combination of both hormones 
shows a minor (9%) but significant (Wilcoxon, 2p < 0.05) additional effect. 
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of S-phase cells (a), and growth of MCF-7 cell cultures (b), compared to controls. Medium was 
renewed daily, and hormones were present from time 0 up to 26 h. Data for both a and b are plotted 
as means ± s.d. of triplicate incubations. 
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However, this small additional effect regarding the percentage of cells in S-phase after 
24 h did not result in an increase of cell number after 72 h. The maximal increase in 
the percentage of cells in the S-phase occurred 24 h after start of stimulation. A 
decline in the percentage of S-phase cells was observed after 24 h. In subsequent 
experiments we observed that this decline occurred irrespective of a medium change 
2 h after reaching maximal stimulation. In cultures treated with oestradiol for 1 h (data 
not shown) or 26 h (Figure 3a), followed by incubation in the absence of oestradiol, 
a second wave of S-phase cells, starting after 36 h from time point zero, was 
observed. This second wave was not observed after preincubation with insulin only. 
Figure 3b shows the growth curves. Twenty-four hours after hormone addition the 
amount of cells per flask appeared identical in both the stimulated and the control 
groups. This implies that the increase in the percentage of cells in S-phase during this 
time period is due to recruitment of cells of these quiescent growing cultures into the 
cell cycle, and not to an increase in cell number due to a sUbpopulation of rapidly 
proliferating cells. The pattern (as shown in figure 3a for I nM oestradiol) and extent 
of stimulation were identical for lower dosages of oestradiol (0.03 and 0.5 nM used) 
(data not shown). In addition, a short 1 h pulse of 1 nM oestradiol resulted in a 
similar stimulatory effect after the pulse compared to the continuous presence of 
oestradiol (at 21 h, 60 vs 60%, and at 30 h, 38 vs 36% cells in S-phase). In contrast 
a 1 h pulse of insulin was not as effective as the continuous administration (Table I). 
In separate experinlents the effects of doxorubicin were studied. The presertce of 
doxorubicin during the last 6 h of a 21 h incubation with or without 1 nM oestradiol 
did not affect the amount of S-phase cells at 21 h (Table II). However, after the 
subsequent addition of complete growth medium at 21 h, the S-phase cells, in the 
doxorubicin treated cultures completely accumulated in the late S- and G,M-phases, 
measured 2 (Figure 4) and 5 days (Table II) later. After 5 days 59% of the oestradiol 
stinlUlated cells were accrued in tile late S/G,M-phases and 34% of the cells in the 
unstimulated controls. The accumulation of doxOlUbicin treated cells in the late 
S/G,M-phases of the cell cycle has also been described for lymphoblasts [13]. 
DISCUSSION 
Kinetic resistance can be one of the explanations why slowly growing tumours like 
breast cancer fail to respond to cytotoxic therapy [1]. Preclinical research has shown 
that growth of breast tumours can be accelerated by several hormones and growth 
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factors. Theoretically this growth stimulation can be used to recruit quiescent cells into 
the cell cycle, rendering them more vulnerable to the lethal effects of concomitant 
cytotoxic drugs. /11 vitro studies indicated that the combination of growth stimulation 
and cytotoxic therapy can lead to an enhanced cell kill in breast cancer [2-5]. 
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Effects of a 6 h incubation with doxorubicin on MCF-7 cells in S-phase (a) administered for the latter 
6 II of a 21 h stimulation period with oestradiol (left) compared to control (right), measured 
immediately after doxorubicin incubation. b shows accumulation of cells (black spot on the right in 
the figures) in the late SIGzM-phases 2 days after this 6 h incubation with doxorubicin. 
Several clinical studies already make use of this concept of recruitment. Most of the 
studies report a higher complete remission rate andlor a longer survival [6-9]. Little 
is known, however, about the optimal duration, scheduling and dosages of this 
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honnono-chemotherapy, and about the effect of this combined modality on cell cycle 
kinetics. 
In order to establish the magnitude of cytokinetic resistance in the treatment of 
breast cancer and to investigate optimal conditions to overcome this phenomenon, 
accurate measurement of changes in cell cycle kinetics due to therapy must be 
available. DNA histograms obtained with PI-fluorescence are widely used for the 
study of cell cycle kinetics. In this study we have shown that using this method the 
amount of (semi-) synchronised cells which appear in the early S-phase of the cell 
cycle after growth stimulation is underestimated when graphical or simple filling 
methods are used to establish the amount of S-phase cells. 
Table I Effect of time to exposure to oestradiol or insulin on percentage of cells 
in S-phase 
Cells in s-phase (%) 
Continous stimulation 1 h phase 
Additions at 21 h at 30 h at 21 h at 30 h 
Control 14 ± 1 16 ± 1 14 ± 1 15 ± 2 
Oestradiol (1 nM) 60 ± 1 36 ± 1 60 ± 4 38 ± 2 
Insulin (1. 7 I'M) 42 ± 7 29 ± 1 21 ± 1 18 ± 1 
MCF-7 cells were stimulated with hormones for 1 h or continously for 21 or 30 h, and were 
harvested at 21 or 30 h after start of hormone addition. Percentage of cells in S-phase was measured 
by dual-parameter flow cytometry. Data are the means ± s.d. of duplicate incubations. 
When there is a non-Gaussian distribution of cells in the S-phase, only very 
sophisticated mathematical methods can predict with some accuracy the amount of S-
phase cells from the histogram. 
Moreover, DNA histograms do not discrinlinate between cells arrested in S-phase and 
cells actively synthesising DNA. Dual-parameter flow cytometry can overcome these 
problems by a sharp discrinlination between the cells in the separate phases of the cell 
cycle. With the method of BrdUrd incorporation followed by anti-BrdUrd FITC 
incubation, cells exhibiting green fluorescence are cells in S-phase actively 
synthesising DNA. This method allows us: (i) to define the time period required for 
cells to appear in the early S-phase after growth-stimulation; (ii) to assess small diffe-
rences in the maximal percentages of cells in the S-phase after different treatment 
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modalities; (iii) to establish kinetic changes after cytotoxic treatment; and (iv) tb 
investigate changes in the duration of the different phases of the cell cycle after 
hormonal-chemotherapeutic perturbation. In this study we have shown that a 6 h 
incubation period with doxorubicin (O.21'g mr-') does not affect the percentage of cells 
in S-phase at the end of the doxorubicin incubation period. Recruitment of quiescent 
growing MCF-7 cells into the cell cycle was not blocked in these first 6 h. However, 
after 2 and 5 days all cells in S-phase have accumulated into the late SIG,M-phases 
in both oestrogen-stimulated and control groups. 
Table II Effect of doxorubicin incubation on the cell cycle distribution of MCF-7 
cells 
Additions 
Control 
Oestradiol (10M) 
Control + doxorubicin 
Oestradiol + doxorubicin 
Cells actively synthesising DNA (%) 
At the end of 
dox incubation 
25 ± 1 
57 ± 1 
25 ± 2 
57 ± 1 
5 days later 
27 ± 1 
15 ± 1 
6 ± 1 
(34 % late SIG,M) 
3 ± 1 
(59 % late SIG,M) 
MCF-7 cells were incubated with and without oestradiol (10M) for 21 h, and with and without 
doxorubicin (0.2 pg mI- I) for the last 6 It of this period. Cell cycle distribution was assessed at the 
end of doxorubicin incubation and 5 days later. Data are the means ± s.d. of duplicate incubations. 
In addition hardly any cells were synthesising DNA at these timepoints, indicating the 
absence of cells going from GoGc to S-phase. This suggests that doxorubicin in this 
concentration and for this incubation period blocks MCF-7 cells, not only in the late 
S/G,M-phases, but also in the GoG,-phase of the cell cycle. In view of the fact that 
cells in the G,M-phase are most sensitive to radiotherapy [14], treatment of cancer 
patients with doxorubicin followed by radiotherapy might be of clinical value. In 
conclusion, dual-parameter flow cytometry is a reliable method to investigate 
cytokinetic changes in perturbed cells. The method can be of help in designing the 
optimal timespan, dosages and combinations of growth factors and chemotherapeutic 
drugs, resulting in an optimal cytotoxic effect in the recruitment concept, with respect 
to the management of breast cancer. 
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SUMMARY 
III vitro exposure of estrogen-receptor negative (ER-) EVSA-T human breast 
cancer cells to insulin and/or estradiol had no effect on cell cycle distribution, in 
contrast to a 3 to 5-fold increase in the percentages of cells in the S-phase of the cell 
cycle in the ER + MCF-7 cell line. Estrogen pretreatment of MCF-7 cells followed 
by incubation with doxorubicin resulted in an augmented inhibition of cell growth 
compared to unstimulated controls. This delay in growth was accompanied by a 
decrease in the percentages of cells actively synthesizing DNA, and by an augmented 
percentage of cells exhibiting a G2M-amount of DNA at the end of a 6-9 days period 
of culture in complete growth medium. 
INTRODUCTION 
Anti-hormones decrease the growth fraction of hormone responsive breast tumors, 
leading to an accumulation of cells in the GoGr-phase of the cell cycle. This influence 
of auti-hormones on cell cycle kinetics could be one of the reasons of the 
disappointing results of combined endocrine- and chemotherapy, because most 
chemotherapeutic agents exert their effect mainly on cells in the S- and G2M-phases 
of the cell cycle. Even adverse effects of the combination of tamoxifen with 
chemotherapy have been reported in subsets of patients [I). 
In contrast to this growth inhibition, several hormones and growth factors are known 
to accelerate the growth of sloWly proliferating breast tumors, leading to the 
recruitment of a popUlation of quiescent or GoG,-phase cells into the S- and G2M-
phases of the cell cycle. Several clinical studies have already applied the principle of 
hormonal recruitment of breast cancer cells into the active phases of the cell cycle 
followed by chemotherapy [2-6). No uniform conclusions can be made yet due to a) 
the use of different therapeutic schemes; b) the possibility of inadequate recruitment 
due to incomplete reversion of the anti-estrogenic effect of tamoxifen, the 
synchronizing agent in several trials; c) the absence of proof of concealed recruitment 
in most of the studies. 
We investigated the following in the ER+ MCF-7 and the ER- EVSA-T breast cancer 
cell line: 
1) The effects of growth-promoting hormones and of doxorubicin on the kinetics of 
the tumor cells as measured by dual-parameter flow cytometry (Plianti-BrdUrd 
FITC). 
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2) The effects of estrogen pretreatment followed by incubation with doxorubicin on 
the growth of the cell cultures. 
MATERIALS AND METHODS 
Cell culture 
Culture conditions for both cell lines were identical to those described previously 
[7]. MCF-7 cells were maintained in RPMI-1640 medium containing 5 I'g/ml phenol 
red, supplemented with 10% heat -inactivated (30 min at 56·C) bovine calf serum 
(BCS) , 100 U/ml penicillin, 100 I'g/ml streptomycin, 50 I'g/ml gentamycin and 10 
I'g/ml porcine insulin. EVSA-T cells were maintained in HamlF12 DMEM medium 
containing 8.6 I'g/ml phenol red, supplemented with 5% heat-inactivated BCS, 
antibiotics and insulin. For experiments, logarithmical growing cell cultures were 
trypsinized and seeded in T25-flasks at a density of 0.5 x 10" cells per flask in 
experimental medium, i.e. RPMI-1640 or HamlF12 DMEM medium without phenol 
red and insulin, supplemented with antibiotics and 4.5 % (MCF-7) or 2.5 % (EVSA-T) 
steroid-hormone depleted fetal calf serum. Cells were precultured for 2' days. 
Experimental medium without additions (control) or supplemented with 1 oM estradiol 
(Merck, Darmstad FRG), 1.7 I'M insulin or the combination of both was successively 
added to the cell cultures for upto 24 h. In hormone-chemotherapy experiments MCF-
7 cell cultures pretreated with estradiol (10M) for 19 hours were incubated for 30 
minutes or 23 hours with experimental medium containing respectively 3 and 0.06 I'M 
doxorubicin (Adriablastina, Farmitalia, Milan, Italy). After the 23 hour incubation 
period with doxorubicin, cells were washed and cultured further in complete growth 
medium. After the 30 minutes doxorubicin incubation and washing, the cells were 
cultured for another 24 hour in experimental medium in the absence of doxorubicin, 
followed by culturing in complete growth medium. The cell number per flask was set 
at regular intervals, as indicated in the figures. 
Assessmelll of cell cycle distriblltioll by jlowcytometry 
Bromodeoxyuridine (BrdUrd, Serva, Heidelberg, FRG) at a final concentration 
of 10 oM, was added to the cultures 30 min before harvesting. After this incubation 
cells were washed twice and were harvested by a 5 min incubation at 37·C with 0.5 
mI trypsiniEDTA (0.05:0.02%; Biochrom, Berlin, FRG) in 2 ml PBS, and the 
addition of 1 ml trypsin inhibitor (0.1 mg/ml; Sigma St Louis, MO, USA) in PBS. An 
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aliquot of the cell suspension was collected for assessment of the cell number , nsing 
a hemocytometer. The remainder of these cells were stored in 2 ml of 70% ethanol 
(-20°C) before preparation for analysis by flow cytometry. The labeling- and staining 
procedures as well as the fluorescence measurement by flow cytometry were 
performed as described previously [7]. 
RESULTS 
We have previously shown that the addition of estradiol and/or insulin to the 
medium of slowly proliferating ER + MCF-7 cell cultures results, after a lag-period of 
6-12 h, in a rapid increase of the percentage of cells in the S-phase of the cell cycle. 
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Figure 1 
Effects of a 24 hour incubation with 1 oM estradiol (a), 1.7 I'M insulin (b). or a combination of both 
hormones (c) on the increase in the percentage of S-phase cells in MCF-7 and EVSA-T cells, 
compared to controls (x=controi: 0.01 % ethanol). Data are the means ± SD oftripJicate incubations. 
The maximum of this increase is reached 18-24 h after the addition of the hormones 
[7]. In the initial experiments of the present study, the effects of estradiol (1 nM), 
insulin (1.7 uM) or a combination of both were examined in the ER' EVSA-T cell 
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line. In Fig. 1, the effects of a 24 h incubation with estradiol and/or insulin on the 
percentages of cells in the S·phase of the cell cycle in EVSA-T cells are compared 
with the effects of the hormones in the MCF-7 cell line. Under steroid-hormone 
deprived cnlture conditions the EVSA-T cell line proliferates faster than the MCF-7 
cell line, and no growth-stinmlating effects of the hormones are observed in EVSA-T 
cells in contrast to the MCF-7 cells. 
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Figure 2 
Effects of a 19-h pretreatment with estradiol (l nM), followed by a 23-h incubation with doxorubicin 
(60 nM) (E,/dox: .01.) on the growth of MCF·7 cells, as compared to unstimulated cultures (dox:.) 
and (0 the control cultures not incubated with doxorubicin (with liz: .6., control without Ez: 0). Data 
are the means ± SD of triplicate incubations. 
The impact of estradiol pretreatment on the ultimate cytotoxicity of doxorubicin was 
investigated in subsequent experiments. MCF-7 cells were incubated with 1 nM 
estradiol 19 hours prior to incubation with doxorubicin. Doxorubicin was administered 
to the cultures at a low concentration (60 11M) for 23 h. or at a high concentration (3 
I'M) for 30 min. Figure 2 shows an example of growth of MCF-7 cells pretreated for 
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19 h. with or without I nM estradiol followed by a 23-h. incubation with 60 n¥ 
doxorubicin. 
Estradiol pretreatment resulted in au enhanced cytotoxic effect of doxorubicin, as can 
be seen in the much slower increase in cell number in these cultures from day 5 
onwards. 
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Figure 3 
Effects of a 19 h-pretreatment with estradiol (l oM). followed by a 30 min-incubation with 
doxorubicin (3 pM) (E,Idox: "'), on the growth of MCF-7 cells, as compared to unstimulated 
cultures (dox: .) and to control cultures not incubated with doxorubicin (with ~: .6., control without 
~: 0). Data are the means ± SD of triplicate incubations. 
The unstimulated cultures incubated with doxorubicin grew almost as rapidly in the 
presence of doxorubicin as the unstimulated control cultures. Fig. 3 shows the growth 
curves ofMCF-7 cells stimulated with I nM estradiol for 19 h. followed by incubation 
with doxorubicin (3 I'M) for 30 min. Growth in the unstimulated cultures is markedly 
retarded by doxorubicin compared with the cultures not incubated with doxorubicin, 
but there is nevertheless a small increase in cell number after 5 and 8 days of culture 
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inhibited in growth by doxorubicin. However, in the cultures pretreated with estradiol 
followed by doxorubicin even no increase in cell number is observed during this 
period. 
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Figure 4 
Effects of estradiol pretreatment followed by a 30 min-incubation with doxorubicin (3 p.M) on the cell 
cycle distribution of MCF-7 cells (E,/dox: A, dox: e). Data are the means ± SO of duplicate 
incubations. 
In addition to assessment of cell number as a result of hormono-chemotherapy, the cell 
cycle distribution was measured at the same time points as the cell counts were 
obtained. Fig. 4 shows the cell cycle distribution on days I to 8 from the experiment 
depicted in Fig. 3. A 30 min-incubation with doxorubicin has no immediate effect on 
the percentages of cells in the S-phase of the cell cycle both in the non-stimulated (18 
vs 20% S-phase cells) and estradiol-stimulated (46 vs 49% S-phase cells) cultures. 
Cells present in the S-phase directly after estrogen pretreatment and doxorubicin 
incubation (= day I in Fig. 4) accumulated in the (late S-) G,M-phase of the cell 
cycle at day 2, and remained there for the following days. 
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On the other hand when doxorubicin was administered in a low concentration for 23-
h, after or withont estradiol pretreatment (Fig. 2), accumulation of S-phase cells into 
the late S-G,M-phase was less pronounced (maximal amount of cells in the late S-
G,M-phase: 30%, data not shown). 
DISCUSSION 
Endocrine therapy and chemotherapy act in different ways, and possibly exert 
their effects on different tumor cell populations in heterogenous breast cancer. 
Therefore, combinations of growth inhibitory anti-hormones with chemotherapy are 
applied. However, the results of clinical trials are so far not spectacular and even 
conflicting results were obtained [I]. 
On the other hand, evidence was found that estrogens could promote the growth 
of (slowly proliferating) breast cancers. Weichselbaum et al. [8] used this principle of 
hormonal recruitment in MCF-7 cells, and showed that growth stimulation of MCF-7 
cells with 17 ~-estradiol resulted in a enhanced cytotoxic effect of successively 
administered I-~-D-arabinofuranosylcytosine, an S-phase specific chemotherapeutic 
drug. Our results show that estradiol andlor insulin can recruit hormone-responsive 
MCF-7 breast cancer cells into the proliferative phase of DNA-synthesis of the cell 
cycle, whereas no growth stimulation of the hormones was found in the ER EVSA-T 
cell line. When these growth-stimulated MCF-7 cells were incubated with doxorubicin 
at the moment that the highest percentages of S-phase cells were found, a significantly 
improved cytotoxic effect of doxorubicin was observed. Assessment of the cell cycle 
distribution, as a result of hormone-chemotherapeutic perturbation with the high 
doxorubicin concentration, shows that the percentage of cells actively synthesizing 
DNA drops rapidly in the cultures pretreated with estradiol. The drop in the 
percentage of S-phase cells is accompanied by a long-term accumulation of cells into 
the (late) S-and G,M-phases of the cell cycle, an effect which lasts at least until the 
end of the experiments. The lower concentration of doxorubicin, applied for a 
prolonged period, has a less pronounced effect on cell cycle distribution. 
These results support findings reported by several investigators. In ER + breast 
cancer cells a higher cytotoxic effect of chemotherapy after hormonal priming was 
observed [2,8-11]. Paridaens et al. [2] found a synergistic cytotoxic effect in the MXT 
mouse manUllary tumor when cyclophosphamide was administered 24 h, and not 48 
h, after estradiol pretreatment, whereas the synergistic effect was optimal when 
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estradiol was used in the dose that had led to the greatest mitogenic stimulation. This 
suggests that the improved cytotoxicity of cyclophosphamide on the tumor cells is due 
to recruitment of the cells into the active phases of the cell cycle, rather than to the 
simultaneous presence of both drugs in the cell. Epstein et al. [12-14) found that 
estrogen potentiates the cytotoxicity of VP-16 in the T-47D breast cancer cell line, not 
dependent upon cellular commitment to DNA synthesis, but by recruiting a clonogenic 
subpopulation characterized by increased topoisomerase II levels localized to an 
activated Gl-phase cell subset. On the other hand Shaikh et al. [15,16) reported a 
synergistic cytotoxic effect in MCF-7 cells pretreated for 48 hours with Dledroxyprog-
esterone acetate (MPA) followed by incubation with vincristine, methotrexate or 
doxorubicin. The concentration of MPA used in these experiments had little effect on 
cell cycle distribution. Even exposure to doxorubicin before MPA led to an additive, 
but not synergistic cytotoxic effect. Osborne et al. [17) described an improved 
cytotoxic effect on MCF-7 cells from the combination of tamoxifen pretreatment 
followed by administration of doxorubicin or hydroxy-cyclophosphamide but a 
decreased cytotoxic effect was found when tamoxifen was followed by melphalan or 
fluorouracil. This might be caused by effects of tamoxifen on the intracellular 
transport of these cytotoxic drugs. 
The results reported in most studies show that growth stimulation of slowly 
proliferative breast cancer with estradiol followed by chemotherapy seems worthwhile. 
Even specific combinations of anti-hormones and chemotherapy may be of interest. 
However, little is still known about the effects of combined- or sequential treatment 
of hormones and chemotherapy on tumor cells. Besides the kinetic implications of 
(anti-) hormones on breast cancer cells, combinations and sequences of (anti-) 
hormones and chemotherapy can lead to changes in: the fluidity of the cellular 
membrane, enzyme activation, drug-uptake and -metabolism, binding of drugs to 
molecular targets, or in the repair of drug-induced damage, all with possible 
consequences for the cytotoxicity. For clinical reasons it seems to be advisable not to 
combine both treatment modalities, outside coutrolled trials, until more of the 
mechanisms of action is revealed. 
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SUMMARY 
Kinetic resistance to cytotoxic drugs may account for the moderate responsiveness 
of breast cancer to chemotherapy. In the present study the ill vitro effects of estradiol-
mediated DNA stimulation on the cellular uptake of the DNA intercalating drug 
doxorubicin (DOX) were examined in MCF-7 human breast cancer cells. Using the 
fluorescent properties of the drug, the cellular uptake was investigated by high 
performance liquid chromatography (HPLC), and by flow cytometry. The uptake of 
OOX (0.01-2 I"g/ml) by MCF-7 cells in suspension, incubated for 1 and 6 h, showed 
a strong correlation between the incubation concentration of DOX and the cellular 
uptake of the drug as measured by HPLC and flow cytometry. Simultaneous exposure 
of MCF-7 cells, in monolayer culture, to DOX (0.04-0.2 I"g/ml) and estradiol (I nM) 
for 1-24 h showed no significant difference in uptake of the drug compared to control 
cultures exposed to OOX in the absence of estradiol. Neither was there a significant 
difference in uptake of DO X when MCF-7 cells were pretreated with estradiol (1 uM) 
for 16-24 h followed by a 0.5,1,6 and 21123 h incubation with DOX (0.01-2 I"g/ml). 
Pretreatment with estradiol did not affect the retention of DOX as measured 24 h after 
a 0.5 h incubation with DOX (2 I"g/ml). Furthermore, fluorescence microscopy 
revealed no difference in the cellular DOX distribution pattern of estradiol-stimulated 
MCF-7 cultures compared to unstimulated cultures. From this study we can conclude 
that, for the human MCF-7 breast cancer cells ill vitro, the uptake, retention, and 
cellular distribution of DOX is not influenced by estrogenic manipulation. 
INTRODUCTION 
OoxOlubicin (DOX) is a major drug in the treatment of breast cancer. Used as 
first-line single agent therapy, the drug induces a response in about 40% of the 
patients with disseminated breast cancer [1]. With multi-drug regimens containing 
DOX, response rates up to 60% can be achieved [1-3]. However, in spite of the 
promising results of multi-drug chemotherapy reginlens in adjuvant therapy, where 
curation can be achieved in a small subset of patients [4], responses in disseminated 
breast cancer are short term and few patients remain in a durable complete remission. 
The mechanism of action of OOX has been extensively studied in the past years, 
and it is the common view that the anti-tumor activity and most of the toxicities are 
the result of free radical formation and/or DNA intercalation, the latter resulting in 
inhibition of the activity of the topoisomerase II enzyme [5-7]. One of the major 
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problems of treatment with DOX is the intrinsic or acquired resistance of tumor cells 
to the drug. The P-glycoprotein-associated multidrug resistance, or MDR-I, is one of 
the mechanisms of resistance to cytotoxic agents that has been extensively studied in 
recent years [8-10). Several modifiers of MDR-I have emerged that have shown, ill 
vitro, to be able to restore cytotoxicity in resistant cells. It appeared that this recovery 
of cytotoxicity is accompanied by decreasing drug-efflux and increasing intracellular 
drug concentration, or by inducing redistribution of the drug from the cytoplasm to 
the nucleus [11-13). 
Because breast cancer is usually a slowly proliferating tumor with a low 
percentage of cells present in the S- and G2M-phase, kinetic resistance is another 
possible mechanism of resistance of tumor cells to DOX. Although not strictly phase 
specific, DOX exerts its main action on proliferating cells. We and otller investigators 
have shown, ill vitro, that quiescent growing human breast cancer can be pushed into 
the cell cycle, with an optimum in the percentage of S-phase cells (up to 60 %) 
between 18 and 24 h after hormone administration [14). These hormone manipulated 
cells appeared to be more vulnerable for the cytotoxic effects of subseq~ently 
administered chemotherapeutic drugs [15-18). Furthermore, also ill vivo Remvikos et 
at. found evidence of a positive relationship between the proliferative activity (high 
S-phase fraction) of breast cancer before treatment and the clinical regression after 
neoadjuvant chemotherapy [19). However, others could not confirm this observation 
[20). 
In this study we investigated whether the observed increase in cytotoxicity after 
hormonal manipUlation was accompanied by alterations in cellular uptake, retention 
and distribution pattern of DOX. We monitored, ill vitro, in the estrogen-receptor 
positive MCF-7 cell line, the effects of estradiol on the cellular uptake, retention and 
distribution pattern of DOX using high performance liquid chromatography, flow 
cytometry and fluorescence microscopy. 
MATERIALS AND METHODS 
Cell culture 
Culture conditions were identical to those described before [18). MCF-7 cells 
were maintained at 37°C in 5% CO2 in air in RPMI-1640 medium containing 21 mM 
4-(2-hydroxyethyl)-I-piperazineethanesulfonic acid (HEPES) and 51'g/ml phenol red, 
supplemented with 10% heat-inactivated (30 min at 56°) bovine calf serum (BCS), 10 
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ruM NaHCO" 100 U/m! penicillin, 100 Jlg/m! streptomycin, 45 Jlg/ml gentamicin, 2 
ruM glutamine and 10 Jlg/m! porcine insulin (growth medium). To compare 
measurement of DOX fluorescence by HPLC and flowcytometry, logarithmically 
growing cell cultures were trypsinized and 1 x 10' cells were suspended in 4 m! 
growth medium containing 0.01-2 Jlg/ml DOX (Adriablastina, Parmitalia, Milan, 
Italy). A cell sample without DOX was used in parallel incubations in order to 
measure endogenous fluorescence of the cells. The cells were incubated in the dark, 
in a shaking water bath at 37°C for 1 and 6 h. 
Por growth stimulation experiments cells were seeded in T2S-flasks at a density of 0.5 
x 10' cells per flask in 4 m! experimental medium, i.e. RPMI-I640 medium with 
HEPES but without phenol red and insulin, supplemented with antibiotics, glutamine, 
NaHCO" and 4.5% steroid-hormone-depleted fetal calf serum (DCC-PCS). DCC-PCS 
was obtained by treating PCS twice with 0.5% charcoal and 0.05% dextran T-70 
(w/v) for 45 min at 50° C and an intermediate incubation with 2 U/m! sulfatase for 2 
h at 37°C. Medium was renewed after 24 h. Twenty-four hours later 4 m! 
experimental medium supplemented with estradiol (1 uM) (Merck, Darmstad, PRG), 
or the vehicle alone (control), was added to the cells for up to 24 h. DOX was added 
to the cultures simultaneously with estradiol and control, or !6 - 24 h after the 
addition of estradiol and control. The duration of incubation with DOX as well as the 
incubation concentrations are indicated in the text or legends to the figures. 
Cell harvest 
DOX incubations were terminated by washing monolayer cultures and cells in 
suspension twice with phosphate buffered saline (PBS). Innnediately after incubation 
with OOX or 24 h later, in which case cells were refed for 24 h with drug-free 
hormone-depleted experimental culture medium, monolayer cultures were harvested 
by a 5 min incubation at room temperature with 0.5 ml trypsiniEDTA (0.05%/0.02 %; 
Biochrom, Berlin, PRG) in 2 m! PBS, followed by addition of 1 m! trypsin inhibitor 
(0.1 mg/m!; Sigma SI. Louis, MO, USA) in PBS. Cells incubated in suspension were 
centrifuged for 5 min at 100 g, whereafter DOX-containing medium was discarded. 
An aliquot of the cell suspension was collected for measurement of DOX fluorescence 
by flow cytometry and/or for determination of DOX distribution in the cell by 
fluorescence microscopy. The remainder of the cells was stored at _20°C until 
extraction of DOX and measurement of fluorescence by high performance liquid 
chromatography (HPLC) was performed. 
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The impact of washing and trypsinization on the DOX content of the monolayer 
cultures was investigated with estradiol-stimulated and control cultures. After a 4 h 
incubation with 0.2 I'g/ml DOX, cells were washed twice with icecold PBS and 
scraped from the flasks, or washed and trypsinized at room temperature. No difference 
in nptake of DOX in the cells, as measured with flowcytometry, was observed 
between both cell harvest procedures (data not shown). 
Measurement of DOX uptake by HPLC 
The method used to measure DOX uptake by the tumor cells is a modification 
from the method described by Israel et al. [21]. Borate buffer (200 1'1,0.5 M, pH 9.8) 
and 3 ml chloroform/methanol (4: I) were added to 1 ml of cell suspension (cell 
numbers were approximately the same in estradiol-stinmlated and control cultures) in 
a borosiliconized glass tube and shaken for 15 min. After centrifugation for 10 min 
at 1000 g, the lower organic layer was dried by vacuum centrifugation. Dried samples 
were reconstituted with 130-250 1'1 methanol and an aliquot of 100 1'1 was injected 
onto a reverse phase Bondapack Phenyl column (Waters Associates, Milford, USA), 
prepacked with 10 I'm particles in a 250 x 4.6 urnl stainless steel column, which was 
used for separation. The mobile phase consisted of (0.45 I'm filtered) 0.1 % 
ammonium-formate buffer, 70% acetonitrile (Baker Chemical Co., Jackson, USA) 
(70:30), pH 4.0. Anunonium-formate buffer was prepared by mixing 5 m1 
ammoniullthydroxide 20% (Baker Chemical Co., Jackson, USA) with 1000 ml H20 
(HPLC grade). The pH was set at 4.0 with formic acid 98% (Baker Chemical Co., 
Jackson, USA). The flow was set at 1.5 ml/min. Detection of DOX was accomplished 
at an excitation wavelength of 480 nm, using a Gilson Spectra-Glo fluorometer 
(Middkton, WI, USA). Retention tinles and areas of the peaks were recorded and 
integrated by a Shimadsu Model CR 3A integrator (United Technologies Packard, 
Delft, The Netherlands). Concentrations were quantified by using 4-deoxyrubicin as 
an internal standard. The detection limit after extraction from biological fluid was 10 
ng DOX/ml. The metabolite doxorubicinol was detected. 
Measurement of DOX uptake by jlowcytometry 
The DOX content of individual cells was measured with a Becton and Dickinson 
flow cytometer (Facscan), using a 15 mW argon-ion laser lightbeam tuned at 488 nm, 
which is close to the absorption maximum of DOX. At least 1 x 104 cells were 
analyzed from each sample. Data analysis was performed using the Facscan research 
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program of a Hewlett Packard 310 system. Fluorescent intensities were recorded with 
linear amplification. The value of the OOX uptake of a sample was obtained as the 
difference of the mean fluorescence intensity of the sample and the corresponding 
blanc sample. 
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Figure 1 
Correlation of DOX incubation concentrations and resulting cellular fluorescence as measured by 
HPLC (A) and flow-cytometry (B). MCF-7 cells (1 x 106/4 Ill!), in suspension were incubated for 1 
(0) and 6 h (e) with 0.01-2 pg/ml DOX at 37° C. Data of duplicate incubations are shown. 
Assessment of cellular disfribmioll of DOX 
For measurement of OOX distribution, cells pretreated with and without estradiol 
followed by incubation for 0.5-72 h with 0.2-1I'g/ml OOX were viewed with a Zeiss 
Axioskop (Carl Zeiss BV, Weesp, The Netherlands) fluorescence microscope equiped 
with a HBO 100 lamp (6 V, 20 W) and a 450 - 490 urn filter. Photographs were made 
after 2-5 min exposure time. 
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Statistics 
In 21 experiments with varying doses and duration of DOX exposure, DOX uptake 
was measured with and without estradiol pretreatment. The number of replications for 
each condition varied between 2 and 8. The mean DOX uptake was calculated for each 
experiment over the replication with and without estradiol pretreatment. Analysis of 
variance (ANOVA), adjusted for experiment, was applied to test for the effect of 
estradiol pretreatment on DOX uptake. 
RESULTS 
Comparison of HPLC alld j1owcytometry for measuring DOX uptake 
Measurement of DO X uptake by HPLC is time consuming, whereas measurement 
of fluorescence by flow cytometry is a much more simple method, but is said to be 
hampered by quenching. Therefore we compared both methods with MCF-7 cells 
exposed to a wide range of DOX concentrations. MCF-7 cells in suspension were 
incubated for 1 and 6 h with DOX concentrations ranging from 0.01-2 J'g/ml. The 
cellular fluorescence was measured by HPLC and flow cytometry. Figure 1 shows the 
relation between the incubation concentration of DOX and the uptake of the drug by 
the tumor cells as measured by HPLC (Fig. IA) and flowcytometry (Fig. IB). For 
both methods a strong correlation exists between the incubation concentration of DOX 
and the cellular uptake of the drug. 
Effect of simultaneous administration of estradiol and DOX on cellular DOX uptake 
To investigate whether simultaneous incubation of estradiol and DOX influences 
the uptake of the drug, MCF-7 cells growing in a monolayer culture in hormone-
deprived experimentalmediuIl1 for 48 h were exposed to 1 nM estradiol or the vehicle 
alone (control) and to 0.04-0.2J'g/ml DOX for a period of 1-24 h. In both hormone-
treated and control cultures no significant differences in the uptake of DOX were 
observed 'as measured by flowcytometry (Fig. 2) and HPLC (data not shown). 
Effect of estrogen pretreatmelll on the uptake of DOX 
In previous studies we showed that estradiol stimulation resulted after 18-24 h in 
an about 3 to 5-fold increase in the percentage of cells in the S-phase of the cell cycle 
[14]. In MCF-7 cells growing as a monolayer culture we investigated whether this 
stimulation resulted in changes in the cellular uptake of DOX. MCF-7 cells cultured 
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MCF-7 cells, ill monolayer culture, grown for 2 days in hormone-deprived culture medium were 
incubated for 1-24 h with estradiol (1 nM, open symbols) and DOX (0.04 [.:\] - 0.1 [oj - 0.2 [V] 
Itg/ml), or no estradiol and DOX (solid symbols), Mean cellular fluorescence was measured with 
flowcytometry. at regular time intervals as indicated in the figure. Data are the means of duplicate 
incubations ± S.D. 
in hormone-deprived experimental medium were incubated with 1 nM estradiol. After 
16-24 h cultures were exposed for 0.5, I, 6 or 21123 h, to different concentrations of 
DOX (2 I'glml for the 0.5 h, 0.1 and 0.2 I'glml for the 1 h, 0.2 I'glml for the 6 h, 
and 0.02 I'glml for the 21123 h incubations). In these 21 experiments the uptake of 
DOX in hormone-stimulated and control cells was measured by HPLC. Table 1 shows 
the mean uptake per experiment together with the number of replications and the 
standard deviations. A large variation in the DOX uptake was observed between 
experinlents. For all incubation periods and incubation concentrations of DOX tested, 
there is no significant difference in the uptake of the drug as a result of estradiol 
pretreatment (Fig. 3). The same results were found when cells were only stimulated 
76 
Chapter 5 
with estradiol for 1 h (followed by a 19 h culture period in hormone-deprived 
medium) followed by incubation with DOX (data not shown). 
Tahle 1: Uptake of DOX hy MCF-7 cells as measured by HPLC 
DOX uptake (ng/106 cells) 
Exp. DOX Duration Estradiol Not 
inc. conc. of DO X stimulated stimulated 
("g/m]) exposure (h) N (mean) (SD) (mean) (SD) 
A 2 0.5 2 119 1 102 12 
B 2 0.5 6 45 12 65 18 
C 2 0.5 6 75 14 66 10 
D 0.1 1 4 25 4 17 2 
E 0.2 1 • 4 64 10 26 2 
F 0.2 1 4 36 4 49 9 
G 0.2 1 4 52 14 54 12 
H 0.2 1 4 51 5 54 12 
I 0.2 1 3 31 3 25 5 
J 0.2 1 3 29 7 28 5 
K 0.2 6 3 93 13 81 10 
L 0.2 6 6 121 41 84 22 
M 0.2 6 4 179 23 271 59 
N 0.2 6 8 71 19 55 21 
0 0.2 6 6 176 76 155 62 
P 0.2 6 3 100 16 75 5 
Q 0.2 6 2 105 9 102 25 
R 0.2 6 6 289 54 236 63 
S 0.02 21 4 34 8 41 5 
T 0.02 23 4 23 4 33 10 
U 0.02 23 2 30 6 63 32 
N: number of incubations per experiment 
SD: standard deviation 
Effect of "ormonalmanipulation on cellular retention and distribution pattern of DOX 
Estradiol-mediated growth stimulation can result in an enhanced cytotoxicity of 
chemotherapy as we and other investigators have shown before [15-18]. To investigate 
whether cellular retention of DOX rather than a higher uptake of the dmg could 
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MCF~7 cells (0.5 x 106 cells) grown for 2 days in hormone-deprived culture medium, were stimulated 
with I nM estradiol for 16-24 h prior to incubation with DOX (2 ~g/ml for 0.5 h; 0.I10.2 ~g/ml for 
I h, 0.2 ~g/ml for 6 h; and 0.02 ~g/ml for 2I123 h). The uptake of DOX in the estradiol-stimulated 
and control cultures as measured by HPLC are shown with the letters depicting the code of 
experiment as described in Table 1. Data shown from 21 independent experiments with n=2 to n=8 
incubations per experiment. 
account for the improvement of cytotoxicity as we observed under certain experimental 
conditions, cellular uptake of DOX was measured by HPLC 24 h after a 0.5 h 
incnbation with DOX (2 ",g/ml). Uptake of DOX as measured immediately after 
incubation was 74.6 ± 14.2 ngllO' cells and 66.3 + 9.8 ngllO' cells in respectively 
estradiol-stimulated (n = 6) and control (n = 6) cultures. After 24 h, no differences 
in DOX content of the cells were found, estradiol pretreated cultures had retained 33.9 
± 10.7 ng DOXIlO' cells (n = 4) vs 35.8 ± 7.3 ng DOX/lO' cells (n = 4) in the 
control cnltures. 
DOX exerts its main effectivity as intercalating drug. Therefore we assessed the 
distribution pattern of the cellular fluorescence using a fluorescence microscope. 
MCF-7 cells growing in a monolayer culture and pretreated with and without 1 nM 
estradiol for 18 h were incubated for 0.5, 1, 3, 24, 48 and 72 h with 0.2-1 ",g/ml 
DOX. Under all conditions tested, fluorescence was mainly localized in the nucleus 
78 
Chapter 5 
of the cells. An example of the fluorescence of the cells pretreated with estradiol 
followed by iucubation with DOX (0.2 I'g/ml) for 3 h is shown iu Fig. 4. 
DISCUSSION 
Measurement of DOX fluorescence by HPLC is a reliable but time consumiug 
method. Analysis of the DOX content of cells by flowcytometry is a very elegant and 
simple method, but is said to be influenced by quenchiug when the drug is iutercalated 
in the DNA. Therefore we compared the DOX-associated fluorescence, as measured 
by flow cytometry, with the DOX call tent of breast cancer cells as measured by 
HPLC, using a wide range of DOX incubation concentrations. Like others [22) our 
data show a good correlation between the anthracycliue incubation concentration and 
the mean cellular fluorescence in the tumor cells as measured by both methods, 
whereas measurement of DO X fluorescence by HPLC has the advantage of quantifyiug 
DOX uptake. Compared to germ-cell tumors and hematological malignancies, which 
can be cured by chemotherapy, breast cancer is primarily relatively sensitive to the 
lethal effects of chemotherapeutic drugs, but development of drug-resistance iu the 
course of therapy is a major problem. From research iu the field of multidrug 
resistance we know that reversal of multidrug resistance with calcium-channel 
blockers, steroids, calmudoliu antagonists or cardiac agents, can be accompanied by 
an increased uptake of the cytotoxic drug as well as by a shift in iutracellular drug-
distribution from cytoplasmatic to nuclear localization [11-13). 
Kinetic resistance may also account for the moderate responsiveness of breast 
cancer to the cytotoxic effects of chemotherapy. Several authors described an 
iucreasing uptake of DOX progressively with cell cycle traverse, and an enhanced 
cytotoxic effect of chemotherapy on cells in the S-G,M phase of the cell cycle [23-25). 
This observation could explain the better cytotoxic effect of chemotherapy iu the 
rapidly proliferating tumors, containing a high percentage of cells in the S-phase of 
the cell cycle. 
We have previously shown that stimulation of hormone responsive MCF-7 human 
breast cancer cells ill vitro with estradiol, resulted in an iucrease iu the percentage of 
S-phase cells within 24 hours [14). When these stimulated cells were subsequently 
iucubated with DOX an enhanced cytotoxic effect of the drug was observed [18). 
Therefore we investigated iu this study whether treatment with estradiol and DOX was 
accompanied by an altered uptake, differences in retention or by a shift in iutracellular 
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drug distribution. In spite of a clear increase in the percentage of cells in S-phase due 
to a 16-24 h pretreatment with estradiol (the percentages of cells in S-phase ~ugmented 
between 2- and 6-fold due to this hormonal manipulation; data not shown), no 
significant increase in uptake of DOX in estradiol pretreated MCF-7 cells was found 
in 21 separate experiments using a 0.5, 1, 6, and 21123 h incubation with different 
concentrations of DOX. 
Figure 4 
MCF-7 cells grown for 2 days in hormone-deprived culture medium. were stimulated with 1 oM 
estradiol for 18 h prior to a 3 II incubation with DOX (0.2 ug/ml). The figure shows at the right side 
the light microscopic picture of Ihe cells and at the left side the cellular distribution of DOX. 
Photographs of fluorescent cells were made after 180 sec exposure time. Distribution of cellular 
fluorescence showed only nuclear fluorescence in both estradiol stimulated and control cultures. 
To investigate whether drug efflux could be influenced by estradiol pretreatment, the 
DOX concentration of the tumor cells was measured after another 24 hours of culture 
in hormone- and drug-free experimental medium. Again no differences in intracellular 
drug concentration were found in MCF-7 cells. 
Intracellular drug distribution was investigated using fluorescence microscopy. No 
difference in DOX distribution within the cells was observed due to hormonal 
manipulation. The flnorescence was predominantly localized in the nucleus of the 
cells. 
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Several other investigators have found an enhancement of the cytotoxic effect of 
chemotherapeutic drugs after growth stimulation of breast cancer cells in vitro [15-17]. 
However, it is clear from the work of Epstein et al. [26-28], Shaikh et al. [29,30], 
and Osborne et al. [31] that not only the stimulatory effect on DNA-synthesis by the 
hormones can be considered responsible for the enhancement of the cytotoxic effect 
of chemotherapy. Already minimal estradiol-mediated growth stimulation of T47D 
cells [26-28], or medroxyprogesterone acetate pretreatment of MCF-7 cells (without 
any effect on cell cycle distribution) [29,30] could enhance the cytotoxic effects of 
several chemotherapeutic drugs. Even tamoxifen pretreatment followed by doxorubicin 
or hydroxycyclophosphamide [31] resulted in an increased cell kill in MCF-7 cells, 
whereas tamoxifen followed by melphalan or fluorouracil resulted in the opposite 
effect. Therefore, mechanisms other than growth-stimulation may play a role to 
explain the augmented cytotoxic effect of some combinations of hormones and 
chemotherapy, for estrogen may even have an opposite effect. Estradiol is for instance 
also found to induce topoisomerase-II, the enzyme critical for replication, transcription 
and recombination of DNA [32], and in rat pituitary cells estradiol can induce the 
MDR resistance pump, leading to drug efflux [33], both mechanisms that can protect 
cancer cells from the lethal effect of chemotherapy. In contrast to our preliminary 
experiments using culture medium with male human sennn, from the present study 
(using culture medium with DCC-FCS) we have to conclude that simultaneous 
administration or pre-treatment of MCF-7 breast caucer cells with estradiol aud DOX 
has no influence on the uptake of DOX by the tumor cells, neither did we' fInd an 
enhanced retention of DOX due to estradiol stimulation, nor was there a difference in 
the localization of DOX in the tumor cells due to the hormonal manipUlation. 
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ABSTRACT 
Purpose: In this randomized phase III study the efficacy of estrogenic recruitment 
followed by chemotherapy was compared with the efficacy of chemotherapy alone as 
adjuvant treatment in resectable breast cancer. 
Patients and Methods: A total of 328 patients less than 66 years of age with stage 
IIIIIIA breast cancer were randomly allocated to FAC or FAC + EE, (ethinyl-
estradiol), irrespective of receptor status. FAC was given every 4 weeks for 4 cycles 
and consisted of 5-fluorouracil500 mg/m" doxorubicin 50 mg/m" cyclophosphamide 
500 mg/m2, Lv., day 1. In the recruitment arm FAC was preceded by 0.5 mg EE, 
given orally, both 24 hours and just before the chemotherapy. There were no 
significant differences regarding patient and tumor characteristics between the 
treatment arms. 
Results: From 318 evaluable patients, 124 showed a relapse and 70 patients have 
died after a median follow-up of 3.3 years. No significant differences between the two 
treatment groups were found with respect to relapse-free, local recurrence-free and 
overall survival both in univariate and in multivariate analysis adjusted for age, 
menopausal status, tumor size, number of positive nodes, grade and steroid receptor 
status. 
COl/clusion: Hormonal recruitment of breast cancer cells had no influence on the 
efficacy of subsequent chemotherapy with FAC compared to FAC alone in stage 
IIIIIIA breast cancer patients, after a relatively short follow-up. In view of the fact 
that slowly proliferative tumors might be more sensitive to this hormonal 
manipulation, longer follow-up is necessary for definite conclusions. 
INTRODUCTION 
Both adjuvant endocrine treatment and chemotherapy of primary breast cancer result 
in a significant improvement of disease-free and overall survival, but the absolute 
benefit is linlited. I New treatment modalities or new drug combinations are warranted 
to improve clinical treatment outcome. Combining anti-hormonal treatment with 
chemotherapy generally has led to no, or only very modest improvement in subgroups 
of patients. 
Experimental studies of our and other groups have shown that estrogens or other 
steroids can induce the semi-synchronous recruitment of a popnlation of quiescent 
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breast cancer cells into the cell cycle.2", The hormone-induced proliferation can make 
these cells more vulnerable for the cytotoxic effect of subsequent chemotherapy. 3.5·' 
Apart from the beneficial long-term effects of chemotherapy-induced castration it 
might be possible that in premenopausal women the relative good results of adjuvant 
chemotherapy can also partiy be explained by accidental natural hormonal prinling 
during some courses of chemotherapy, when the chemotherapy is administered after 
rising plasma estradiol levels during the menstrual cycle. Indirect clinical support for 
this hypothesis can be the observation of a negative interaction of the combination of 
the anti-estrogen tamoxifen with chemotherapy in premenopausal women. 10.11 
In a number of initial phase II studies in metastatic or locally advanced disease the 
application of prinling of tumor cells by estrogens appeared to be promising as shown 
by relatively high objective (65%-75%) and complete (22%-47%) response rates."·14 
Lippman et ai. 13 found also a longer duration of response with inlproved survival in 
subgroups of patients. Based on these (pre)clinical studies we initiated tWs early 
randomized adjuvant study, comparing the effects of 4 courses of chemotherapy with 
FAC (5-fluorouracil, doxorubicin, and cyclophophamide) with the same chemotherapy 
preceded by estrogenic recruitment in stage II and lIlA breast cancer patients. 
PATIENTS AND METHODS 
Eligibility criteria 
Women with prinlary resectable breast cancer, and at least one histologically 
verified positive axillary lymph node were eligible for this study if the following 
conditions were fulfilled: age < 66 years, pathological staging classification TI-
T 3AN + MO according to the definitions of the American Joint Connnittee on staging, 
treated by modified mastectomy or surgery according to Halsted, and chemotherapy 
initiated within 15 days after the surgical procedure. Patients with breast conserving 
therapy were excluded. Oral contraceptives should have been stopped at least 2 weeks 
before the start of chemotherapy. Ineligibility criteria were: Karnofsky performauce 
status < 80, white blood cell counts < 3.5 x 10'11 or platelet counts < 100 x 10'/1, 
abnormal liver function or disturbed renal function (bilimbin > 30 ,"moIlI, 'YGT > 
30 lUll, serum creatinine > 120 ,"moIlI), previous treatment for breast cancer, 
bilateral breast cancer, other neoplasms (except adequately treated basalioma or stage 
0-1 squamous carcinoma of the cervix uteri), current pregnancy or lactation, rapidly 
progressive fatal illness other than carcinoma, and cardiac diseases as congestive heart 
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failure or myocardial infarction less than 6 months before diagnosis of breast cancer. 
There were no exclusion criteria for receptor status or histological grades. All patients 
gave informed consent to the study. This study was approved by the Dutch Cancer 
Society. 
Pre-study screening and follolV-up studies 
Investigation procedures performed before entry to this trial included history, 
physical examination, laboratory investigations including hemoglobin, white blood cell 
count, platelet count, liver function test (bilirubin, alkaline phosphatase, ASAT, 
ALAT, LDH, ')'GT) and renal function (urea, creatinine), chest X-ray, mammogram 
aud bone-scan. Tumor specinlens were assayed for estrogen receptor (ER) and 
progesterone receptor (PgR) levels by ligand binding assay or enzyme immunoassay 
as described before. 15 Following completion of the treatment the patients were checked 
every 6 months for 5 years and than yearly thereafter. At each follow-up visit history 
and physical examination were performed. Chest X-ray, mallllllography, a complete 
blood cell count and chemistry profile were performed on an annual basis. 
Chemotherapy and dose modifications 
The patients were randomized to receive FAC chemotherapy alone or FAC preceded 
by hormonal recruitment. The FAC regimen consisted of 4 cycles of fluorouracil 500 
mg/m" doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2, administered 
intravenously (IV) once every 4 weeks, starting within 15 days after surgery. In the 
recruitment arm the same chemotherapy was administered, but each course was 
preceded by the oral administration of 0.5 mg ethinyl-estradiol 24 hours before, and 
at the time of the administration of the chemotherapy. A 4-weekly interval between 
the courses of chemotherapy was used in order to prevent postponement of 
chemotherapy after estrogen stimulation in a substantial number of patients due to 
cytopenia. The dose of ethinyl-estradiol (0.5 mg) was chosen because similar dosages 
of estrogensl6 caused plasma total- and unconjugated estradiol levels as found in the 
luteal phase of the menstrual cycle (200-700 pg/ml) which appeared to increase 
proliferation indices in endometrium, breast,17 and breast cancer. I' Adjuvant 
chemotherapy was started within two weeks after surgely because some initial trials 
showed that early chemotherapy before radiotherapy caused better relapse-free survival 
than delayed chemotherapy. 19.20 During the fIrst course of chemotherapy the total dose 
of cyclophosphamide was divided over 5 days because some experimental studies 
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showed an increase of the labeling index in locaJ21 and distant" tumor foci after 
extirpation of the primary tumor. In addition Nissen-Meyer et al.23 observed a 14 % 
improvement of relapse-free survival by one short-course of cyclophosphamide 
administered immediately post surgery. At the time of scheduled retreatment, therapy 
was postponed for 1 or 2 weeks if WBC was < 3 x 109/1 and or platelets < 100 x 
109/1. When at 2 weeks of delay no full hematological recovery was reached, doses 
had to be modified according the following scheme: 50 % reduction of the dosage of 
all 3 agents when WBC was 2.0-3.0 x 10'/1 or platelets 75-100 x 109/1, and the patient 
went off study when WBC was < 2 x 109/1 or platelets < 75 x 109/1. 
Radiotherapy 
Radiotherapy to the thoracic wall (or incidentally also to the regionallymphnodes) was 
administered in case of a narrow tumor resection area « 1 cm from the muscular 
thoracic wall) and started after the 4 courses of chemotherapy. The total dose of 
radiotherapy administered was 46 Gy. 
Statistics 
Primary endpoints for this study were relapse-free and overall survival. The trial was 
designed to detect an increase of 50 % in the median relapse-free survival with a power 
of90% at 5 % significance level. Therefore 432 patients has to be entered in the study. 
The expected duration of accrual was 4 years. The accrual rate of the trial was lower 
than expected and the trial was closed after 6.5 years when 328 patients had been 
entered. Acturial survival probabilities and curves were calculated with Kaplan-Meier 
method. In relapse free survival analysis patients counted as failure at relapse or at 
death; all other patients were censored at last contact. In the analysis of distant-
metastasis free period, patients were censored at last contact or death, if no previous 
distant metastasis had been observed. The same applies to the analysis of local 
recurrence free period. Differences in survival or relapse free survival between groups 
and associations between continous covariates and failures rates were analysed and 
tested with Cox proportional hazards model. The test for difference in (relapse free) 
survival between the two treatment arms was done both without and with adjustment 
for prognostic factors. 
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Table 1 Patient cbaracteristics 
FAC+ FAC Total 
recruitment 
Patients entered 166 162 328 
Patients evaluable 161 157 318 
Mean age Cyr) 48.4 48.5 48.5 
Menopausal status 
pre 100 93 193 
post 56 60 116 
unknown 5 4 9 
Tumorsize 
pTI 26 24 50 
pT2 122 110 232 
pT, 13 23 36 
Positive nodes 
1-3 80 85 165 
4-10 68 50 118 
>10 13 20 33 
unknown 0 2 2 
Grade 
well differentiated 1 3 4 
moderately differentiated 23 26 49 
poorly differentiated 79 74 153 
unknown 58 54 112 
Surgery not radical 6 6 12 
ER (finol) 
,,;10 37 33 70 
;0:10 112 113 225 
unknown 12 11 23 
PgR (finol) 
,,;10 53 39 92 
>10 74 88 162 
unknown 34 30 64 
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RESULTS 
Patient alld tll/llor characteristics 
In this multicenter study 16 institutions participated, each contributing between 2-80 
patients. A total of 328 patients were randomized between October 1985 and May 
1992, 162 to FAC alone and 166 to FAC preceded by estrogenic recruitment. Nine 
patients were found to be ineligible (5 on FAC and 4 on FAC recruitment). Reasons 
for ineligibility were: performed lumpectomy 3 patients, pT4 tumor 3 patients, distant 
metastases 2 patients, and ongoing oral anticonceptive therapy 1 patient. One patient 
was not evaluable because CMF chemotherapy was administered. The two treatment 
groups are well balanced with respect to the patient- and tumor characteristics as 
indicated in Table 1. For the whole group of patients the median follow-up is 3.3 
years. The mean number oflympbnodes examined was 13 (range 2-31), and the mean 
number of positive nodes was 5 (range 1-28). 
Treatment characteristics 
Treatment was started at average 12 + 2.7 days (mean + SD) after surgery. For all 
3 chemotherapeutic drugs the mean percentage of total dosages administered varied 
between 97.8 % and 99.1 %, without any difference between the two treatment arms. 
Treatment was well tolerated. The side effects were as expected for this well known 
regimen. There were no toxicity related hospital admissions and no treatment related 
deaths. 
A total of 73 patients (38 in the FAC-recruitment arm and 35 in the FAC arm) were 
treated with radiotherapy. In 71 patients radiotherapy was applied to the thoracic wall 
and in 15 patients also the regionallympbnodes. Of the 71 patients who were treated 
with radiotherapy to the thoracic wall, 5 (7%) experienced a chestwall relapse, and 
of the 245 patients not treated with radiotherapy 23 (9.4 %) had a chestwall recurrence. 
Relapse·free alld overall survival 
With respect to relapse-free (p=0.79), local recurrence-free (p=0.97), distant 
metastasis-free (p=0.60) and overall survival (p=0.69) we found no significant 
differences between the two treatment groups. Neither were there any differences in 
the type of disease recurrences (Table 2). The respective survival cnrves are shown 
in Fignre 1. The treatment group without estrogenic recruitment showed a slightly 
lower failure rate (relative hazard rate (RHR) between 0.91 and 0.99) but these 
differences were not significant (p > 0.60). For the whole patient population the 
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survival percentages for these 4 parameters after 1, 2, and 5 years are indicated in 
Table 3. 
Table 2 Type of recurrences 
PAC+ PAC Total 
recruitment 
Locoregional recurrences (n - 55) 
Scar 7 8 15 
Chest wall s. c. 6 7 13 
Skin diffuse 5 3 8 
Supraclaviculair 11 10 21 
Axillary 7 4 11 
Distant metastases (n = 117) 
Bone 38 37 75 
Liver 12 16 28 
Lung 11 7 18 
Lymph nodes 9 6 15 
Brain 4 6 10 
Skin 2 2 4 
Second breast 3 0 3 
Other 13 8 21 
Table 3 Acturial survival rate 
Dr 2..yr J....)'!: 
Local recurrence-free 96% 86% 74% 
Distant metastases-free 90% 76% 50% 
Relapse-free survival 88% 70% 46% 
Overall survival 97% 89% 65% 
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, -
Relapse-free survival 
Local recurrence-free period 
years 
Overall; relapse-free; distant metastasis-free and local recurrence-free survival by arm (-- FAC+ 
estrogenic recruitment, ----- PAC) 
TIle role of clinical prognostic factors 
As expected, patients with large tumors (p = 0.001), Wgh numbers of positive nodes 
(p < 0.0001) and negative steroid receptor status (p = 0.42) showed a worse relapse-
free survival (Figure 2). With respect to age, in this study we found no association 
between menopausal status and relapse-free survival, but patients younger than 40 
years tended to have a higher relapse rate. Also iu a multivariate analysis includiug 
these clinical prognostic factors, we found no significant difference regardiug relapse 
rate between the two treatment arms (p = 0.57). 
In this study we iuvestigated the clinical impact of the assessment of the percentage 
of positive nodes versus the number of positive nodes, usiug 3 subgroups for each 
parameter. For the number of positive nodes the subdivision was iu 1-3 (n = 165), 4-10 
(n = 118) aud > 10 (n =33), while for the percentage of positive nodes the subdivision 
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was in < 40% (n=203), 40-80% (n=61) and> 80% (n=39). Both factors were 
statistically WgWy significantly related with relapse rate, but the percentage of positive 
nodes turned out to be a better predictor (p = 2 X 10" vs p = 1 x 10-<>. 
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Relapse-free survival according to age, ER status, tumor size. differentiation grade, % of positive 
nodes, and number of positive nodes. 
The 5 year relapse-free survival varied in the subgroups according to number of 
positive nodes between 22 % and 60 %, and int the subgroups according to percentage 
of postive nodes between 7% and 59%. Note that the subdivision according to 
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percentage of positive nodes gives a better separation with more patients in the good 
and very poor prognosis groups, than the subdivision by number of positive nodes 
(Figure 2), 
DISCUSSION 
The concept of hormonal stimulation before antitumor therapy was already applied 
many decades ago, Around 1940 radiotherapists used estrogen treatment in the waiting 
time prior to radiotherapy assuming that estrogens could make breast cancer more 
vulnerable for radiotherapy by growth stinmlation in contrast to estrogen withdrawal 
by castration which can result in objective tumor remission, Later on similar studies 
with androgen-priming before radiotherapy were performed in metastatic prostate 
cancer. ",2. However, these studies were more empiric and not based on preclinical 
testing of the principle in different models, 
More recently, several laboratory studies showed that short-term pretreatment of tumor 
cells with estrogens can increase the antitumor efficacy of cytostatic drugs,3,5-9 A few 
investigators demonstrated that also in patients with (locally advanced) breast cancer 
estrogenic pretreatment during one or several days increased the proliferation rate of 
the tumors,27-29 However, this procedure of estrogenic recruitment of tumor cells prior 
to chemotherapy appeared to have disappointing antitumor effects in patients with 
advanced disease in comparison with the results of experimental preclinical studies, '0 
Initially, some of the phase II studies applying the principle of estrogenic recruitment 
therapy in locally advanced (Table 6) and metastatic disease (Table 7) showed relative 
high (complete) response rates,12,I.,29,31,32,34-'. 
Subsequently a number of randomized studies using different treatment regimens were 
performed (Table 6 and 7),13,33,37-42 Most studies found no difference in response rate 
between the treatment arms, Seymour et al. observed even a detrimental effect of 
estrogenic recruitment on the efficacy of chemotherapy, but in this study all 
chemotherapy was administered on day I and diethylstilbestrol (DES) from day I to 
day 6, which might have resulted in tumor flare after the chemotherapy,·1 
In contrast, Ingle et al. using the intravenous CMF regimen found a higher response 
rate after pretreatment with DES (39 vs 25%; p = 0,06),42 Overall, in these 
randomized studies no significant effects were found with respect to progression-free 
and overall survival. 
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Tahle 6 Clinical trials of hormonal recruitment strategies 
in locally advanced hreast cancer 
Author (yr) Pts. Hormonal Chemotherapy CR OR 
(N) therapy (%) (%) 
Swain '87 70 Tam/Premarin * FACM 49 93 
Conte '87 39 DES *FAC 15 72 
Fabian '94 28 Estradiol *FAC 89 NA 
Vinblastine 
TIP Survival 
(months) (months) 
34 39 
NA NA 
35 57 
------------------------------------------------------------------------------------------
Baldini '93 108 DES * FAC 6 60 22 47 
* id. 13 72 20 50 
Abbreviations: CR: Complete response, OR: overall response, TIP: median time to progression, 
Survival: median overall survival, Tam: tamoxifen, DES: diethylstilbestrol, F: fluorouracil, A: 
doxorubicin, C: cyclophosphamide, NA: not available, id: identical chemotherapy. 
Based on all these studies, it can be concluded that estrogenic recruitment before 
chemotherapy does not improve the antitumor effects of chemotherapy; only in 
various subgroups of patients some benefit of the hormonal manipulation was found 
The potential reasons for these disappointing results in locally advanced and metastatic 
disease can be suboptimal treatment regimens (with respect to type and dose of 
estrogen, tamoxifen therapy, type and timing of chemotherapy and duration of 
treatment), prior existence of chemotherapy drug resistance, and especially tumor 
heterogeneity. The latter two reasons are expected to be less important in early breast 
cancer. However, also in our first adjuvant study applying the principle of estrogenic 
recruitment therapy, we fonnd no additional benefit of such hormonal manipulation. 
The absence of a benefit can be explained by several reasons. Apart from those 
mentioned above with respect to advanced disease, it might be possible that after a 
median follow-up of 3.3 years only those tumors with an initial high proliferation rate 
have already recurred. These at the start of treatment already rapidly proliferating 
tumor cells are potentially less sensitive for further stimulation by estrogens in contrast 
to slowly proliferating or dormant tumor cells. It might be anticipated that 
pretreatment with estrogens is more effective in tumors with a low S-phase fraction, 
which is a favourable prognostic factor associated with longer relapse-free survival. 
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Table 7 Clinical trials of hormonal recruitment strategies 
in metastatic breast cancer 
Author (yr) Pts. Hormonal Chemo- CR OR TIP Survival 
(N) therapy therapy (%) (%) (months) (months) 
Allegra '83 32 TamIPremarin *FM 47 69 NA NA 
Eisenhauer '84 35 Tam/Premarin 'FM NA 10 NA NA 
Paridaens '87 57 AG/Estradiol 'FAC 35 75 NA NA 
Benz '87 18 Tam/Estradiol ' PM 28 39 NA NA 
Fabian '94 22 Estradiol 'FAC NA 50 4 17 
Vinbl. 
Hug '94 63 Premarin 'FAC 13 76 17 29+ 
------------------------------------------------------------------------------------
Lippman '84 108 Tam/Premarin 'FACM 22 65 16 19 
* id. 18 65 12 17 
Lipton '87 35 AGlEstradiol 'FAC 14 62 NS NS 
AG * id. 7 64 
Paridaens '93 154 AG/Estradiol 'FAC 14 64 14 24 
AG * id. 21 64 20 29 
Conte '87 116 DES ' FEC 24 54 9 18 
* id. 16 57 9 14 
Conte '96 258 DES ' FEC 15 50 11 20 
* id. 12 51 9 17 
Seymour '93 39 DES' 'CNV 11 26 7 13 
* id. 25 55 10 15 
Ingle '94 163 DES ' CMF 6 39 4 12 
* id. 4 25 4 13 
Abbreviations: CR: complete response, OR: overall response, TIP: median time to progression, 
survival: median overall survival, Tam: tamoxifen, DES: diethylstilbestrol, AG: aminoglutethimide, 
F: fluorouracil, M: methotrexate. A: doxorubicin, C: cyclophosphamide, Vinbl.: vinblastine, E: 
epidoxorubicin, V: vincristine, N: mitoxantrone, NA: not available, NS: not significant, id: identical 
chemotherapy, 0: postmenopausal patients on DES also received AG. 
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Therefore, it might be possible that after a longer follow-up the survival curves in our 
study will diverge. 
In conclusion, in our adjuvant study thusfar we did not fInd any benefIt of 
pretreatment with ethinyl-estradiol on the efficacy of FAC chemotherapy. However, 
we need longer follow-up before making defInite conclusions. 
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SUMMARY 
Weekly low dose mitoxantrone (3 mg/m2) plus doxorubicin (8 mg/m2) was 
administered as second-line chemotherapy to 33 patients with advanced breast cancer. 
Four ont of 28 evaluable patients (14%) obtained a partial response with a median 
duration of 34 weeks (range l8-6r weeks), while 8 patients (29%) showed stable 
disease with a median duration of 28 weeks (range II + -60 weeks). Gastrointestinal 
toxicity and alopecia were mild. Grade II and III leukopenia occurred in 63 % of the 
courses without serious infectious disease. Four patients experienced an asymptomatic 
drop of 16-20% in the left ventricular ejection fraction (LVEF) after relatively low 
cumulative doses of each drug, and one patient with a history of pericarditis 
carcinomatosa and mediastinal irradiation developed a heart failure. In conclusion, this 
second-line combination treatruent had moderate activity in breast cancer and caused 
only few subjective side effects, especially with respect to gastrointestinal symptoms. 
INTRODUCTION 
Combination chemotherapy appears to be more effective than single agent therapy 
in inducing responses in disseminated breast cancer. First-line treatruent with 
cyclophosphamide, methotrexate and fluorouracil (CMF) induces a response in about 
40-50% of the patients with a median duration of response of less than a year [1). 
Second-line chemotherapy in CMF-refractory patients often consists of single agent 
treatment with (4' -epi-)doxorubicin or mitoxantrone in a 3-weekly high dose schedule. 
However, only about 20-30% of these patients achieve a remission, frequently of short 
duration, while toxicity is often considerable especially by treatment with anthracyclin-
es [2-4]. 
When (4'-epi-)doxorubicin or mitoxantrone are administered in low dose schedules 
every week or twice a month, the drugs can still be active, with remission rates of 
about 30% (0-59%) in patients with advanced breast cancer [5-22). Gastrointestinal 
toxicity and alopecia are significantly less with these low-dose schedules. 
Cardiotoxicity is a major problem of long-term (4'-epi-)doxorubicin treatment, 
while mitoxantrone occasionally produces such toxicity. Doxorubicin cardiotoxicity 
is probably induced by the intracellular formation of free radicals and stimulation of 
membrane lipid peroxidation in the heart muscle cells [23). In experimental stndies 
with hearts of rats, evidence was found that mitoxantrone did not form free radicals, 
and had a strong inllibitory effect on the lipid peroxidation [24,25]. In addition 
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mitoxantrone was fonnd to cause a concentration-dependent inhibition of doxorubicin 
stimulated lipid peroxidation in liver microsomes of rabbits [26]. These data suggest 
tbat mitoxantrone might have an inhibitory effect on the occurrence of doxorubicin-
induced cardiotoxicity. Furthermore, low-dose schedules of doxorubicin seem to 
produce less cardiotoxicity [5,6,27,28]. In view of tbese data it appeared attractive to 
combine doxorubicin and mitoxantrone at weekly dosages. Therefore, we initiated a 
phase II study witb tbe combination of low doses of doxorubicin and mitoxantrone in 
a weekly schedule as second-line chemotherapy for patients with advanced breast 
cancer. 
PATmNTS AND METHODS 
Eligibility criteria of the protocol included: patients witb measurable or evaluable 
lesions, age less than 80 years, World Healtb Organization (WHO) performance score 
2 or less, life expectancy of more than 2 montbs, serum bilirubin less than 40 pmol/I, 
WEC above 3.0 x 10'/1, platelets above 100 x 10'/1, no prior therapy with 
antbracyclines or mitoxantrone. Patients with a history of recent cardiac disease, or 
witb metastases in the central nervous system were excluded. Metastatic disease of all 
patients had to be resistant to previous endocrine therapy and to fust-line 
chemotherapy witb CMF (cyclophosphamide, methotrexate and fluorouracil). The 
protocol (DDHK 88-18) was approved by 2 different committees, both a protocol 
review and a medical ethics committee. All patients gave oral informed consent before 
entering tbe study. 
On-study evaluation consisted of medical history, physical examination, tumor 
measurements, complete blood count (Hb, WBC, platelets), automated blood 
chemistry, left ventricular ejection fraction (L VEF, using radionuclide multigated 
analysis with intervals of initially 12, subsequently 8 or 4 weeks), bonescan, bone and 
chest X-rays and liver CT-scan (in case of liver metastases). 
Treatment consisted of mitoxantrone 3 mg/m2 plus doxorubicin 8 mg/m2 as weekly 
sequential intravenous injections via a running infusion with physiologic saline during 
a few minutes. Responses were defmed according to WHO criteria. Duration of partial 
response was measured from initiation of therapy until time of tumor progression. 
Drug toxicity was also evaluated according to WHO criteria. 
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Table 1 Patient characteristics 
Number of patients entered: 33 
Number of evaluable patients: 28 
Menopausal status: 
pre 1 
post 26 
peri or unknown 6 
Age: 
median (range) 57 (40-74) 
WHO Performance Status: 
median (range) 1 (0-2) 
Metastatic sites per patient: 
median (range) 3 (1-4) 
RESULTS 
Patients characteristics are indicated in Table 1. Thirty-three patients entered the 
study. Twenty-eight patients were evaluable for response and toxicity. Five patients 
were not evaluable because of early withdrawal or lack of response evaluation (within 
the fIrst 8 weeks). Reasons to stop the treatment were: patient refusal (2), radiation 
therapy for pain (1), discovery of brain metastasis 1 week after start of treatment (1), 
and hyperbilirubinemia 1 week after start of treatment (1). These 5 inevaluable 
patients died between 0.5 and 8 months after start of treatment. 
Table 2 Type of responses and time to progression 
(WHO criteria) 
CR 
PR 
SD 
PD 
104 
Number of patients 
(%) 
o 
4 (14) 
8 (29) 
16 (57) 
Mean duration in weeks 
(range) 
34 (18-67+) 
28 (11 + -60) 
within 2-14 weeks 
Chapter 7 
Responses are shown in Table 2. No complete responses were observed. A partial 
response (PR) was achieved in 4 out of 28 patients (14%) with a median duration of 
34 weeks (range 18-6" weeks), while 8 patients (29%) showed stable disease (SD) 
with a median duration of 28 weeks (range 11 + -60 weeks). One patient had early 
progressive disease after 2 weeks of treatment. Fifteen other patients showed tumor 
progression within 5-14 weeks after start of treatment. 
Progression-free survival and overall survival curves of the evaluable patients are 
shown in Fig. 1. 
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Progression~free and overall survival of all evaluable patients measured in weeks from start of 
treatment. 
Toxicity is presented in Table 3. Leukopenia grade II occurred in 48 % and grade 
III in 15% of all cycles. Gastrointestinal toxicity was very mild. Serious hair loss 
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grade II and III occnrred in only a minority of the patients and was probably still 
related to the previous eMF treatment. 
In 10 of the 12 patients who achieved a PR or SD, LVEF was repeated at least once. 
Three patients received a "doxorubicin equivalent" dose (cumulative doxorubicin dose 
+ cumulative mitoxantrone dose x 5) of more than 550 mg/m2, i.e. 720, 795, and 850 
mg/m2. LVEF of these patients dropped from 65 to 53%, 76 to 61 %, and 80 to 73% 
respectively. LVEF of two other patients receiving a cumulative "doxorubicin 
eqnivalent" dose of 195 and 292 mg/m2 dropped from 89 to 75% and from 76 to 64% 
respectively. In four other patients treated with "doxorubicin equivalent" cumulative 
doses of 209 to 500 mg/m2 L VEF remained stable to the base-line value. Thus, in non 
of these 9 patients did LVEF decrease to below the critical limit of 50% and none of 
them showed any clinical sign of cardiotoxicity. One patient, with previous mediastinal 
irradiation and pericarditis carcinomatosa, developed a cardiac failure in the presence 
of a drop in the absolute level of the LVEF from 78% to 29%, after being treated 
with a "doxorubicin equivalent" cumulative dose of 478 mg/m2. She was successfully 
treated with digoxin and diuretics. 
Table 3 Percentage of side-effects (WHO grading) 
Grade 0 1 2 3 
Leukopenia * 15 22 48 15 
Thrombocytopenia * 80 9 9 2 
Mucositis * 96 4 
Diarrhea* 94 6 
Nausea/vornlting* 84 11 5 
Alopecia** 82% 18% 
* Percentage of courses with side effect events as recorded in all 
(100%) weekly chemotherapy courses. **Alopecia is expressed as 
the percentage of patients experiencing various grades (0/1 and 213) 
of hair loss. 
DISCUSSION 
Several studies have shown that chemotherapy with weekly low doses 
of (4'-epi)doxorubicin or mitoxantrone can be as effective as the 3-weekly high-dose 
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schedules in inducing remissions in patients with advanced breast cancer, whereas 
toxicity of the low doses is considerable less [5-22,27,28]. Treatment results of 18 
studies using "weekly" low dose (4' -epi-)doxorubicin or mitoxantrone in patients with 
advanced breast cancer are shown in Tables 4 and 5. Table 4 summarizes the 
treatment results of7 studies concerning a total of311 patients of whom less than 50% 
had been treated before with chemotherapy for advanced disease. Overall, 93 of the 
311 patients (30 %) treated with weekly low-dose anthracycline or mitoxantrone 
responded objectively. The mean percentage of response of the 7 separate series of 
patients was 32% (range 10-48%). Table 5 shows the treatment results of 11 studies 
concerning 361 patients of whom more than 50% had been pretreated with various 
types of chemotherapy. During this second-line chemotherapy 110 out of 361 patients 
(30 %) responded. The mean percentage of response of the individual series was 29 % 
(range 0-59%). Response durations in the studies vary widely. Based on response data 
available in 12 of these 18 studies, the median duration of response is about 6-7 
months. In our study we combined mitoxantrone and doxorubicin in weekly low-dose 
schedules in order to achieve a low toxicity profIle with preserved activity. 
Table 4 Low-dose doxorubiciu (Dox), 4'-epi-doxorubicin (Epi-dox), or 
mitoxantrone (Novantrone) mainly used as first-line chemotherapy 
in advanced breast cancer 
Drug Dosage 
Dox 15 or 20 mg 
Dox 20mg 
vs 
VAC 
Dox 20mg 
vs 
Epi-dox 50mg 
Epi-dox 12 mg/m2 
Epi-dox 20 or 40 mg 
Epi-dox 20mg 
Novantrone 3.3-6 mg/m2 
Number of eval. patients:311. 
Treatment 
interval 
(weeks) 
1 
1 
3 
2 
1 
1 
1 
1 
Nof 
eval. 
pts 
50 
62 
66 
81 
68 
42 
25 
41 
10 
Number of patient' achieving CRlPR:93/31l (30%). 
Responses Prior 
(CRJPR) chemother. 
-(-'n)~-(-%:-) - (% pts) 
7 14 44 
19 31 0 
24 35 
29 36 0 
15 22 
18 43 12 
12 48 <24 
4 10 17 
4 40 0 
Mean % CRJPR of all 7 individual ,eries: 32% (range 10-48%), 
Ref. 
(5) 
(6) 
(7) 
(8) 
(9) 
(10) 
(11) 
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Subjective side effects, gastrointestinal toxicity, and alopecia were mild witb this 
combination therapy, but leukopenia regularly needed postponement of the 
chemotherapy. In spite of these clear toxic effects on bonemarrow function, the 
combination of weekly low-dose mitoxantrone and doxornbicin showed "moderate" 
antitumor activity (14% PRJ as second-line chemotherapy in patients witb metastatic 
breast cancer. However, in an additional 29% of the patients a SD was observed for 
11 + -60 weeks with nearly the same median duration of progression-free survival as 
for partial responders (28 vs 34 weeks). This median duration of SD (about 6-7 
months) in our patients is not different from that of the objective responders reported 
in the otber studies (Table 4 and 5), i.e. 6-7 months. The overall response rate 
(CR/PRISD) of 43% also is generally not different from that reported in otber studies, 
Table 5 Low-dose doxorubicin (Dox) or 4'-epi-doxorubicin (Epi-dox) mainly nsed as 
second-line chemotherapy in advanced breast cancer 
Drug Dosage Treatment number Responses Prior Ref. 
interval of (CRlPR) ehemother. 
(weeks) eval. (% pts) 
pts. 
(n) (%) 
Dox 0.4 mg/kg' 1 29 11 38 100 (12) 
Dox 0.5-1 mg/kg 1 31 11 35 heavily (13) 
pretreated 
Dox 20 mg/m2 1,3,1,3 60 16 27 87 (14) 
Dox 6-12 mg/m2 1 34 20 59 > 62 (15) 
Dox 5-11.5 mg/m2 1 20 3 15 100 (16) 
Dox 8-12 mg/m' 1 17 2 12 70 (17) 
Dox 10 mg/m2 1 24 0 0 > 96 (18) 
Dox 12 mg/m2 1 30 8 27 97 (19) 
Dox 20mg 1 48 9 19 56 (20) 
Epi-dox 20 mg 1 39 20 51 51 (21) 
Dpi-dox 15 mg/m2 1 29 10 34 52 (22) 
Number of eval. patients: 361. 
Number of patients achieving CRlPR: 110/361 (30%). 
Mean % CRfPR of all individual series: 29% (range 0-59%). 
* Therapy with initial loading course (days 1-3 and 8-10). 
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even in comparison with high-dose mitoxantrone 3-weekly in the fIrst-line (40%) as 
reported by Harris et aJ. [29]. Striking in our study was the clear dose-limiting 
bonemarrow depression in spite of the low dosages of the drugs used. However it has 
to be noted that the relatively high incidence of leukopenia compared to 3-weekly 
schedules is influenced by the frequent weekly measurement of WBC in this weekly 
dose regimen. 
In vitro studies with the combination of both drugs had suggested a possible 
protective effect of mitoxantrone towards doxorubicin-induced cardiotoxicity [26]. This 
possible protective effect of mitoxantrone towards doxorubicin-induced cardiotoxicity, 
however, was not observed in two clinical studies that combined the drugs in 3-weekly 
"high-dose" schedules [30,31]. From our study we camlot make deflnite conclusions 
in this respect. Although 4 patients showed a signifIcant relative decrease (16-20% of 
the pretreatment value) of LVEF, non of them decreased below an absolute value of 
50% with the exception of the patient with previous mediastinal irradiation and 
carcinomatous pericarditis. 
It can be concluded that second-line combination treatment of weekly low-dose 
lnitoxantrone plus doxorubicin is a well tolerated drug regimen for patients with CMF-
resistant tumors. The antitumor efficacy is comparable to that of other second-line 
chemotherapeutic regimens in the absence of serious side effects, but postponement 
of drug administration was regularly needed because of the occurrence of leukopenia. 
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SUMMARY 
In a phase II study, 27 patients with metastatic breast cancer were treated with 
oral etoposide as second-line chemotherapy at a dose of 50 mg/m'/day for 21 days, 
which courses were repeated every 4 weeks. Twenty-one patients were evaluable for 
response, and twenty-five for toxicity. In two (10%) patients a partial response was 
observed with a duration of 60 and 122 weeks respectively, and seven patients (33 %) 
showed stable disease. Gastrointestinal toxicity was usually mild, though relatively 
frequent. Anemia grade II and III was observed in 20 % of all courses « 10 % of all 
measurements), and leukopenia grade III and IV was observed in 22 % of all courses 
« 10% of all measurements). There was one toxic death. 
Reviewing the literature we calculated a response rate of intravenous etoposide 
treatment of 8 % in 276 patients with metastatic breast cancer from 7 studies (response 
rates ranging between 0-14%), while (chronic) oral treatment caused a response rate 
of 19% in 145 patients from 8 different studies (response rates ranging between 0-
35%). 
INTRODUCTION 
The prognosis of patients with disseminated breast cancer refractory to or relapsing 
from first-line chemotherapy is poor. All currently applied cytotoxic drugs yield low 
response rates (10-30 %) with a median duration of response of about 6 months or less 
and frequently considerahle toxicity (1). Therefore, new approaches are warranted. 
Because breast cancers contain usually a relatively low percentage of proliferating cells 
within the cell cycle, prolonged exposure to a cytotoxic drug is theoretically attractive. 
Etoposide (VPI6-213), a semisynthetic podophyllotoxin derivate with a wide 
antitumor activity, is a cell cycle phase-specific drug acting in the late S- and early G,-
phase of the cell cycle with schedule dependency (2). Activity of the drug is probably 
more related to duration of exposure to tumor cells rather than to the area under the 
curve (AUC) (3-5). Etoposide has been used in clinical trials for approximately 20 
years withont clear efficacy in breast cancer, but recently there is renewed interest in 
this drug because of the application of new treatment schedules (6,7). There is clinical 
evidence that chronic daily administration of oral etoposide can induce responses in 
patients with different chemotherapy refractory solid tumors (8,9). 
Out of the four breast cancer patients in a phase I trial using prolonged low-dose oral 
etoposide (8), one had an objective response and one patient with non-measurable 
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disease had a subjective response. Based on these data we initiated a phase II study 
with daily oral administration of etoposide as second-line chemotherapy in patients 
with metastatic breast cancer. 
PATIENTS AND METHODS 
Eligibility criteria of this study included patients with measurable or evaluable 
lesions, age less than 80 years, World Health Organization (WHO) performance score 
(PS) 2 or less, life expectancy of more than 2 months, serum bilirubin less than 20 
I'mo1/l, WBC above 3.0 x 10'/1, platelets above 100 x 10'/1, no prior therapy with 
etoposide. Patients with a history of recent cardiac disease, or patients with metastases 
in the central nervous system, were excluded. Metastatic disease of all patients was 
considered resistant to previous endocrine therapy and to first-line chemotherapy. All 
patients gave oral informed consent before entering the study. 
On-study evaluation consisted of medical history, physical examination, tumor 
measurements, complete blood count (Hb, WBC, platelets), automated blood 
chemistry, bonescan, bone and chest X-rays and CT-scan or ultrasound of the liver 
in case of liver metastases. On follow-up complete blood count was performed weekly 
and response evaluation was performed after every second course. 
Treatment consisted of etoposide 50 mg/m2/day, orally for three consecutive weeks, 
in a twenty-eight day cycle. Responses and toxicity were defined according to WHO 
criteria. Duration of complete and partial response was measured from initiation of 
therapy till time of tumor progression. 
RESULTS 
Twenty-seven patients entered the study. Patients characteristics are indicated in 
Table 1. Two of the 27 patients were ineligible (PS: 3 and bilirubin 43 I'mo1/l). All 
25 eligible patients were evaluable for toxicity. The total number of courses of 
etoposide administered was 90 (mean: 3.6; median 2, range 1-25). Gastrointestinal 
toxicity was usually mild. Twenty-one patients had no or only mild complaints of 
nausea (WHO grade 0-1), while four patients (16%) experienced nausea and vomiting 
grade II-III for which reason one of them was hospitalized. Alopecia was often related 
to previous chemotherapy, while in three patients the first hair loss (grade II-III) was 
undoubtedly etoposide-induced. LeUkopenia grade III and IV occurred in 15 patients 
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Table 1 Patient characteristics 
Number of patients entered 
Number of eligible patients 
Number of patients evaluable 
for response 
for toxicity 
Age 
median (range) 
WHO performance status 
median (range) 
Number of organ systems involved 
median (range) 
Time from first sign of metastatic disease 
to start of etoposide (months) 
median (range) 
No of prior hormonal therapies 
median (range) 
Prior chemotherapy 
adjnvant 
chemotherapy for metastatic disease 
Cyciophosphamide/Methotrexate/Fluorouracii 
Cyciophosphamide/Doxorubicin/Fluorouracil 
Cyciophosphamide/EpirubicinlFluorouracil 
Site of metastatic lesion 
liver 
lung 
pleura 
bone 
lymph node 
skin 
breast 
27 
25 
21 
25 
54 (37-76) 
1 (0-2) 
3 (1-5) 
19 (4-81) 
1 (0-4) 
7 
27 
18 
8 
1 
10 
7 
6 
17 
5 
11 
6 
(60%), in 22 % of all courses and in < 10% of all measurements; anemia grade II and 
III was observed in 9 patients (36%), in 20% of all courses and in < 10% of all 
measurements. Mild to moderate thrombocytopenia was infrequent (grade I-II: in 3 % 
of all measurements). One patient died during the leukopenic period. 
Four of the 25 eligible patients were not evaluable for response because of early 
withdrawal (within the fIrst 3 weeks). Reasons to stop the treatment in these 4 patients 
were: severe nausea and vomiting (1), analysis of polyuria (1), anemia (1), and sudden 
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death in a patient with an axillary thrombosis two weeks after start of therapy. No 
complete responses were observed in21 patients evaluable for response. Two patients 
(10%)(95 % confidence interval 1-30%) achieved a partial response with a duration of 
60 and 122 weeks, respectively. The first responding patient was treated before with 
hormonal therapy for 3 months without success, followed by 12 courses of FEe 
chemotherapy with stabilisation of the disease. During etoposide treatment the lytic 
bone metastases showed fair sclerosis. The second patient had been treated for three 
years with two lines of endocrine therapy, followed by 23 conrses of CMF 
chemotherapy with a partial response. During etoposide therapy the puhnonary lesions 
showed a partial response and the bone lesions remained stable. 
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Figure 1 
I 
o 
Median survival time 
Overall survival 
survival L-_______ -, 
months 
Seven patients (33 %) had stable disease with a median duration of 19 weeks (range 
9+ -32 weeks). Progressive disease from the start of treatment was observed in twelve 
patients. For the 21 evaluable patients the median time to progression was 2 months 
(mean: 4.3 months) and the median survival time was 8.3 months (mean: 11.3 
months) (Fig. 1). 
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Table 2 Etoposide as ;,: second· line single agent therapy in metastatic breast cancer 
Treatment schedule No. of Response (CR + PRJ Ref. 
eval. pts n % 
Intravenous administration 
100-250 mg/m' q every week 14 0 0 10 
45 mg/m' days 1-5 q 3 wk 60 3 5 11 
75 mg/m' days 1-5 q 3 wk 59 5 8 
50-70 mg/m' days 1·5 q 3 wk 35 5 14 12 
50-70 mg/m' CI days 1-5 q 3 wk 31 4 13 
60-135 mg/m' twice weekly 24 1 4 13 
125 mg/m' days 1,3,5 q 3-4 wk 19 0 0 14 
100·125 mg/m' days 1,3,5 q 4·5 wk 19 2 11 15 
300-450 mg/m' days 1·3 q 4 wk 15 1 7 16 
Total 276 21 8 
Treatment schedule No. of Response (CR + PRJ Ref. 
eval. pts n % 
Oral administration 
75-125 mg/m' days 1·5 q 3 wk 14 0 0 10 
200 mg/day days 1-5 q 2·3 wk or 20 0 0 17 
300-400 mg/day days 1-5 q 2 wk 
50 mg/m'/day; days 1-21 q 4 wk 4 25 8 
50 mg/m'/day; days 1-21 q 4 wk 18 4 22 18 
50 mg/m'/day; days 1-21 q 4 wk 43 15 35 19 
50 mg/day; days 1·14 q 4 wk 10 10 20 
50 mg/m'/day; days 1-21 q 4 wk 25 5 25 21 
50 mg/m'/day; days 1-21 q 4 wk 21 2 10 This 
study 
Total 145 28 19 
CI = continuous infusion 
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DISCUSSION 
Treatment results of second-line chemotherapy in metastatic breast cancer are 
disappointing and remissions are usually of short duration (1). Therefore, testing of 
new treatment modalities remains of utmost importance. 
In the past twenty years etoposide has been extensively used in the treatment of 
patients with a variety of solid tumors. Most experience with etoposide in breast 
cancer is obtained with intravenous (i. v.) treatment schedules. Table 2 sununarizes the 
treatment results with etoposide in this disease. Seven studies (concerning 276 patients) 
applied i. v. etoposide as a single agent in previously treated patients. Response 
percentages varied from 0-14%, with an overall response rate of only 8% (10-16). 
Thus these short-term intravenous schemes of second-line chemotherapy with etoposide 
have shown only moderate activity in breast cancer, while toxicity was generally 
considered acceptable with myelosuppression emerging as the most frequent side 
effect. 
Treatment results of eight studies (including our study) using oral etoposide as 
second-line chemotherapy in metastatic breast cancer are also shown in Table 2 
(8,10,17-21). In the studies of Cavalli et al. (10) and Falkson et al. (17) using a high 
dose oral regimen for five days no responses were observed. However, because the 
cytotoxic effect of etoposide is more related to the duration of tumor cell exposure to 
the drug rather than to the AUC, prolonged exposure might theoretically result in an 
augmented anti-tumor effect (3-5). In a phase I trial (8) one out of 4 patients with 
breast cancer responded to a long-term lOW-dose etoposide reginlen. The 
recommended dose for following phase II studies was therefore 50 mg/m2/day for 21 
days in a 28 day cycle. We performed a phase II study using this reginlen but 
achieved only 10% remissions. Palombo et al. (18), Martin et al. (19) and Atienza et 
al. (21) performed similar studies in breast cancer patients pretreated with 
chemotherapy. They reported higher response rates i.e. 22%, 35% and 25%, 
respectively (Table 2). On the other hand Calvert et al. (20) reported the same 
response rate of 10% in a subgroup of 10 patients treated with 50 mg etoposide per 
day after previous chemotherapy. In this heterogeneous study higher response rates 
were observed in a subgroup of chemotherapy naive patients (45% response) and at 
a higher dose (100 mg/day) reginlen (35 % response, regarding mainly patients not 
treated with chemotherapy before). When taking together all literature data, (chronic) 
oral etoposide treatment caused an objective response in 19% of 145 patients (Table 
2) (8,10,17-21), mostly of short duration. Responses can occur in all types of 
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metastatic sites. The toxicity observed in our study is comparable with that of other 
studies with leukopenia as the most serious side effect. Also Calvert et aJ. (20) and 
Atienza et aJ. (21) reported the occurrence of toxic deaths, although this outpatient 
regimen appeared to be quite manageable. 
In conclusion, second-line chemotherapy with etoposide has only moderate 
activity in patients with metastatic disease in the presence of significant but 
manageable toxicity. Newer agents such as taxol and taxotere might therefore be of 
greater interest (22,23), but maybe etoposide can be of greater value in combination 
with these or other active agents. 
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ABSTRACT 
Background: The data available on the role of carboplatin and etoposide in breast 
cancer, especially in patients with no or minimal prior therapy are limited. 
Patiel/ts and methods: We performed a phase-II study with carboplatin and 
etoposide as fIrst line treatment in 34 patients with metastatic breast cancer. The 
treatment regimen was carboplatin 300 mg/m2 day 1, and etoposide 100 mg/m2 days 
1, 3 and 5, every four weeks. 
Results: Of 33 evaluable patients, two achieved complete responses (6%) lasting 
4 and 5 months, 7 patients (21 %) achieved partial responses with a median duration 
of 6+ (range 5 - 8) months, 15 patients had stable disease, and 9 progressed during 
treatment. The major toxicity was myelosuppression. WHO grades 3 or 4 
leukocytopenia or thrombocytopenia were seen in 15 and 10 patients, respectively. 
One formally ineligible patient with an impaired renal function died 14 days after the 
start of treatment because of a septicaemia in the presence of a grade 4 
leukocytopenia. Besides this patient no other patient presented with granulocytopenic 
fever. 
Conelusion: In view of the observed response rate of 27 % (95 % confIdence 
interval 11 % - 43 %) we think that carboplatin and etoposide given in this dose and 
schedule has probably no clear advantage over the more commonly used regimellS. 
INTRODUCTION 
The data available on the role of carboplatin and etoposide in breast cancer, 
especially in patients with no or minimal prior therapy are limited. In previously 
chemotherapy treated patients a low activity has been reported for both carboplatin and 
etoposide (1-3), however when administered to previously untreated patients both 
agents have been shown to be active with a response rate of 15% for etoposide in 20 
patients and a response rate of 14%,35%, and 20% for carboplatin in 7,34, and 20 
patients, respectively (4-7). In a recently reported phase II trial with carboplatin given 
as a single agent using a pharmacokineticaIIy guided dose schedule a response rate of 
25 % was reported in 40 patients. It is noteworthy that only one of the 13 previously 
treated patients responded compared to 9 of 27 patients who had not received previous 
chemotherapy (8). Also in a randomized trial the combination of etoposide and 
cisplatin given as fIrst line treatment yielded a 63 % respollSe rate in 65 patients versus 
a 48% response rate on "CMF" in also 65 patients (9). In this study we investigated 
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the activity and toxicity of the combination of carboplatin and etoposide as ftrst line 
treatment for metastatic disease. 
MATERIALS AND METHODS 
Between the end of 1989 and the beginning of 1993 patients with metastatic breast 
cancer were entered in the study. Eligibility requirements included measurable or 
evaluable disease, no prior chemotherapy for metastatic disease, WHO performance 
status s:2, white blood cell count ;:'3500/"L, platelet connt ;:, 100,000/"L, serum 
creatiuine s: 150 "moIlL, serum bilirubin s:25 "mol/L, and informed consent. 
Adjuvant chemotherapy was allowed when given more than one year before entry in 
this study. Treatment consisted of carboplatin 300 mg/m2 day 1, and etoposide 100 
mg/m2 days 1,3, and 5, every four weeks. Complete blood counts were performed 
weekly. In case of a white blood cell count < 3000/ "L or a platelet count 
< 100,000/ pL on the day of retreatulent, chemotherapy was postponed until recovery 
for a maximum of two weeks. Tumor response and toxicity were evaluated by 
standard WHO criteria (10). The initial planned statistical size of the study was 50 
patients anticipating a true response rate of 40 %. However after 34 patients the pa-
tients accrual was stopped because of the observed response rate. 
RESULTS 
Patients characteristics are listed in Table 1. Of the 34 entered patients, one patient 
was formally ineligible because of an elevated serum creatinine at the start of 
treatment. This patient was readmitted to the hospital 14 days after start of treatment 
because of a septicaemia with a clostridia species in the presence of a grade 4 
thrombocytopenia and leukocytopenia. The patient died two days after admission. 
Two patients (6%) achieved a complete response lasting 4 and 5 months. One of these 
patients had lymph node and liver metastases and the other had mUltiple skin 
metastases and a malignant pleural effusion. A partial response was observed in 7 
patients (21 %) with a median duration of 6+ months (range 5-8 months). Fifteen 
patients (45%) had stable disease with a median duration of 5 months (range 4-15 
months), and 9 patients had progressive disease. After progression 28 patients were 
treated with second-line chemotherapy. The four patients who achieved an objective 
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Table 1 Patient charactistics 
No. patients 
Median age (years) 
Range 
Peformance (ECOG) 
o 
1 
2 
Adjuvant treatment 
Chemotherapy 
Hormonal treatment 
Previous hormonal treatment for metastatic 
disease 
Only one prior regiment 
Two prior regimens 
Menopausal status 
Premenopausal 
Postmenopausal 
Dominant metastic site 
Visceral 
Bone 
Soft tissue 
No. of metastatic site 
One 
Two 
;?; Three 
Disease-free interval 
None 
< 2 years 
;?; 2 years 
Interval from first metastases to study 
registration 
None 
< 2 years 
;?; 2 years 
Interval initial diagnosis and start 
chemotherapy 
Median (months) 
Range 
34 
58 
29-73 
15 (44%) 
10 (29%) 
9 (26%) 
11 (32%) 
4 (12%) 
19 (56%) 
12 
7 
8 (24%) 
26 (76%) 
14 (41 %) 
9 (26%) 
11 (32%) 
5 (15%) 
19 (56%) 
10 (29%) 
4 (12%) 
14 (41 %) 
16 (47%) 
15 (44%) 
11 (32%) 
8 (24%) 
31 
0-206 
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response to second-line chemotherapy alI had responded to the previous treatment with 
carboplatin and etoposide. Median survival recorded from the start of chemotherapy 
for alI patients was 15 months. 
A total of 142 courses were administered with a median of 5 courses per patient. 
WHO grades 3 or 4 leukocytopenia or thrombocytopenia were observed in 15 (44%) 
and IO (29%) patients, respectively. No cumulative hematological toxicity was 
observed. Besides the already mentioned ineligible patient no other patient presented 
with granulocytopenic fever during treatment. Nausea and vomiting was grade 1 in 16 
(47%) patients, grade 2 in 8 (24%) patients and grade 3 in 10 (29%) patients. A grade 
1 mucositis was observed in 2 (6%) patients and a grade 2 in 2 (6%) patients. 
Alopecia was common in those patients who received more than 2 cycles of 
chemotherapy. 
DISCUSSION 
The most commonly used chemotherapy regimens for patients with metastatic 
breast cancer are either "CMF" based or include an anthracycline. The observed 
differences in response rates between the various reginlens are at least in part 
explained by differences in patient selection. Although the combination of carboplatin 
and etoposide has been given as second-line treatment and both agents have been 
included in high dose chemotherapy reginlens, this combination has not properly been 
tested as a first-line treatment. 
We investigated the activity of the combination of carboplatin and etoposide in patients 
with metastatic breast cancer who were either chemotherapy-naive or had only been 
treated with adjuvant chemotherapy. The predominant toxicity with this regimen 
consisted of thrombocytopenia and leukocytopenia. Althongh we observed one toxic 
death in a patient with renal impairment, the hematological toxicity was not cumulative 
and easily manageable in alI other patients. The non-hematological toxicity with this 
regimen was mild and consisted mainly of nausea and vomiting and alopecia. 
In 33 evaluable patients we observed with tWs regimen an objective response rate of 
27 % (95 % confidence interval I 1% - 43 %) with a median response duration of 6 
months. Although not tested in a randomized study we think that in view of the 
observed response rate and toxicity this regimen has probably no clear advantages 
above the more commonly used regimens. Higher response rates might be observed 
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with a dose intensification of both drugs. However such regimens necessitate the usage 
of intensive hematological support. 
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SUMMARY 
Purpose: The EORTC Breast Cancer Cooperative Gronp carried ont a randomized 
trial to compare doxorubicin with epirubicin as second-line chemotherapy in patients 
with metastatic breast cancer. 
Patients and methods: Two hundred and fifty-nine patients with at least one site of 
metastatic disease entered this trial, of whom 232 patients were eligible. Treatment 
consisted of doxorubicin 75 mg/m2 or epirubicin 90 mg/m2 Lv. every 3 weeks. 
Results: The overall response rates for doxorubicin and epirubicin were 36 % and 
28 % respectively (p = 0.173). The median time to progression was 23 weeks for 
doxorubicin and 19 weeks for epirubicin (p = 0.063) and the median duration of 
response was 40 weeks for doxorubicin and 32 weeks for epirubicin (p = 0.059). The 
median survival was 47 weeks for doxorubicin and 44 weeks for epirubicin (p 
= 0.196). 
Leukocyte count on retreatment day (p = 0.011) and platelet nadir (p = 0.031) were 
significantly lower in the doxorubicin treated group. Also mucositis (p < 0.001), 
diarrhea (p = 0.005) and hemorrhage (p = 0.048) were significantly worse in the 
doxorubicin arm. Nine patients on doxorubicin and 2 patients on epirubicin 
experienced congestive heart failure (CHF). 
Conclusion: At the dose levels used in this study, no statistical differences in 
response rate and survival were found between the two treatment arms. Treatment 
with doxorubicin tended to result in a slightly longer duration of response and time to 
progression but doxorubicin was more toxic than epirubicin. 
INTRODUCTION 
Doxorubicin is among the most effective chemotherapeutic drugs in the treatment 
of metastatic breast cancer. Used as a single agent doxorubicin induces response rates 
of approximately 40% as tlrst-line chemotherapy and about 20% as second-line 
therapy after failure or relapse on combination chemotherapy [1,2]. 
Although the acute toxicities of doxorubicin are manageable, the major cumulative 
dose-limiting toxic effect of the drug is the development of congestive heart failure 
(CHF), which Illay be irreversible and lethal [3,4]. The risk of CHF induction with 
doxorubicin is limited at a cumulative dose of less than 550 mg/m2, but increases 
rapidly thereafter, preventing the continuation of the use of the drug beyond this dose. 
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Since the early 1970's there has been a continuous search for antlu'acycline analogues 
with a more favourable therapeutic profile than doxorubicin. A number of 
anthracycline derivatives of lower cardiotoxic potential in animal models have been 
introduced into clinical trials, of which one is epirubicin, an analogue resulting from 
the epimerization of 4' -hydroxyl of doxorubicin [5j. The mechanism of action of 
epirubicin is similar to that of doxorubicin: binding to DNA and inhibiting synthesis 
and function of nncleic acid [6j. 
Experimental and phase I studies in breast cancer suggested that epirubicin had a 
more favourable therapeutic index than doxorubicin, Le. similar antitumor activity but 
less toxicity [6-9j. In the early phase II studies in metastatic breast cancer epirubicin 
showed antitumor activity comparable to that of doxorubicin [lOj. The toxicities 
enconntered with epirubicin therapy were: leucopenia, nausea and vomiting and no 
severe life threatening cardiac toxicity up to a cumulative dose of about 1000 mg/m2. 
In view of these early data the EORTC Breast Cancer Cooperative Group decided 
to conduct a randomized phase IIfIll study comparing directly epirubicin with 
doxorubicin, both given as single agents in patieuts with metastatic breast cancer 
relapsing after previous chemotherapy without anthracyclines. The dose levels selected 
for epirubicin and doxorubicin were 90 mg/m2 and 75 mg/m2, respectively. Both drugs 
were administered as an Lv. bolus injection every 3 weeks. Based on data of previous 
investigations, epirubicin 90 mg/m2 was anticipated to induce degrees of 
myelosuppression equivalent to doxorubicin 75 mg/m2 [8,10j. Hematological growth 
factors were not used in this study. 
PATIENTS AND METHODS 
Eligibility criteria 
Patients with metastatic breast cancer were eligible for this study, after giving 
informed consent according to the rules of the participating institution. 
Measurable or evaluable progressive disease was required as well as a performance 
status (WHO) better than 3. Liver enlargement, pleural effusion, ascites, bone marrow 
involvement and osteoblastic lesions were not considered as evaluable disease. No 
more than one previous combination chemotherapy reginlen without anthracyclines, 
as adjuvant therapy or for metastatic disease, could have been applied. Other exclusion 
criteria included renal (creatinine> 1 ,2mg/dl) and/or hepatic (bilirubin> 1,5 mg/dl) 
dysfunction, congestive heart failure, significant arrhythmia, bilateral bundle branch 
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block or history of myocardial infarction as well as previous or concurrent 
malignancies (except adequately treated carcinoma in situ of the cervix and/or 
carcinoma of the skin). 
Table I Accrual per institution 
Institution 
Finsen Center/Rigshospitalet, 
Copenhagen 
U.H. Gasthuisberg, Leuven 
Azienda Ospedaliere, Parma 
Rotterdam Cancer Institute 
Medical University, Gdansk 
Institut J. Bordet, Brussels 
U. H. Leiden 
U .H. Dijkzigt, Rotterdam 
U.H. SI. Radboud, Nijmegen 
Spaarne Hospital, Haarlem 
Total 
Study design 
Responsible physicians 
Dr. H.T. Mouridsen 
Dr. M. Andersson 
Dr. J. Wildiers 
Prof. G. Cocconi 
Dr. J.G.M. Klijn 
Prof. J. J assem 
Prof. R. Paridaens 
Prof. A. T. van Oosterom 
Dr. T.A.W. Splinter 
Dr. L.V.A. Beex 
Dr. C.A.M. De Swart 
N (%) 
73 (28.2) 
53 (20.5) 
41 (15.8) 
32 (12.4) 
27 (10.4) 
14 ( 5.4) 
13 ( 5.0) 
3 ( 1.0) 
2 ( 0.8) 
1 (0.04) 
---
259 
Eligible patients were randomized between epirubicin and doxorubicin treatment 
by telephoning to the EORTC Data Center. Patients failing either epirubicin or 
doxorubicin, after 2, 3 or 4 courses, were to be crossed over to doxorubicin or 
epirubicin, respectively. Originally the study was started as a randomjzed phase II 
trial, but after an interim analysis had been performed, it was continued as a phase III 
trial. 
Treatmelll protocol 
The doses of epitubicin and of doxorubicin were 90 mg/m2 and 75 mg/m2 
respectively. Both drugs were administered as an i. v. bolus injection and cycles were 
repeated every 3 weeks. 
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Table II 
DOX EPI Total 
Patient material 
Entered 128 131 259 
Ineligible 10 17 27 
Total eligible 118 114 232 
Non-evaluable 16 12 29 
Evaluable 102 101 203 
Reasons for ineligibility 
Prior or concomitant treatment 2 2 4 
Too low WBC at entry 2 1 3 
Poor performance status 2 5 7 
Cardiovascular disease at entry 2 2 4 
No measurable disease 2 2 4 
No ioformation 0 2 2 
Brain metastases 0 2 2 
Previous endometrial cancer 0 1 1 
Total ineligible 10 17 27 
Reasons for non evalnability 
Death before treatment started/poor 2 3 
condition preventing start of 
treatment 
Early stop of treatment for toxicity 4 2 6 
Refused treatment/lost to follow-up 5 I 6 
Incomplete/missing data I 6 7 
Additional/incorrect treatment 4 3 7 
Total eligible not fully evaluable 16 13 29 
Dose modificatiolls 
Treatment was delayed by I week if WBC were < 3 x 10'/1 or platelets < 100 
x 10'/l at the scheduled time of the subsequent cycle. Further dose adjustments were 
made as follows: 50% of the dose if after I week delay the WBC count was between 
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2 and 2,9 x 10'/1 and/or platelets between 50-99 x 10'/1, or postponement for another 
week if the WBC count was < 2 x 10'/1 or platelets < 50 x 10'/1. If postponement 
was required for > 3 weeks the patient went off study. The dose was also reduced 
to 50% if bilirubin level ranged between 2 aud 3 mg/dl, and to 0% with a bilirubin 
level above 3 mgt dl. 
Treatmellf duration 
Patients with remission or stable disease after two courses continued treatment until 
the disease progressed. On disease progression patients on epirubicin or on 
doxorubicin having received less than 5 courses were to be crossed over to 
doxorubicin or epirubicin, respectively. Treatment was to be stopped at a cumulative 
dose of 550 mg/m2 of doxorubicin and initially also for epirubicin. After 100 patients 
had been entered, the maximum epirubicin cumulative dose was increased to 900 
mg/m2. Therapy was also discontinued in case of congestive heart failure, severe 
persistent side effects or hematological toxicities requiring treatment delay for more 
than 3 weeks, or due to patient refusal. 
Pretreatmellf and follow-up studies 
Baseline investigations included history and physical examinatiOli, performance 
status, tumor measurements, complete blood count, chemistries, chest X-ray, a bone 
scau or skeletal survey, ECG and preferentially measurement of isotopic left 
ventricular ejection fraction (LVEF). All baseline investigations were repeated after 
2 courses and thereafter every 3-6 weeks. Chest x-ray, bone scan and/or bone surveys 
were repeated every 12 weeks. WBC and platelet nadirs were measured weekly during 
the fIrst two treatment cycles. 
Evaluation of response and toxicity 
Patients were evaluable for response if they had received at least two courses of 
chemotherapy and if tumor measurements had been repeated at 6 weeks. Assessment 
of response was done according to the DICC criteria [11]. Toxicity was assessed 
accordiug to the WHO criteria [12]. Duration of complete or partial response was 
measured from the date of randomization until the date of progressive disease. All 
cases were subjected to extramural review performed by both the study coordinator 
(A.T. van Oosterom) and an external reviewer with respect to eligibility and 
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evaluability, treatment effectiveness, toxicity, the correct"reporting of the data 
described in the fIles and their representation on the forms. 
Table III Patient characteristics at entry (aU eligible patients) 
DOX EPI 
(N = ll8) ( N = ll4) 
Age (median, rage) 56 yr (31-75) yr 56 yr (34-73) yr 
Performance statns WHO l'! % l'! % 
0 38 (32) 35 (31) 
1 49 (42) 53 (46) 
2 28 (24) 25 (22) 
Unknown 3 ( 2) 1 ( 1) 
Prior endocrine therapy 
None 31 (26) 33 (29) 
Ablative 22 (19) 19 (17) 
Additive 43 (36) 48 (42) 
Both 13 (11) 10 ( 9) 
Unknown 9 ( 8) 4 ( 4) 
Prior chemotherapy 115 (98) 110 (97) 
Dominant site 
Soft tissue 37 (31) 27 (24) 
Bone 32 (27) 31 (27) 
Visceral 49 (42) 56 (49) 
Menopausal status 
Pre-menopause 0 ( 0) 4 ( 4) 
Natural menopause 71 (60) 80 (70) 
Artificial menopause 38 (32) 25 (22) 
Unknown 9 ( 8) 5 ( 4) 
Statistics 
The response to treatment and degree of toxicity were compared using the chi-
square test for proportions and the chi-square test for linear trend. Leukocyte and 
platelet values were compared using the Wilcoxon rank sum test. Progression and 
survival curves were computed based on the Kaplan-Meier product limit estimate and 
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compared using the logrank test. Adjustment for imbalances in prognostic factors was 
done by means of retrospective stratification. 
RESULTS 
Patient characteristics 
Within this study (EORTC 10811) 259 patients were randomized by 10 institutions 
between June 1982 and May 1986, 128 to doxorubicin and 131 to epirubicin (Table 
I). The present analysis is based on a median observation time of 2.6 years. 
Twenty-seven patients were ineligible, and twenty-nine additional patients were not 
evaluable (Table II). The characteristics of the 232 eligible patients are given in Table 
III. The two treatment groups were well balanced with respect to age, performance 
status, and prior hormono- or chemotherapy. 
Table IV Number of treatment courses without 
cross-over (all eligible patients) 
DOX EPI 
(N = 118) (N = 114) 
N (%) N (%) 
0 2 ( 2) 1 ( 1) 
1 11 ( 9) 5 ( 4) 
2 13 (11) 18 (16) 
3 10 ( 9) 13 (11) 
4 14 (12) 13 (11) 
5 11 ( 9) 8 ( 7) 
6 6 ( 5) 22 (19) 
7 28 (24) 21 (18) 
8 8 ( 7) 6 ( 5) 
9 9 ( 8) 1 ( 1) 
10 2 ( 2) 1 ( 1) 
11 1 ( 1) 2 ( 2) 
12 1 ( 1) 2 ( 2) 
13 1 ( 1) 0 ( 0) 
14 1 ( 1) 0 ( 0) 
15 0 ( 0) 1 ( 1) 
median number 
of cycles 5 5 
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Table V Treatment duration and dosages (all eligible patients who started the 
treatment) 
DOX EPr 
(N = 116) (N = 113) 
Duration of treatment (days) 
median (range) 127 (1-314) 113 (1-323) 
N with information 116 113 
Dosage 
Total dose (mg) 
median (range) 568 (80-1476) 800 (140-2250) 
N with information 101 97 
Total dose (mg/m2) 
median (range) 383 (47-911) 447 (88-1452) 
N with information 92 93 
Total dose (mg/m2/week) 
median (range) 23 (10-38) 27 (12-49) 
N with information 90 92 
Total dose as % of the 
plalmed dose 
median (range) 90 (41-154) 91 (40-162) 
N with information 90 92 
Relative dose intensity N % N % 
< 70% 14 (16) 13 (14) 
70-89% 30 (33) 31 (34) 
90-109% 32 (36) 35 (38) 
;0, 110% 14 (16) 13 (14) 
N with information 90 92 
Reductions 
No 52 (58) 64 (70) 
At least once 38 (42) 28 (30) 
Delay 
No 42 (47) 51 (55) 
At least once 48 (53) 41 (45) 
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For the dominant site, a small imbalance was observed: visceral lesions were more 
frequent in the epirubicin arm and there were more soft tissue lesions in the 
doxorubicin arm. 
Treatmel/l duration alld dosages 
Three eligible patients never started their treatment, one patient in the doxorubicin 
arm had an episode of infection soon after randomization, and another one refused to 
start the treatment. One patient in the epirubicin arm had died suddenly before the 
treatment was started. 
Table VI Response rate (all eligible patients) 
N 
Complete response 5 
Partial response 38 
No change 37 
Progression/EDINot 38 
eval. 
Progression 18 
Early death due to 1 
malignant disease 
Early death due to 3 
toxicity 
Not evaluable 16 
Two-sided P-value for 
trend 
% of responders 
CRor PR 
no objective response 
Two-sided P-value for 
comparison of the % 
of response 
138 
43 
75 
DOX 
(N = 118) 
EPI 
(N = 114) 
(%) N 
( 4) 2 
(32) 30 
(31) 45 
(32) 37 
(15) 23 
(1) 0 
( 3) 0 
(14) 14 
P = 0.324 
(36) 32 
(64) 82 
P = 0.173 
(%) 
( 2) 
(26) 
(40) 
(33) 
(20) 
( 0) 
( 0) 
(13) 
(28) 
(72) 
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Table IV shows the number of courses administered. The median uumber of treatment 
courses was 5 in both arms; I to 14 cycles In the doxorubicln arm and 1 to 15 cycles 
in the epirubicin ann. 
In Table V treatment duration and total dosages administered are depicted. The median 
duration of treatment was 127 days in the doxorubicin arm (range 1 to 314 days) and 
113 days in the epirubicin ann (range I to 323 days). The median dose of drug 
received per square meter was 383 mg in the doxorubicin arm (range 47 to 911 mg) 
and 447 mg In the epirubicln arm (range 88 to 1452 mg). The median dose intensity 
was 90% in the doxorubicln arm (range 41 to 154%) and 91 % in the epirubicin arm 
(range 40 to 162%). Fifty-three percent of the patients In the doxorubicin arm and 
45 % of the patients In the epirubicln arm had at least one cycle delayed. Dose 
reductions occurred In 42 % and 30% of the patients in the doxorubicin and epirubicln 
arms, respectively. Twenty-one patients on doxorubicin and 16 on epirubicln stopped 
prematurely the treatment because of toxicity or treatment refusal. 
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Including the non evaluable patients, the response rate (CR + PR) was 36 % for 
the doxorubicin arm (95% CI: 28-45%) and 28% for the epirubicin arm (95% CI: 20-
36%, Table VI). This difference of8% in the response rate (95% CI: -3% - +20%) 
is not significant using the chi-square test (p = 0.173). Likewise it is not significant 
using a test for linear trend (p = 0.324 for CR vs PR vs NC vs other). The response 
according to the dominant site of disease is presented in Table VII. When stratified 
by the dominant site of the disease, the conclusions are the same. The duration of 
response among the complete (CR) and partial (PR) responders is presented in fignre 
1. The median duration of response as measured from the date of randomization was 
40 weeks for doxorubicin and 32 weeks for epirubicin. Using the logrank test, this 
difference is just not significant (p = 0.059). 
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T bl VllR a e esponse oy ommant SI e b d ·t 
CR PR NC PO/EO/NE N 
N (%) N (%) N (%) N (%) 
Soft tissue 
~ ~~ m~ g~~ g~~ OOX 3 12 11 11 37 EPI 1 10 9 7 27 
Bone 
j 5~ g~~ _f~~~ -g~~ OOX 1 12 12 7 32 EPI 1 9 13 8 31 
Visceral 
~ 51 ggl ~~il ml OOX 1 14 14 20 49 EPI 0 11 23 22 56 
P-value for a trend 
in response stratified P = 0.436 
by dominant site 
P-value for the 
comyarison of the P = 0.236 
% ° r:ronse (CR + PRJ 
stratifi by dominant site 
Time to progression for all eligible patients is presented in figure 2. The median time 
to progression was 23 weeks for doxorubicin and 19 weeks for epirubicin. Using the 
logrank test with or without adjustment for dominant site, this difference is not 
statistically significant (unstratified p = 0.063, stratified p = 0.085). Figure 3 shows 
the duration of overall survival for all eligible patients. The median survival for 
patients treated with doxorubicin was 47 weeks and for patients treated with epirubicin 
44 weeks (unstratified p = 0.196, stratified p = 0.385). An analysis of tinle to 
progression and duration of survival in all randomized patients yielded similar results. 
A total of 5 patients initially treated with epirubicin were crossed over to doxorubicin 
treatment because of progressive disease. None of these patients responded. Among 
9 patients not responding to first-line doxorubicin, 1 PR (11 %) was observed with the 
use of second-line epirubicin treatment. 
Toxicity 
The hematological toxicity is presented in table VIII. It is expressed either as nadir 
or as retreatment day (frrst day of next cycle) values computed as the worst reported 
value over all cycles. The difference in the lowest leukocyte count on retreatment day 
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Table VIII Hematological toxicit,!: (an eligible l!atients who started the treatment) 
DOX EPI P-value' 
(N = 116) (N = 113) 
Leukocytes (10'/1) 
Nadir over the whole 
treatment period 
median (range) 2.5 (0.2-3.9) 2.8 (0.2-4.0) 
N with information 60 56 P = 0.150 
Worst retreatment value 
over the whole treatment 
median (range) 3.6 (2.0-10.3) 3.9 (2.3-12.7) 
N with information 103 107 P = 0.011 
Nadir over the first two 
cycles 
median (range) 2.5 (0.2-3.9) 2.7 (0.2-4.0) 
N with information 42 38 P = 0.429 
Worst retreatment value 
over the first two cycles 
median (range) 4.0 (2.2-10.5) 4.3 (2.5-17.5) 
N with information 103 107 P = 0.030 
Platelets (10'/1) 
Nadir over the whole 
treatment period 
median (range) 88 (8-206) 143 (27-335) 
N with information 24 22 P = 0.031 
Worst retreatment value 
over the whole treatment 
median (range) 244 (50-592) 266 (105-552) 
N with information 102 107 P = 0.077 
Nadir over the first two 
cycles 
median (range) 77 (8-301) 127 (27-335) 
N with information 19 17 P = 0.163 
Worst retreatment value 
over the first two cycles 
median (range) 290 (50-656) 279 (107-692) 
N with information 102 107 P = 0.778 
IWilcoxon Rank Sum test 
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Table IX Non hematological toxicity (worst grade reported during the treatment period 
for aU eligible patients who started the treatment) 
Grade Total P-value 
0 1 2 3 4 
Oral 
DOX 57 26 24 7 0 114 
EPJ 89 l3 10 I 0 113 P<O.OOI 
Diarrhea 
DOX 88 11 12 2 1 114 P=0.005 
EPJ 103 4 6 0 0 113 
Haemorrhage 
DOX 104 5 4 1 0 114 
EPJ 111 0 2 0 0 113 P=0.048 
Nausea! 
Vomiting 
DOX 9 20 46 31 8 114 
EPJ 6 28 49 26 4 113 P=0.304 
Fever 
DOX 90 11 12 0 2 115 
EPJ 93 12 8 0 0 113 P=0.215 
Alopecia 
DOX 10 4 15 81 2 112 
EPJ 15 2 l3 80 1 III P=0.483 
Infection 
DOX 89 14 9 1 2 115 
EPJ 93 9 6 3 1 112 P=0.546 
was significant between the doxorubicin and epirubicin arm (p = 0.011) with a lower 
valne in the former arm. The platelet nadir (based on 46 patients) was significantly 
lower in the doxorubicin arm (p = 0.031). Three patients died in the doxorubicin arm 
with infectious complications during leUkopenia, whereas no toxic deaths were 
observed in the epirubicin anu. The non-hematological toxicities are presented in 
Table IX, displaying the maximal toxicity assessed per patient excluding information 
after crossing over. 
Mncositis and diarrhea were significantly lower in the epirubicin treated patients than 
in the doxorubicin treated patients (p < 0.001 and p = 0.005, respectively). There 
were also less hemorrhages with epirubicin than with doxorubicin (p = 0.048). 
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Concerning cardiotoxicity, 9 patients in the doxorubicin arm and 2 patients in the 
epirubicin arm experienced clinical CHF. However, sporadic measurements of L VEF 
precluded detailed assessment of cardiotoxicity. 
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There is virtually no cure of disseminated breast cancer. Therefore, treatment of 
metastatic disease is palliative, and aims at symptom relief and prolongation of life. 
In this situation side-effects of therapy should be minimal. 
The objective of the present study (started in the eighties) was to compare the 
activity and toxicity of doxorubicin with its presumed equally effective but less toxic 
derivate epirubicin as second-line chemotherapy in patients with metastatic breast 
cancer. To the best of our knowledge this is the largest randomized trial directly 
comparing the two anthracyclines in advanced breast cancer. Eight smaller randomized 
studies in metastatic breast cancer have compared the efficacy of mono therapy with 
144 
Chapter 10 
both drugs given on an equimolar or equimyelotoxic base (Table X). In the four 
studies comparing epirubicin with doxorubicin on an equimolar base no differences in 
response percentages between the two treatment arms were observed [14,16,18,20]. 
However, the numbers of patients included in those studies were small, precluding any 
firm conclusions. Toxicity, however, was generally more pronounced in the 
doxorubicin treated patients. 
Table X Doxorubicin vs Epirubicin as siugle agent therapy in metastatic breast 
cancer 
Author Year No. of Dose mg/m2 Response rates % 
patients DOX EPI DOX EPI Ref 
Brambilla 1986 42 75 75 52 62 14 
Perevodchikova 1987 30 90 90 33 33 16 
Lawton 1990 56 70 70 36 32 18 
Gasparini 1991 43 20' 20' 38 36 20 
. ", .................. ,", ......... ... " ..................... " ............ .............. " ............... .................................. .. ........................... 
Jain 1985 52 60 85 25 25 13 
Taguchi 1986 63 40 60 35 56 15 
Hortobagyi 1989 48 60 90 29 26 17 
Perez 1991 138 60 90 47 49 19 
Bontenbal 1996 233 75 90 36 28 this 
stodX 
I: Weekly administrations 
The four other studies compared the two drugs on an expected equimyelotoxic base 
with doses of epirubicin ranging from 1.4 to 1.5 times the dose of doxorubicin 
[13,15,17,19]. Similarly noue of these studies showed significant differences in 
response rates, duration of response or survival between the two treatment arms. In 
the largest of these four studies, bone marrow toxicity of doxorubicin 60 mg/m2 and 
epirubicin 90 mg/m2 were ahnost superimposable, and the same results were found for 
gastro-intestinal toxicity [19]. 
The efficacy of equimolar doses of epirubicin and doxorubicin as part of a drug 
combination with fluorouracil and cyclophosphamide (FEC vs FAC) was investigated 
in two large randomized trials [21,22]. Response percentages, duration of response 
and time to progression did not differ in the two treatment arms. However, the 
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epil1lbicin combination showed a lesser degree of myelosuppression, nausea and 
vomiting. 
In our study no significant differences in response rates were observed between the 
two dl1lgs, with 36% versus 28% objective responses (CR + PR) for doxol1lbicin and 
epimbicin respectively. There was at best a trend in favor of doxol1lbicin for the 
median duration of response (40 vs 30 weeks), and for the median time to progression 
(23 vs 19 weeks), but the differences were small and duration of survival was the 
same in both groups. An explanation for the small differences we observed in time to 
progression and duration of response can possibly be found in the initial design of the 
study, where treatment had to be stopped after a cumulative dose of 550 mg/m2 was 
reached for both drugs. Indeed, 14 patients in the epimbicin arm stopped treatment 
after a cumulative dose of 500-600 mg/m2. Reduction of the treatment period could 
have influenced the time to progression and duration of response as was found in the 
studies of Ejlertsen et aJ. and Coates et aJ. [23,24]. On the other hand dose reductions 
occurred more frequently in patients treated with doxol1lbicin (42 vs 30%). 
The increased toxicity seen with doxorubicin gives rise to the question if we used 
an insufficient dose of epirubicin. Bone-marrow toxicity is historically used to relate 
the dose of one dl1lg to another [25]. At the time this study started clinical experience 
suggested that doxol1lbicin 75 mg/m2 and epimbicin 90 mg/m2 would induce 
comparable degrees of myelotoxicity [8,10]. In 1990 Mouridsen reviewed ten years 
of clinical experience with epirubicin, and calculated the equitoxic dose ratio for the 
hematologic toxicity of dOXOlUbicin and epimbicin to be 1:1.2. [26]. Drug dosages 
chosen in this study fulfilled this criterium. Furthermore, Bastholt et aJ. compared the 
efficacy and toxicity of 4 different dose levels of epil1lbicin in patients with metastatic 
breast cancer [27]. An increase of the dose from 90 mg/m2 to 135 mg/m2 resulted in 
increased toxicity but had no impact on the efficacy of the dl1lg. 
In conclusion: a trend to but just no significant difference in efficacy is achieved 
with doxol1lbicin 75 mg/m2 and epirubicin 90 mg/m2 in the treatment of advanced 
breast cancer. On the other hand, the treatment with epil1lbicin is associated with 
significantly less side-effects. 
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SUMMARY 
Suppression of the secretion of prolactin, growth hormone and insulin like growth 
factor I might be important in the growth regulation and treatment of breast cancer. 
Because estrogens may counteract the antitumor effects of such treatment, the 
combination of an anti-estrogen (tamoxifen), a somatostatin analogue (octreotide) and 
a potent anti-prolactin (CV 205-502) might be attractive. In this respect we performed 
a fIrst exploratory long-term study on the feasibility of combined treatment and 
possible clear differences in endocrine and antitumor effects during such combined 
treatment versus standard treatment with tamoxifen alone. Twenty-two postmenopausal 
patients with metastatic breast cancer (ER andlor PR positive or unknown) were 
randomized to receive either 40 mg tamoxifen per day or the combination of 40 mg 
tamoxifen plus 75 p.g CV 205-502 orally plus 3x 0.2 mg octreotide s.c. as fIrst-line 
endocrine therapy. An objective response was found in 36 % of the patients treated 
with tamoxiren alone and in 55 % of the patients treated with combination therapy. 
Median time to progression was 33 weeks for patients treated with tamoxifen and 84 
weeks for patients treated with combination therapy, buth the numbers are to small for 
hard conclusions. There was no difference in overall postrelapse survival between the 
two treatment arms. With respect to the endocrine parameters there was a signifIcant 
decrease of plasma IGF-l levels in both treatment arms, while during combined 
treatment plasma growth hormone tended to decrease and plasma prolactin levels were 
strongly suppressed; in some patients also insulin and TGF-a decreased during the 
triple therapy. Although there was no signifIcant difference in mean decrease of 
plasma IGF-l levels between the two treatment arms, combined treatment resulted in 
a more uniform suppression of IGF-I. Therefore, the addition of a somatostatin 
analogue and an anti-prolactin may potentially enhance the efficacy of anti-estrogens 
in the treatment of breast cancer due to favorable endocrine and possible direct 
antitumor effects. Large phase II trials using depot formulations (in order to increase 
the feasibility) of somatostatin analogues are warranted to demonstrate the potential 
extra benefIcial antitumor effects of such combination therapy. 
INTRODUCTION 
Different steroid hormones, peptide hormones, growth factors and other trophic 
substances are involved in the growth regulation of human breast cancer (1-2). 
Estrogens, especially estradiol, are the most potent growth stimulatory hormones of 
150 
Chapter 11 
breast cancer. Therefore, endocrine treatment of metastatic breast cancer usually 
employs antisteroidal agents such as tamoxifen resulting in response rates of 30-40% 
(3). 
Together with estradiol, insulin like growth factors (IGFI and IGF2), are the most 
potent mitogens for breast cancer cells (1.4,5). The growth effects of both are 
mediated predominantly via IGFI receptors, which have been demonstrated in 67-93 % 
of primary human breast cancers (6-9) at higher density than in normal or benign 
breast tissue (10). In vivo, pituitary-derived growth hormone (GH) regulates endocri-
nologically the secretion of IGF-l (ll,12), but possibly has also regulatory effects on 
local IGF-l secretion within (tumor) tissues (12-14). In addition, in breast cancer local 
production of GH with potentially a paracrine function has been described (15). In 
vitro, physiological concentrations of the lactotrophic hormones GH and prolactin 
(PRL) can stimulate the growth of breast cancer cells (16-19). In primary human 
breast cancers receptors for these lactotrophic hormones have been demonstrated in 
13-72% of series of tumors investigated depending on the techniques used (19). 
Furthermore, increased plasma levels of both GH (20) and PRL (20,21) as well as of 
IGF-I (22) bave been found in patients with breast cancer. Therefore suppression of 
GH, PRL and IGF-I secretion might be important in the treatment of breast caucer. 
Suppression of GH and IGF-l secretion can be induced by somatostatin and its 
analogues (ll,14,23-26). Interestingly, also receptors for somatostatin (SSTR) have 
been demonstrated in 36-67 % of primary human breast cancers (2,9,27,28) and in 
even 75 % by in-vivo receptor scintigraphy,(29) indicating that somatostatin analogues 
can affect directly tumor growth. Indeed, previously we (30) and others (ll,31) 
showed direct growth inhibitory effects of somatostatin analogues on human breast 
cancer cell-lines. 
Based on the data mentioned above, it can be concluded that somatostatin 
analogues and antiprolactins can have beneficial direct and indirect effects on the 
treatment of breast cancer. However, thus far single treatment with these ageuts 
showed only minor activity in postmenopausal patients with metastatic breast cancer 
(2,26,32-38). Because unopposed estrogen action can overrule the growth inhibitory 
effects of somatostatin analogues (30) and/or antiprolactins, combination treatment 
with an antiestrogen, a somatostatin analogue and an antiprolactin might be of value 
and can potentially increase the efficacy of single treatment with tamoxifen alone. In 
view of the fact that also tamoxifen affects growth factor secretion (1,39-45) such 
combination treatment might be extra attractive. However, clinical results of such 
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combined treatment modality have not yet been reported. In the present paper, we 
report on the feasibility and the endocrine and long-term antitumor effects of combined 
treatment with tamoxifen, the somatostatin analogue octreotide and a new potent 
dopamine agonist (the antiprolactin CV 205-502) in comparison with those of single 
treatment with tamoxifen, in addition to an elaborate overview and discussion of 
literature data. 
PATIENTS AND METHODS 
The study was performed after approval by a local Human Investigations Commit-
tee (trial DDHK 88-30). Between August 1989 and May 1991, 22 postmenopausal 
patients with previously untreated metastatic breast cancer were randomized after prior 
informed consent to be treated within this trial. The patient characteristics are summar-
ized in Table 1. Two patients were not evaluable: one stopped treatment with 
octreotide within 2 days not tolerating daily injections and another patient stopped 
single treatment with tamoxifen within two months because of detection of an 
endometrial carcinoma. Later on, one patient appeared to be perimenopausal according 
to a rise in estradiol levels after start of treatment with tamoxifen. Therefore, this 
patient was not included in the analysis for estradiol levels. Presently, the mean 
follow-up of all 20 evaluable patients is 3 years (range 3 months - 6 years). Within 
this follow-up period all but 2 patients showed progressive disease and 14 died. 
The patients were randomized to be treated with either tamoxifen 40 mg per day or 
with the combination treatment consisting of 40 mg tamoxifen, 75 p.g of the dopamine 
agonist CV 205-502 (®Norprolac) and the somatostatin analogue octreotide 
(®Sandostatin) 200 mg tid subcutaneously every day. Dose modification was not 
allowed. The duration of treatment varied from 6 weeks to more than 6 years. Patients 
were evaluated for toxicity and response every 6-12 weeks. Measurements of tumor 
response were performed according to the UICC criteria. 
Plasma samples for measurement of basal hormone and growth factor concentrations 
(Table 2) were taken before and regularly between 4-24 weeks after start of treatment 
(fig. 1). Plasma peptide hormones and growth factors were measured by radio-
innnunoassays and radioreceptor assay (TGF-a) as described before (46). Plasma 
estradiol levels were measured by radioimmunoassay. 
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Table 1 Patient Cbaracteristics 
Tamoxifen Combination Total 
therapy 
Number of patients entered: 12 10 22 
Number of patients evaluable: 11 9 20 
Menopausal status: 
post 10 9 19 
peri I 0 1 
Age: Mean (range) 59 (49-71) 62 (49-73) 60 (49-73) 
WHO Performance Status: 
0 6 5 11 
1 3 2 5 
2 2 2 4 
Disease sites: 
soft tissne 3 3 6 
lymph nodes I 1 2 
bone 9 6 15 
liver 4 I 5 
lung 2 3 5 
Number of disease sites: 
1 5 5 10 
2 5 3 8 
3 0 I 1 
4 1 0 1 
Receptor status 
(in tumor or metastases): 
ER and/or PR positive 10 6 16 
ER and PR unknown 1 3 4 
Statistical methods 
The expected accrual rate per year was 60 patients. Becanse of a much lower 
actual recruitment, especially due to refusal of daily injections in the combined 
treatment arm, the trial was closed after inclusion of 22 patients in 2 years. Because 
of the relatively low number of patients in this study the analysis of the data has been 
prinlarily descriptive, directed at the calculation of response rate, progression-free 
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survival with actuarial methods and a description of the endocrine effects of the 
treatments by calculation of the change in plasma concentration levels from baseline. 
Because of the lintited power of this study to detect differences between treatment 
arms, all p-values reported in this paper should be regarded as exploratory. The 
logrank test was used for the comparison of progression free survival. The Mallll-
Whitney non-parametric two sample test was used to compare the change in plasma 
levels in both treatment groups. 
Table 2 
Hormone/ 
Mean plasma levels of hormones and growth factors 
before and during treatment 
Treatment No. of Pretreatment Absolute chauge 
Growth factor eval. value from pretreatment 
patients (mean ± value (mean ± SD) 
SD) 
E2 -TAM N = 7 87 ± 75 
(pmol/I) - Combined N = 6 83 ± 80 
nGH -TAM N=lO 0.8 ± 1.2 
(I'g/I) - Combined N = 7 2.6 ± 3.1 
PRL -TAM N=lO 5.2 ± 1.9 
(I'g/I) - Combined N = 7 8.0 ± 5.2 
Insulin -TAM N=lO 25.7 ± 
(mUll) 15.3 
- Combined N = 7 57.5 ± 
41.4 
TGF-a -TAM N=lO 0.30 ± 
(ng/ml) 0.14 
- Combined N=8 0.39 ± 
0.13 
IGF-l -TAM N=lO 149 ± 64 
(ng/mJ) - Combined N = 8 137 ± 39 
* p-values indicate differences in decrease between the two treatment groups 
- TAM = tamoxifen 
-21 ± 63 
-17 ± 74 
p=O.48* 
+1.23 ± 1.78 
-1.3 ± 3.32 
p=O.10 
-0.77 ± 2.62 
-5.5 ± 4.85 
p=O.OO6 
+ 15.6 ± 39.8 
-32 ± 37.6 
p=O.02 
+0.02 ± 0.09 
-0.08 ± 0.12 
p=O.l1 
-62 ± 47 
-69 ± 28 
p=O.63 
- Combined = combination treatment with tamoxifen, octreotide and CV 205-502 
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RESULTS 
a.Endocrine effects of treatment 
Figure I shows the absolute change from baseline in plasma hormone and growth 
factor concentrations for all patients with evaluable measurements. Since no trend was 
apparent in the values during treatment from one month after the start of treatment, 
for each patient all these values measured between 4 and 24 weeks are summarized 
by the mean. Table 2 shows the mean pretreatment values and the absolute mean 
change of each of the endocrine parameters from pretreatment values. Pretreatment 
basal estradiol levels were comparable in both treatment groups and the values during 
treatment did not show a systematic change. Basal GH showed a small decrease in 4 
of 7 investigated patients during combined treatment and in none of 10 patients during 
single treatment with tamoxifen (fig. I), but in view of differences in pretreatment 
values and a large variation during treatment there was only a trend for a difference 
(p=0.10) between the two treatment arms (Table 2). Most interesting was the 
significant decrease (p < 0.0002) of plasma IGF-I levels during treatment (fig. I), 
i.e. overall a mean decrease of 49 % during combined treatment and 38 % during single 
treatment with tamoxifen. This decrease showed no significant difference between the 
two treatment groups, either absolutely (p=0.63, Table 2) and percentually (p=0.21). 
However, IGF-I suppression was more uniform during combined treatment in contrast 
to a strong variation in response during tamoxifen treatment (fig. I). With respect to 
plasma prolactin levels the combined treatment caused a clearly significant suppression 
of prolactin secretion due to the antiprolactin CV 205-502, while tamoxifen had no 
significant effect (fig. I, Table 2, p=0.006). 
With respect to the other endocrine parameters, some patients showed a decrease of 
plasma insulin and TGF-e< levels during combined treatment (fig. I), but differences 
in overall results between the two treatment arms (Table 2) were only found for 
insulin (p=0.02) and not for TGF-e< (p=O.l1). 
b.AlI/itllmor effects 
Five (55 %) of 9 patients treated with the combination therapy showed an objective 
response compared to 4 (36 %) out of II patients treated with tamoxifen alone (Table 
3). Median time to progression was 84 weeks for the patients treated with combination 
therapy versus 32 weeks for patients treated with tamoxifen. Progression-free survival 
was slightly better for patients treated with the combination of drugs than those treated 
with tamoxifen alone (Fig. 2), but the numbers of patients in this feasibility study are 
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too small to draw definite conclusions. There was no difference between the two 
treatment arms with respect to overall postrelapse survival. 
Tamoxifen Combination t~eatment 
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Figure 1 
Effect of tamoxifen (left side of panel) and of combination treatment (right side of panel) on plasma 
hormone and growth factor concentrations. The zero~lines represent the basal pretreatment values, 
while the absolute individual changes are indicated as determined 4-24 weeks after start of treatment. 
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c.Toxicity 
Treatment with the triple endocrine combination therapy appeared to be feasible, 
but a significant number of potentially eligible patients refused randomization because 
of the inclusion of three daily subcutaneous injections with Sandostatin within one of 
the treatment arms. However, subjective side-effects were minimal in both treatment 
arms. During combination therapy, shortly after start of treatment, slight nausea grade 
1 (WHO) was observed in a minority of the patients, but no serious complaints were 
reported. One patient with diabetes mellitus had a persistent fall in plasma glucose 
levels during combined therapy needing reduction of daily insulin dosages (maybe as 
a consequence of suppression of glucagon secretion by octreotide). The most important 
side-effect was the development of asymptomatic gallbladder stones in one patient 
treated with combination therapy. 
Table 3 Type of responses and time to progression (in weeks) 
CR PR SD PD 
Tam 1 3 3 4 
(162) (32,66,78) (25,39,159) (10-21) 
Combination 2 3 2 2 
treatment (171,209) (84,86,115) (22,36) (7,11) 
DISCUSSION 
The relative role of PRL, GH and IGF-I in the development and treatment of 
human breast cancer is not clearly understood. All three peptides have been observed 
to be increased in plasma of a variable percentage of breast cancer patients (20-22). 
GroWtll stimulation of breast cancer cells by these peptides can be blocked by 
monoclonal antibodies (47-50). In addition, all three peptides (1,15,47,48,51,52) and 
their receptors (1,6-9,19) have been demonstrated in animal mammary tumors and/or 
human prinlary breast cancers suggesting a role in autocrine/paracrine cell growth 
regulation. However, nearly all endocrine therapies are focused on antagonism of 
estradiol, the primary mitogen for human breast cancer (3). 
Some trials have tested the value of suppression of prolactin secretion by dopamine 
agonists (antiprolactins) (26,32, 34-38,53). Initial trials using single dopaminergic 
treatment with L-dopa or bromocriptine showed poor results (35-38). Two studies 
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investigated combination therapy of bromocriptine with antisteroidal treatment. 
Dogliotti et aJ. (54) found that bromocriptine in combination with high dose progestins 
reduced the percentage of patients with progressive disease, but Bonneterre et aJ. (55) 
observed no additional antitumor effect of bromocriptine to tamoxifen. This might be 
explained by the fact that progestins can increase plasma PRL levels (56), while in 
contrast tamoxifen has rather inhibitory effects on PRL secretion (57-59). Other 
authors (19,26,41) assumed that the lack of antitumor effects by single dopaminergic 
treatment may have been due to the presence ofhGH, which is also a lactogen and can 
bind to lactotrophic receptors (19). However a few pilot studies using combined 
treatment with bromocriptine and a GH lowering drug such as a somatostatin analogue 
showed no impressive effects in heavily pretreated patients with metastatic breast 
cancer (2,26,32,34). 
In view of the accnmulating evidence regarding the importance of IGFs in the 
growth regulation of breast cancer (1,4), in the past decade there was an increasing 
interest in the GH/IGFaxis especially due to the development of potent somatostatin 
analogues, which agents can suppress the function of the GH/IGFaxis 
(11,14,23,24,26,46). This interest was further increased by the detection of SSTRs in 
breast cancer cell lines and tissues (30,31,60·62) and in about half of primary breast 
cancers (27-29). Indeed, we (30) and others (11,31) demonstrated direct growth 
inhibitory effects by various somatostatin analogues on different breast cancer cell 
lines. Inhibition of cell proliferation seems to be mediated especially by subtypes 
SSTR2 and SSTR5 (24,62). Also in some experinlental animal models somatostatin 
analogues were able to cause inhibition of mammary tumor growth (11 ,14,23,24,63-
66). 
However, in 4 clinical studies (2,26,32-34), treatment of 38 (heavily) pretreated 
patients with octreotide caused only one objective response and 5 times stable disease 
(together 16%) (2). Also in previously untreated patients single fIrst-line treatment 
with octreotide appeared to be less effective than common standard treatment 
modalities, which resulted in early stopping of this treatment arm in an ongoing 
randomized trial of the Mayo Clinics. These disappointing results of single 
somatostatin analogue treatment (or in combination with an antiprolactin) can be 
explained by our observation that estradiol abolished these growth inhibitory effects 
(30). Therefore, already at time of start of the present clinical study, in 1989, our 
study design testing these drugs in combination with an antiestrogen seems to be more 
appropriate. Later on, this approach was supported by the results of different 
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preclinical studies indeed showing additive biological (67) and antitumor effects 
(66,68) of somatostatin analogues to endocrine therapy with tamoxifen or by surgical 
oophorectomy in hormone sensitive tumors in vivo. Meanwhile, tamoxifen appeared 
not only to act by blocking the growth stimulatory effects of estrogens but also to 
modify growth factor secretion (1 ,39-45,67,69-71) and to suppress the GH/IGF-I axis 
(41,59,72) and prolactin secretion (57-59). Tamoxifen and other antiestrogens can 
decrease especially plasma IGF-l-levels (39-45), but also can down-regulate IGF-I-R 
(73) and can suppress IGF-l-induced breast cancer cell proliferation (74). 
Furthermore, both octreotide (11) and anti-estrogens (43-45,74) affect IGF binding 
proteins. Thus additive endocrine and antitumor effects could be expected from 
combination therapy with tamoxifen plus a somatostatin analogue and an antiprolactin. 
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In our study tamoxifen caused rather an increase than a decrease of basal GH 
concentrations. In contrast, in several patients combination treatment tended to 
decrease basal GH levels. Previously, Pollak et al. (25) and Manni et al. (26) showed 
significant suppression of stimulated GH-Ievels (which are less affected by fluctuation 
than basal plasma GH levels during the day) by octreotide treatment. In contrast to the 
basal GH concentration, IGF-I levels are stable during the day. Strikingly, we found 
no additive suppressive effects of tamoxifen and octreotide on mean plasma IGF-I 
concentrations, but combination treatment caused a more uniform suppression ofIGF-
I (fig. I). Both single tamoxifen and combination treatment caused a decrease of about 
40-50%. This might partly be explained by the observation that tamoxifen already 
increases the release of endogenous hypothalamic somatostatin resulting in blunting 
of pituitary GH pulse amplitude (72). However, this does not exclude that clear 
additive endocrine effects might be found in studies using lower dosages of tamoxifen 
(20 instead of 40 mg/day) or higher dosages of somatostatin analogues than used in 
our trial. Recently, Kiang et al (42) reported an interesting observation indicating that 
the type of antitumor response is related with the extent of IGF-I suppression. In our 
study, we were not able to confirm tWs observation. 
With respect to basal plasma insulin and TGF-a concentrations we found no 
impressive differences between the two treatment arms, although the combination 
therapy had a suppressive effect in some patients. Although somatostatin analogues 
might affect LH secretion in premenopausal patients (75), in our postmenopausal 
patients no significant effects on plasma E, levels were observed. This finding 
confirms the results of the study of Malmi et al (26), who also found no effect of com-
bined octreotide/bromocriptine treatment on plasma LH, FSH and E, levels. Finally, 
with respect to prolactin secretion (which is partly influenced by estrogens) the anti-
estrogen tamoxifen tended to decrease plasma PRL levels, but not significantly. 
Interestingly, the new very potent antidopaminergic drug CV 205-502 used in the 
treatment of prolactinomas (76) caused a strong significant decrease of basal prolactin 
levels (with about 70%) also in our patients with normal PRL secretion. This 
suppression is more pronounced than previously reported for bromocriptine. However, 
in contrast to estradiol, it is presently unknown to which plasma levels PRL has to be 
suppressed in order to contribute. to a (potential) extra antitumor effect. 
With respect to the performance of our study, the triple endocrine therapy appeared 
to be feasible in the presence of only few non-serious side effects. However, a 
significant number of potentially eligible patients refused participation in the trial 
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because of the need of three daily injections in one of the treatment arms. This 
problem will be resolved by the application of depot preparations of somatostatin 
analogues, which are increasingly available. Furthermore continuous administration 
of drugs is generally more effective than daily injections as demonstrated for 
octreotide (66,77). In our pilot study the patients treated with the combination therapy 
showed less frequently progressive disease from start of treatment and a longer 
progression-free survival, but the numbers are undoubtedly too small for definite 
conclusions and our results have to be confinned by other but much larger studies. 
In conclusion: the results of different preclinical studies indicate that the addition of 
a somatostatin analogue (with or without combination with an antiprolactin) may 
enhance the antitumor efficacy of antiestrogens in the treatment of breast cancer (66-
68). Our first randomized clinical study on triple therapy showed that in principle such 
an approach is clinically feasible and caused significant endocrine effects. A large 
multicenter randomized study in metastatic breast cancer, using a depot preparation 
of octreotide (instead of daily injections), is warranted to prove the presence of such 
potential extra beneficial antitumor effect. 
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Summary 
Breast cancer is the most important cause of cancer death in women. Although 
adjuvant systemic therapy can cure a minority of the patients, metastatic disease is still 
lethal, and treatment in this stage of the disease is primarily palliative. Therefore, 
there is an urgent need for more effective therapy, andlor drugs with less side-effects. 
The first part of this thesis describes the results of preclinical studies testing the 
concept of recruitment of slowly proliferating (hormone-responsive) MCF-7 human 
breast cancer cells into the cell cycle by estrogens, in order to make the cells more 
vulnerable for the lethal effects of subsequently administered chemotherapy. The 
second part describes the results of several clinical trials a) applying the principle of 
recruitment of cells into the cell cycle followed by chemotherapy, b) administering 
low-dose chemotherapy frequently or chronically to a slowly proliferating tumor like 
breast cancer, and c) testing of new combinations or new analogues of 
chemotherapeutic drugs, and d) investigating the effects of new combinations of 
hormonal therapy. 
Chapter 1 describes the background of the studies presented in this thesis. 
Chapter 2 shows in MCF-7 human breast cancer cells ill vitro tllat the cytotoxic effect 
of doxorubicin is correlated with the drug concentration, exposure time and cellular 
uptake of doxorubicin. 
Chapter 3 shows that, in MCF-7 human breast cancer cells ill vitro, dual-parameter 
flow cytometry (with bromodeoxyuridine (BrdUrd) incorporation and propidium iodide 
(PI) uptake into DNA) allows accurate measurements of the effects of hormones and 
chemotherapy on the cell cycle kinetics. 
Chapter 4 describes in MCF-7 cells the effects of estradiol stimulation on the 
cytoxicity of subsequently administered doxorubicin. Pretreatment with estradiol shows 
an enhanced cytotoxic effect of the drug under the conditions tested. 
Chapter 5 shows that hormonal manipulation has no influence on the uptake, retention 
or cellular distribution of doxorubicin. The drug content in the MCF-7 tumor cells was 
measured with high performance liquid chromatography and f1owcytometry. The 
cellular distribution of doxorubicin was investigated using fluorescence microscopy. 
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Chapter 6 presents the results of the fIrst randomized adjuvant trial in stage WIllA 
breast cancer comparing the effect of FAC chemotherapy alone, with estrogen 
pretreatment followed by FAC chemotherapy. After a median follow-up of 3.3 years 
there is no difference in (local-)relapse-free and overall survival between both 
treatment arms of the study. 
Chapter 7 describes the results of a study investigating the efficacy of a combination 
of doxorubicin and mitoxantrone used as a weekly low-dose regimen in second-line 
therapy of metastatic breast cancer. This drug combination was well tolerated, but the 
response rate was moderate, with only 14 % partial response. 
Chapter 8 shows the results of daily oral low-dose therapy with etoposide as second-
line treatment in metastatic breast cancer. Toxicity of this treatment scheme was 
signifIcant, though manageable. Efficacy was disappointing, with only 10% of the 
patients achieving a partial response. 
Chapter 9 describes the effects of the combination of carboplatin and etoposide as 
fIrst-line chemotherapy in metastatic breast cancer. This combination regimen was well 
tolerated with myelosuppression as the most important side effect. Response rates 
showed no superior efficacy over the standard treatment schemes, with a response rate 
of27%. 
Chapter 10 presents the results of a study performed by the EORTC Breast Cancer 
Cooperative Group. The efficacy of doxorubicin as second-line therapy in metastatic 
breast cancer was compared with the efficacy of the analogue epirubicin. There was 
no signifIcant difference in efficacy between both drugs, but there was a trend in favor 
of doxorubicin. However, the treatulent with epirubicin was associated with 
signifIcantly less side-effects. 
Chapter 11 describes the endocrine- and antitumor effects of a new combination of 
hormonal therapy. The effects of monotllerapy with the anti-estrogen tamoxifen were 
compared with the effects of combined treatment with tamoxifen, tlle somatostatin 
analogue octreotide, and the anti-prolactin CV 205-502. The study was closed early 
because a signifIcant number of potential patients refused participation because of the 
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need of the three daily injections of octreotide in one of the treatment anns. Plasma 
IGP-I levels decreased significantly in both treatment arms, but more uniformly 
during combined treatment, while during combination therapy plasma growth hormone 
tended to decrease and plasma prolactin levels were strongly suppressed. 
Conclusions and perspective 
The newly derived knowledge of kinetic changes in breast cancer cells by estrogens 
and anti-estrogens and the experience that tumors with a high proliferation index are 
most responsive to chemotherapy have led to the assumption that stimulation of DNA 
synthesis in slowly proliferating breast cancer cells followed by chemotllerapy might 
result in enhanced cytotoxicity of subsequently administered chemotherapy. In the 
MCP-7 estrogen-responsive breast cancer cell line we observed a 2 to 6-fold increase 
in tlle percentages of S-phase cells after estrogenic-stimulation, and an enhanced cyto-
toxic effect of subsequently administered doxorubicin (chapter 2-5). Also ill vivo 
estrogens have proven to be able to recruit tumor cells into the cell cycle, but the 
percentages of cells recruited into the active phases of the cell cycle are low and the 
efficacy of chemotherapy is not improved as it is shown in most studies, performed 
in metastatic or locally advanced breast cancer. Also in our adjuvant study, with a 
median follow-up of3.3 years (chapter 6), we found no difference in efficacy of PAC 
chemotherapy alone, compared to PAC preceded by estrogenic recruitment. However, 
follow-up is still short, and differences may only become apparant after many years 
in a slowly proliferating tumor like breast cancer. 
It is clear that estrogenic stimulation alone, followed by chemotherapy will not 
improve clinical outcome in advanced breast cancer. Other means of stimulation of 
DNA synthesis with hormones other than estrogens or with other growth-factors, or 
other sequences of hormones/growth-factors and chemotherapy may be necessary to 
improve treatment efficacy. 
Treatment results of systemic therapies in advanced breast cancer have shown a 
plateau in response rates and survival in the past decades. Whilst awaiting more potent 
new drugs, new schemes and new combinations of chemotherapeutic drugs or 
hormones or new analogues of well known drugs have been explored in an attempt to 
improve clinical outcome and/or diminish side-effects. The new analogue, new drug-
combinations and schemes tested in the studies described in this thesis (chapter 7-11) 
all showed efficacy in metastatic breast cancer, but demonstrated no clear superiority 
over the well known treatment schemes. At this moment we have to state that 
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metastatic breast cancer is still an incurable disease and palliation is the main goal in 
this stage of the disease. 
New promising developments for the near future are the application of chemotherapy 
in high dosages, chemotherapy encapsulated in liposomes, and treatment with the new 
taxoid drugs. Novel approaches in endocrine therapy are the application of new anti-
estrogens, anti-progestins, more potent aromatase inhibitors, long-acting analognes of 
somatostatin, analognes of vitamine A and D, growth factor antagonists, tyrosine 
protein kinase inhibitors, inhibitors of angiogenesis, protease inhibitors, and 
monoclonal antibodies. 
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Chapter 12 
Samenvatting 
Borstkanker is de belangrijkste doodsoorzaak van kanker bij de vrouw. Adjuvante 
systemische behandeling met chemotherapie ofhormonale therapie blijkt in staat in een 
klein deel van de patienten micrometastasen te genezen. Het gemetastaseerde 
mammacarcinoom blijft echter een ongeneeslijke ziekte. Er is dus een grote behoefte 
aan effectiever behandelingsmogelijkbeden en medicamenten met zo weinig mogelijk 
bijwerkingen. 
In het eerste deel van dit proefschrift worden de resultaten beschreven van preklinisch 
onderzoek in de humane hormoon gevoelige mammacarcinoom cellijn MCF-7. Met 
behulp van oestrogenen worden tumorcellen vanuit de rustfase (GOG1-fase) van de 
ce1cyclus de S-fase (DNA synthese fase) ingedreven (recruitment). Onderzocht is of 
deze cellen in de S-fase van de celcyclus gevoeliger zijn voor de letale effecten van 
chemotherapie. 
Het tweede deel van het proefschrift beschrijft de resultaten van klinische studies met 
betrekking tot a) toepassing van het principe van oestrogene recruitment gevolgd door 
chemotherapie, b) het effect van frequent of chronisch toedienen van lage doses 
chemotherapie, c) het effect van niellwe combinaties of niellwe analoga van 
chemotherapie en hormonale therapie. 
Hoofdstuk 1: de achtergronden van de studies die in deze thesis worden beschreven. 
Hoofdstuk 2: er is een positieve correlatie tussen het cytotoxisch effect van 
doxorubicine en de incubatie concentratie, tijd van blootstelling en mate van opname 
van doxorubicine in MCF-7 cellen. 
Hoofdstuk 3: Dubbel-label flowcytometry met bromodeoxyuridine (BrdUrd) 
incorporatie en propidillm iodide (PI) opname stelt OIlS in staat het effect van 
chemotherapie en hormonen op de ce1cyclus kinetiek nauwkeurig te meten. 
Hoofdstuk 4: Oestrogene stimlliatie van MCF-7 cellen gevolgd door doxorubicine 
chemotherapie resulteert in een toename van het cytotoxisch effect van het 
chemotherapellticum, in vergelijking met het cytotoxisch effect van doxorubicine 
aileen. 
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Hoofdstuk 5: Hormonale manipulatie heef! geen invloed op de opname, de retentie 
en de verdeling bimlen de cel van doxornbicine chemotherapie. High performance 
liquid chromatography, fIowcytometry en fIuorescentie microscopie werden gebrnikt 
om de opname door en de verdeling van doxornbicine in de cel te bepalen. 
Hoofdstuk 6: De eerste adjnvante studie bij patienten met stadium II1I1lA borstkanker 
waarin hormonale recrnitment gevolgd door FAC chemotherapie wordt vergeleken met 
FAC chemotherapie aileen, toont na een mediane follow-up van 3,3 jaar dezelfde 
overlevingsresuitaten. 
Hoofdstuk 7: De combinatie van wekelijks lage doses doxornbicine en mitoxantrone 
chemotherapie als 2'-lijn behandeling bij het gemetastaseerde mammacarcinoom wordt 
goed verdragen doch is matig effectief met 14% partieIe remissies. 
Hoofdstuk 8: Dagelijks lage dosis etoposide chemotherapie per os als 2'-lijn 
chemotherapie resuiteert in slechts 10% partiele remissies. Enkele patienten hebben 
forse maag-darm bezwaren tijdens deze behandeling. 
Hoofdstuk 9: De combinatie van carboplatin en etoposide als l'''-lijn chemotherapie 
wordt goed verdragen, doch resulteert in een respons percentage van slechts 27 %. 
Hoofdstuk 10: De EORTC Breast Cancer Cooperatieve Group vergelijkt in een 
gerandomiseerde studie de effectiviteit van doxornbicine en epirnbicine als 2'-lijn 
chemotherapie. Er word geen significant verschil gevonden in effectiviteit tussen beide 
medicamenten hoewel er een trend in het voordeel van doxornbicine lijkt te zijn. 
Epirnbicine heeft echter weI minder bijwerkingen dan doxorubicine. 
Hoofdstuk 11: Het effect van tamoxifen als l"'-lijn hormonale therapie wordt 
vergeleken met het effect van de combinatie van tamoxifen, octreotide (anti-
groeihormoon) en CV 205-502 (anti-prolactine). Er is geen verschil in overleving 
tussen de twee studie armen. In beide groepen daalt de waarde van IGF-l in het 
plasma significant, terwijl in de arm met combinatie tlierapie ook het antiprolactine 
gehalte in plasma duidelijk wordt gesuprimeerd. 
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Conclusies en perspectief 
De nieuw verworven kennis omtrent kinetische veranderingen in borst kanker cellen 
veroorzaakt door oestrogenen en anti-oestrogenen en de ervaring dat tumoren met een 
hoge groeifractie het meest gevoelig zijn voor chemotherapie hebben geleid tot de 
veronderstelling dat stimulatie van de DNA synthese, in een vaak langzaam groeiende 
tumor als borstkanker, gevolgd door chemotherapie zou kunnen resulteren in een beter 
celdodend effect van het chemotherapeuticum. In de MCF-7 oestrogeen-gevoelige 
borstkanker cellijn vonden we na stimulatie met oestrogenen een 2 tot 6-voudige 
toename van het percentage cellen in de S-fase (DNA-synthese fase) van de celcyclus 
en een toename van het celdodend effect van aansluitend gegeven doxorubicine 
chemotherapie (hoofdstuk 2-5). Oak in de patient is bewezen dat oestrogenen in staat 
zijn tumorcellen te recruteren vanuit de rustfase in de actieve fasen van de celcyclus. 
Het percentage cellen dat gerecruteerd wordt blijft echter laag en de effectiviteit van 
aansluitend gegeven chemotherapie verbetert niet zoals blijkt uit de meeste studies die 
zijn verricht in patienten met borstkanker in een vergevorderd stadium. Oak in onze 
adjuvante studie vanden we, na een mediane follow up van ruim 3 jaar (hoofdstuk 6), 
geen verschil in effectiviteit tussen FAC chemotherapie aileen en FAC chemotherapie 
voorafgegaan door oestrogene recrutering. De follow up van deze studie is echter nog 
maar kort en verschillen kunnen, bij een langzaam groeiende tumor als borstkanker, 
pas na vele jaren duidelijk worden. Het is wei duidelijk dat stimnlatie met aileen 
oestrogenen gevolgd door chemotherapie niet zal resulteren in een betere kIinisch 
resultaat voor patienten met borstkanker in een vergevorderd stadium. Andere 
methoden van DNA stimulatie met andere hormonen enlof groeifactoren, of andere 
volgorden van de hormonenlgroeifactoren en chemotherapie zijn waarschijnlijk 
noodzakelijk teneinde te komen tot een betere effectiviteit van de behandeling. 
De resultaten van systemische behandeling met hormonen enlof chemotherapie van 
borstkanker in een vergevorderd stadium tonen de laatste decennia een plateau in het 
aantal responders, in de duur van de respons en in de duur van de overleving. Omdat 
effectievere middelen tegen de ziekte nog ontbreken zijn de laatste jaren nieuwe 
schema's, nieuwe combinaties en analoga van de bekende middelen onderzocht 
teneinde de kIinische resultaten te verbeteren enlof de bijwerkingen te doen 
verminderen. De nieuwe combinaties van chemotherapie en hormonale therapie en het 
analogon uitgetest in de onderzoeken beschreven in dit proefschrift (hoofdstuk 7-11) 
waren allen effectiefbij uitgezaaide borstkanker, doch leidden niet tot betere resultaten 
in vergelijking met de resultaten van de standaard behandelingen. Op dit moment 
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moeten we nog concluderen dat llitgezaaide borstkanker niet te genezen is, en dat 
palliatie in dit stadium van de ziekte het belangrijkste doel van de behandeling is. 
Nieuwe veelbelovende ontwikkelingen voor de nabije toekomst zijn: de toepassing van 
chemotherapie in hoge doses, het toedienen van chemotherapie in liposomen en 
behandeling met een niellwe groep chemotherapeutica, de taxanen. Nieuwe 
ontwikkelingen op het gebied van de hormonale behandeling zijn: de toepassing van 
nieuwe anti-oestrogenen, anti-progestagenen, effectievere aromatase remmers, 
langwerkende analoga van somatostatine, analogen van vitamine A en D, groeifactor 
antagonisten, tyrosine protein kinase remmers, angiogenese remmers, protease 
inhibitoren en monoclonale antilichamen. 
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